ESSENTIAL DRUG LIST FOR KARNATAKA GOVERNMENT

Item

Title: ESSENTIAL DRUG LIST FOR KARNATAKA GOVERNMENT
extracted text: RF_DR_14_A_SUDHA

.T

I.

II.

III.

IV.

•T)

uevs-rnment n...s constituted ux wo. ;it cce c iced Ther :neu—
tic Committee, this Gom;..i ttec deciles
tes th
ths3 truas to be- included
in the tender list. This covers if any drums arc- obsolete ..nd
they are ..eleted
eletcu ~ad other new dross introduced if .'.rx / _;re
included in viic list.
The director of Health c<

ervices.
a ng--lore, .lo.-<tes ten—
ders and procec-dures folloa/eci are a s pur the store pure .ase
manual9

r.s ocr

calender of events on prefixed particular dates
sealed tenders are onene-' by the tender ooeninr Committee in
the presence of th' renrssentative of the each of the oarticipants where rates cuotad by each of the firm ace made known,
Cne set of b e document is ^reserved securely under the custody
(personel) of t’-s Director and remaining other set of on currents
are hancied ever to ths Joint Director Government l.edic: 1 Gtoros.

G o ve r n me n t h a v e constituted a Committee Known as Tx-crts Com ittee o fhe members constituted are by their desim-iicn from diff

erent institutions and inclu'-'ec nri.cticall'/ members from every
s-'oci.lit o this Committee goes through comn.r five
tive st Cement
of the r tes guoted to
’CO v rious items with r.?s active to s.m las
and
cic.es one
chc L.ru
k.'ru.. s. if rhe dru s h.s
■ s z d i: d f u 1.1 f i 11 e d the
o

minimum re uirsments .. s ser ^rugs Uon
Lro 1 ’ ers
e rs stipuletioris , such
control:
as Go. •

..ciu:: cturinj licences, ..on Conviction Certific-tos,
b e s 1 z. z s . osg; ssion of Income
-.ncoa.e -nu. - .;ic.s Tax Clearance Certificate
•

9

re ~ 1 so 1 o o k e ci 1 n t a.
Th :• • • r o c e s . r e j c:: e s

st

or rucoiww id^tion of rxoerts
Corm ;ittee
ti-u same is placed before Hir h rower Committoe constitu.ted by tho government t.-kin; final decisions. ..ltd a view to
imp 1 ema nt ce??tai n Government interest in . ’ a u s , a J Is u n i t s etc.
ac* si es i-1e "■roce dure th.: volley as regards to giv.
’n--• either
oiv?n
ri ce s

•refc re nee or reference to JCUs such ^olicy decisions
^re loft to z.’ie decisions of z':e ■‘ia’.! Tower Committee.
. o.

2

2
Th.- f i n 1.1 recom-;-'?

of t'.iC i.iqh ’ o;ver Jomitt - e:-re submitted to
bo vs rar-io nt f r their scoro-<le Tacirv instractions of : - -o v< rn;'.cat^ hr. to Sontruct is fixed 7 ri c s ? e c t
of the
jocrovcd •■•ith formalities as mroviced in the
Tender ?’otiticsti

VI.

In Government Medical Stores, 3 e
lore-, effects nurc’’ -so of
d r c s a n c ‘ c h e m i c ■.s *rom
rm s only as cer fas requirement
O- the- hoc ■'•■it. 1
end ■ heneve necessary -ith the orgiesion of
Government from fublic doctor Undert tin's or
firms (only from m..f u.-'.ctu??--rs) .

i". y oti': -r

, BILC

QOVT. medical store
^anqa LC)Rh\EHfi nn •

;dia/

o

o''
'•? ' ■ '

\

'

J

'

.■

ALIOUI THSarcHKim CF THJg'.VWiHMeHT MnkM s W
F^LaCC ttv.sDi* -HANGAr C^E-^QO 01
'
'’

UdAlL;

r

Thp Government ModicU .Uoros is locaUd in g„c« vU1ab
■uG cv Ponn,
U hoded by the Joint DixecUr, un Mr tho
ar-mlnl^r Uve conlxol of the bi^ctor of U^lth &
;,rvlffft
• IciF. .bo sUff aancUoned for the Gowxwwnt K<?dicnl jn
.’is no^d hr.low:-v
•
-•

*•»

«n» aM»

«••«»♦.-

««

*• mW

Cu t^gory.
—

-*

?■*

—

• •** ,** ** •** —«'

-««

•

5.
6.
7t
9#
10.

I?*
l

■■•

•‘■;

** **'

**}.
y'

’ ' ■’

' ■ j

*-

*•

•*’

**

Sanctioned bost

i

fw» «M. **M ^0.

i

2,
3.

v--

1

!

«»

**'

;

**»
■'■’

•«. «.» •«’- ....

Sx* *•
•

-• ’

’

.

.■-

Joint director
.
.
Auviutyui uyrgoone.'; . 1 , •■
Oradute Phartcaci&tc
Se««t„y
J';";:"'
■ .. c*
M«n»se>(owic» Suytd.) .;
OnE
Accounts’ SupoxintWent
eno
■ V

.

j.. T“

Wt

First blvislQn.AeeU^intA--'ten .
m
FcohU division.AUUtant; " :-/. '. ‘ .
Second
Thu ty lin.Pr>
Litox/iu Attond«r«y'<;:•^.
/
FiVffit“lv"
.' ■ ’
■' .
tan
ci.sner
:.
yo»«
.
c.,lp»nlpr.
Onc
^-.U, Orawly.
, .■
f

1%
1 6•
17<
We
19*

'■ •-■■.:■

Ihr««

' '

Hnt«« ,
‘’<>ek’:r8 '
■ ' .■ . ’ Belch & Borid
J,:- -<
-’•'•nocrarher . \J

■ - ? ■'TPTAL|

~"

On(1
Forty F,™
Cn0

Ona'hiindrecl thirtythr ve only

T

A--

Ml"

I**

I ho Coycxnawnt: Aiodlc^^toreo 4s'7®.Mb*Oiv4dod

v/*' ’ >
'

3.

•-

a:

r u r c h -a ? n Auction

<

•■

<;••'

■> ••

•

1

-

■'

t

7

9) :;•

• '■■■ •'

'•

•

'

.

■

into nintj.^ntlc

•

1

•

-

■>

;it,; AasteSu^cn
.Fficke.irs**
the'■control of Joint UlMetcx

’

'‘iccount«’5«ctlt»n

','-':

inn «M4 0".

•*#

Asst, Surgeon
■ F*U<At3tD,A F'Ack^ra 5
.

>‘Ackinfl Yard

■*'*•’

•' '.V'

ddy allotiny staff.''^sh^
1. chlr-f :;u!)orvi»^xf^GUon»';;b7V'?'''1;:':
2.

■»«

Undcf the control of Jontrol SIXJ-M
And'^.(4-U*a*»4
■ feons.- ■ i

V?'

V■

» .■‘ 2

•J.

6.

t

'a* btorosdableU -and Injection)

1

tJ’” control of g4Vu

u♦ i\

1
1
4

FOA
Sp/k
Packers
•
•
I
♦n* ■<itnrc»(Tincturo
& Tender)

4
.

,

\
\

I

Urider1 th® control of (rraduto
1 Ph erm CiotR
Bx«duic Fharmucists
FOA ,
SDA
3
/-. ,
. Factors
6
’eZD* .Stores
.- : ' '
■, z
(Instrumentc a?d Equljmonts) Under the control
of Gradute PHsxa<nn>cin ts

;

7.

0.

1
2

.sda:
Packers
,. O.F ■'
CffJc^CAdrinltfr^ticn) ■ j
fiocr^t^ry
Office Supid.
‘FDA',-,,,®?u ■?.••■•
'
Stsnographar
Typist
Foons '
Cycl® Orderly
I.iterate Attendexo
Packers ?.
■
.. .. Oxivors
■

,
\
following Gectlonci^zc^
■■:■■

'

■ '.'.■y

.y

■

■

-'

■■

■■■<-

Secretary
•

■

1
1

■'..

' ‘

F>GA;. ■ /

.

into
-

A...

Office Suptdj

Cash

}

■■■■-•................

•'■

■'..'Ur> e X v .1 ?; o c y Qf f i c ej. f '
Sectioni

3
1 vacant

■ I-

■

■

I

1

Gvcu

<U
Orderly
■ Lit•atten'dtfx ■ 1 '

Audit
Mlsccliamsous
r<.u:m .Section

/ ' &QA .,'■■z'

\;

■:■

' '■ i

■ I

»»

PdCfcojcjS

'

' '3- :
. SDA
■
■
1
. - Llt^attonder
•?

Inward
t

iy;'ln9 'Section.,' :
I.

Cycle

?ordoxiy
Packers

>■

■/

■''ii/M' fj®jj|^aphor

1
2"
1
2

-sr.w'""

•n

SiAVi’V

,

1

, I

»riv*r
■
■ Cleaner.-'. ■
watch & .Ward
r®cn«■

1
1
1
11

2

»

■■' .-3

Tho Joint Dlrmor b<lng tha Hwd of th« In^UtuU^ U
in overlvwl Mapc-rvUion. ajid' contrplUng' authwlty oif <UX tlw
'oction of th& Govt^dicaX Stom» a»loxi?.
>?/' ■

u

' '

\

Tho A59tGuzgeon.holding the poot
uch.nflo of u-.u «»ctlona nd kfi ho 1$ in rank i&o th* Joint
or
ndCTinistrsUvo.iduUes whenever tho Joint vlxcator is cm l«avo.
o.c (),i othoi ouUtfS. IUi •,Chief Supexviaax is xosponsltlo. to xocelvo
oil tho MippUcm fxor. varloua firrao to
oxdcm would boon pJacftd
L’OtJm by th? Joint ,Dlr©Ct0X.< zG^8;-S fluoro, end by the MxccUr of
I'^Mh !■, r.-A- Services, by. vexlfyUs the quality and opaclflncUon of
the rmUHmlg r<uppXivdrby the fW,With th.H of ths app-reved £.afflpl«s
at the tiM of approving -.the H,G,„Wted. Xho ChUf ..upwvloor is ren~
ponsiblo for mintalning a:<Uy. book, for. ^11 the pmohaee®. and
necoasary ent»ei»: undor this slhoa^twre *nd obtalrmi tiv?
'
initials of tho joint Dlre,ctor' ip .token of attosUU-m. Tho C.'S ie
responsible for'the. safe cufttndy_of,,.the, articles xecoivocf till
such
they ara .handed,<?var U--.the^^o©xned otoxes including' oa£>
delivory under hla signature and; obUlittM th* fuU olgn^tuxc of tim
roc«ivGng office from tho .concededUo c.d g .uro r^yogahl* for the aafo custody• 4aaple,e.;/revived fxoja various firms »»t5«r
duced m connecUon3.wi1A.^,ft^;M0^
d^ont^U them '
v-Mcmver require ..fry the’ Joint Director, filrocUr of H^uth a F.ta Sorvi
coa and Urjiexta Comaittyo; or .Hlgh^FOwor CoiMJittec* The C»S vd.U.Jlso
maintain a register ef aaaploe. revived and 'to record iu dls.wal
it Will ho Um xocpoft^liVy-of^/c.S to cae tho.t the varlipwAatoyfi
rnee oro cQirdctiylocMd’©nd'»eaU'<t,with in hU presence attends
of OAsch day and .tok^'deknewiertg^^ef
cenpermd store UweiG'. ' ■
to this ■ effect and repaxt .to'
Director, The Cheif
rvisor; J
roBronelblG to sort out the dea^weect boxea according to. forwarding’not.
He ohall assign 'toe.'dutlep.M.sii^e^n^end cleaning of- the pocki^^r. .
by routine and.
tutor , the ^haaeev^p^jww?' ■■.
e» »3v’cb-duties,.phaAXlbo;r««^^ib|*^':varify: tho rubbiah’-'ey^ydwi '
it 1* removed ’out/oF the; ixmic©^W\to^®o. that, no Govt, property^®'
mixed with the rubbleh^G'.,; '''■'■" '':''' '
’ '
’
2.

£^r4tLU’^i*

<■.'■''<...

■■

■

The Assistant Surgeon ic In^rge.'gf too Tackipg yaxd is haviru
four packing section. The Am,$urgegn‘JLe repponsitole fox' the Cur^oet’
doepatch Of the sr^ctos. He-wlU’ excsxciee. proper supervision'ever th
racking yard during ;too'.'aatuhl..papktog^Ftoe:^t^ifi]> He'l». wsnon« '
filblo for gettingthe compiled indent entered in .too concerned gato
pass hooka unddF.--hi^a|gnature and''-8umtt 18 ha joint Director m to.
n^.Jfui. hc is re^mw^u to
that too staff msm^xs
bin
/

'' WOSk»; «l
4

««£&!■««

'

■

'"■
it Will certify W '
wiperviEion7
witf tfeno under ms dinct
iiH-xvidon and al«o hU u$8iatantc haw to certify th->fc
pockifK, V,rttt donc ln’ p/e7^r7TT—.:
\

l

is aiw reaponoiblo^C^rjJ**’? *" ^...Column®, proyided. Ho
stailMer driver or the Clerk 4

..tu,uly th, XX't"*
1. reaoo,,ciblo
i oc^l wd
Peking matoxlal ia

> 4-frv '

' '

'■

-\

of the flood® to th-® lorry

•< “•“h ‘

»b, mii

th® UM(1„ (te |

Mli^avo^

I

Unt ttw oacklm
packing v,ork doeo not;8Uff??7~—--------------------------

<^cipt,„.r?Xu‘r^ ^50‘'’:-al1

fuU ’'WJanc. Pml ,

Io». .J.nSng l^ndllno oi rackiw’.holr l “Ut"li''ls on<< •,ni' l«<>kawio or
c-f ti- reMa* ! >
U
W.
n»=k.rB
;h, C^X m/u •vta*■■*•cluiUs onr‘' **""*••

r« -in.'1X '“ “-0! *•’ D““1 ‘*uUM> ,te
St«« "n.’ CX ' ’eh

frm ,„. Mln

si lvery „„t;„ X , " L ‘° '%*
of,u^ “1,a!1 ch«“«
.
vv
concerned of th& c‘tib •»
^nd cortlf/ 4<bout 1U cprrcctM^’'
2- .
In-lwl.r. «h»n be vwlfU-d »Ul> 40T
tll#
b«l«.ce and the action „<>f , .
” ^l^tlngj^toc l^r ,,,w pay.UU
•

CiO-Oil' &lwr t

, C viOJl will

Thxi

a

■^ency .hall al.0 »..¥«>«»,».; rw-.i^weluirU of <22
nhk* oom u» .hoxtao®.; •»
’:■'!?•< yttS'^'*;.;'..^.-.’ 9
“n“ t0
■;

"

■'.

sUiXMU£Sm»- ■■-■'•■

?.■

■■

■

”

■

-

■ /■ ■■■

Iho indent i
“*• Ha will have'
neXt
xank U ths Chief Supaxvlfiox
in hi© duties
and watch the oxPGndituxe. . Ho !» x^aj^Uibl© to eoo'that druga which about
bocowst Ume bay», oko
ro.ponolblo to K»UMrf,0 W 1±nJ!r^U,1< .‘“'‘W’? offi«
Able, lie i9
. ?! *»• ®«S». P«w such quantotloo a0
complloM with ana aeni'nafolv
*
Wntit/ pac^ «xo pjopoxly
<•1
, ,
"r..®ftTe*7-M>indentoxxt lie v411 lnVfiF»nr<
w comp a nta about ,.4hy/»hoxt:.8uj>p'iy xectlved froia. they afUr anij obta
ordnra fro® .the Jolnt^UecUXa
V'';\
'
aS'Wr.tt™ obta
;,'5" ‘...' -■'•■/.’•^•.’‘W'.'2 V‘■ ■

, ■ I-

'i?:.

■ *•»♦«<♦>,&

t•

■5. '

in ■

>•

.r

(I

■■■•■ Q;r;'<r:;;r.

.
f

The staff attache-si V> thia sacU.< n are <ji;nt stlny the
Joint biiectcr in floatXh^;te|i^jr^|;^epatin2 cowpar stive . sutwaente,
attending to the preparationy.wibyk*'^' Hate Contract. Watching th®
stock position of■ thw'varWw^Xtto^Wt^ewrthg stores by placing orator#.
to the B.G firms'and preparation ofijsynoptic etatoFient of the financial
ysar with tha halp of Q.Pfi ;<>£<slao account® section.!
They al*o assist in preparation;,thu procvodlnga of .the '.
Ihorepcuttcr. Cora:?, it tee. . Experts' CoofiiittOO; rod .Hl$h Power Cor-r.l ttor 1
Mooting. In addition to the procureiG&nt ,'of Vw AUpplioo in being
ndod tn this section through ft-C f4x«®
gyring sjB&rjpjncy mul whenf’VO
th? Jl.i; flrtpa failg to supply, th&eo will, be procuxod on loan!
pUTCb r
by coiling for quotation? and fallowing putciwo xuleo.
vor t|v* £Innnciul powG-xaJ.^r'thc Joint j'Jlr&ctor exceeds they will obtain
the orctero frota th« 'J/irp.^tar.
Itoalth S. l3.^ Sorvicos. for piocuxoment
rj
r '.’- ?■'.••■■ •■'.■ '..
c-f dm G •etof- .
-dV. • ''■//

' '

5'M

•■

;..,.j ■• /
, !

* •

•.' ■ ‘b

t

" • ‘i' 5’''',

••'

.

•

'

.

•

•

*

Ihie occtlon la placed dixactly under th? ndtuinletrntlvo
control of tho Joint pirectox. ; Accounts.Suptdj is Tosponclblu'for
scrutiny of u.U the bills rocelycrl’and for their pxwr.pl and coii'«cl
dlrooaal, for moling payta<»nto;.t{>;M®-Coneexn^d. He will guide the
Jilnt birector in• various,'pu^cha.^.iranogatl.bn and payiRGnta ccrmctins
to v.he
correctly.•.; He411 .the’rules and condition!
req-rdlnq the purph^cja’.with by th-a .firfts.4"
hoforc y-aauinq .the bills.. ■ Xn.'’ca?^p?J,it>cal'purchases ho'.will verify the
r.uxbase rules carefully and hs W.re^pbnsibl® for any lapse® therein.
'.■■• ' -sOtlyV;;./y-:.-'.

: ■ ■-

’. -l- ' A/pb.--' .t

.

■

■

■

biy

Mo io also responsible} 'X®® ansureing the yrewt payment
,.>y tho miling insUtu ions. He, wlU.:»cruUnlGQ all the conUgont bills
and erisura ;about'ita-Cbrroc.tne»|i::^^;j^^leQ bofore they ax.e submitted
to .ths director fox'COUnterBlgnal^b^H^.'will'have '
bill prepaxaingand bill scrutiny and Internal audit suc^ibn. H« will h»ve th® U main*
tain . I«eantlllaUw/M91.^;?^.;|)l^:XU;VMlO at u» «nd'«» wih . \
month. 'Ho shall;axiongev.fox:-iSin respect of
oach institution® district
on tba '/pf delivery notes , cent to
accounts sections. T|j» Accounts SupoMndent ilsvrcsponslblt’ to malntlan
expenditure u.G RcQlster for tho supplies wide oh billing basis,
reconciliation of receipt and urpdenditw:® 'otej.
. *

.•' *

■ ‘•I*

'

■ •

'*•'

•’.''. ■•■■■'

1'1

■< • I*"'}?

'

■'* j*’'' ‘■''f

'

'

•
■
“-■--- ^
tach.
One'of-tho
eb^XO'-atoxes le inchargo of a Graduto Phfoi-i
maclst and they.ore .'entrusted, witjii, th* following dutisc.> Iho G.Po will,
be personally".rcsponolbic- for-'aafe. custody of articles undvr thair chsj
g© and nhall. takei-'propeir:
takei-'proper:''^xeJi.egwdiiw^tholr/Mge
storage. ’ They will
go
' g^xe''x«goxdl^;thoi.».
storage,
receive the stores
Khtaf■ Jiupcixvlsot
wak? proper cntjcle® 1

■

■

r

.

.-

. .■'

.

■‘■■■I.

"

'•

1

An the stock losgora end keep tin, account nsopei-jy, stor&s 9tox<?a
i'^y will ieM<0
They will be
—•. Jn*w flaceda
««i.onolbl6:1,r prepex »lnuinf,„c
tfay to riny (<111 stock lotfgjiyrg’
»« that both tho xeccipt and Ucnoc
e-rly uno^r t’lfclr- Inltlolo. They ,houi<|
^xg
propwhich .i,rc Ukely to bftcJm
about th£ druq^.
b&rrvd .^rd
taken 6ych action ln
-'fi oro i—
nscoo.^y under the
the r
■>VOj.;l J.ol.s
officer ond t0
- •-’ to Covt. They wm £ubj®lU 3 list
• • ' Ci' dX!.t:iir. V.hlch
virorl t.n pp
aro re-.]’*
roplanlshsd on^o in ®m-y fifteen
r.to.r, ib,>y
t* Hi*

x Z

"6p=uX1«FS‘XXTittlnii
—nu
XXvX1'7TJ

TJlr'V’ij'ntn for
I Fu’ y

t •* r "
' ' ■«> i™ OUTJ wotkinj, tl,«?e and l,.cin„ H,

„

ninqc?,
irr^'pQ

’’‘i'.HWr;

' I: i t

.

n'nle^ of thi>

th-5

■■'-t .-nixlco In the d.ltvexy „„,(,s

'hd dQ-U

J.

.., ’,

fcX

* h» :U^;.-2<s

-y noua vaniited hy the ioVWBn
■■■■

Jho adiMnbnmiv© option consists

■-»’O i6 th® section hf(ad l3f dU ,...„ of Lw ley
i;’"' ^rotary
-<H:roiary Will
vdll check
check m"fiLV'L
all-'fil,,sl

I hr* sr*

v'kVl ........ .

«

y moJ

?‘

«-h tiw
lMWi th;.
:“■;rh■ tUv
x,;,f< ^-'77
s - 'pass©® trirough
.uak ot lf.r -L..,., ,7 K
'
”

e torr I? vul !.n
w »ny r-hoxu^s Mtlcsd win M llc<llMht ^•••‘-’•*•«;<’ ^ «« l- ok
J < r •'
■ 1’■■■■.'-.or joy fuxtijex aqsion^ ' Ke will 1>1..
'’n&t^te '’^ i”t'
.,
L
«I>o«r v,. ebJrt the
’‘'‘‘CN rr; '■' ■-uj.v.ot t»0 Ptecklno
-acc^rciinq to
not! r •»
ic found incnrrarA*. .-f^. >
r if packing In
vi 1? r
^-.Unzscd all corzes ondonca. r^ja'Mr -.
*
■
. :>
.. '.o th*
to t;w ’KM^uw) aj ;»■;1
0 i»nd assist'th^' joint <,
natters Qcverned by xul<?e, '
■■■ U.ocf.o.r
.;U
^■''1 fjHCO

■.

D1M;n fj x: ™ r ‘r,"^i”

■

The Manner Is th© »ecU<.ft#l heed
threuyh wh-.-n
th.r. CCX.J&J> •’
rentUncj* will pass through,
hs will have to arxertge for
t.touticrj of
tha staff
thw~
*
Tie
win
jgei
■
s
i|
in the preacncff of tM joint
the tjrpqlu 0O<!Tt«d
. .
Mr
©ctor
and
mwkod
-r
-ectiona
i
thS'ta to the; eon'C<-zn»<a 'M . '
t la soon by ths Jocretary^ a® is ■
oil confid&ntaii reports and
J tGJrOnElhlo ^0 KMXW. ■. ’
a.Ud
fcV.)Umqnts of
• -/ i’HJ ol 60 prGi'irty ' ' ’
th© staffs of the 0.14^.
th’ «« <

«-

octlrp wn<ler K.E,.5.!t£ecA) sui4/“
O^W^in^jw

to (ho
of

U'* Ir.

’ r-y:'/.>•<.,■ ■ ■ .

’.

a ,°- fU<”
J-

..._

f qX

of

. I' to tBlw©

. ■

conecrondsne® rolatin«
•M*3
^alhUdnco
•-'nd pra^xauofl of salary. ,rt< , ■
advance
and
ta
biU
s
tho GUf.
by

"-’ ur aa ,SOc;-';'

4 * • tf «
I

0

j

I

■

■

i

8

'■

-

of both
action, H« 18 aieo xecponeibi®
out by th©
■

.

,

"U ou'i11 x.pocta,
diU Ond Us5 ^<?iX<mun

UI

*

;

jlhoy will

r
”
r
lv1' *
.tation.xy thcouoh Wwmtab twSrtnt aiiort. 1!'/rl';‘ °l

M’ H’ ”U1 W» «<1 place '

th. Ind.nt, « aXlfoxn,

«w
tlm„ly
pcoeurownu,
♦“’"f
,*”1p “«•«“»»l.t.xa
•> <>* XU ,„«\
h.
1. x..,
on.XM, fq; a™ ?“*UCk

«UCK and Issue
Supply'' ’X “Utlonaxy and
Ot»« 1. u» xcsponsibUity of Olnctox »» o Th©
<* eupp1
B'loxo.
.
<4
autlonoxy
:
Stallunary

eAecUlcal "oxk,,IUii“,ina‘"‘t“Jt^••"••poMfnw m,
---- v‘supply. »r oth„^
u*W»IW>
nalauinanco of v.>Mcx<.t
xe^aXdXng water
M.u?B,
etc>

jumei.Th® SW1, x?tj

a uweouh „sut^ vii
of ail tappais receive and 1U
W^UXta.Uon u .u>8'M11UBny'i
and case worker®.
.

’.

•
'■

•

>

:'
''

/'<•"

.' i x

•' ■.-.

"■

•

■>'

‘

•: .

mm

'

■
'•

■''.

•’

th. .tw «.«„«”~u

■••■■•■'.■

■■'■

' '?■■

V'-i ,;■■.;••■•■

■'1

•■'

.

.

..

-

■'■

.

.

' ■

•
'■■''■

-

'

’

'

.

•■

‘wnu, OM

xn:bx1::‘hatrs‘‘

'
Y™;.A*t«r«u atUnders, ■ ■.<
SUnodxwherr X® ^•PoneibUY'to^eUuin
;
a-■fair copying .■■'
i^Utere and alee te
that th®
?«°«e ^Mhi/wHheut
®y•
’/>-

'• '. ' ■

r'':

i

. .. •

■'•'■■

•

■

'

-4 4 1® ♦

‘

'

9 ■••::. J !

■ J

■

>

.■••

•

■■

v

.

;

.

•.;

.

’

.' ,) ■• ■ ,’

K,'

,. .

• J

'

f
.

I

h

<1*

I

I . ■

■ L.» .

9

I

Two w EsOxe watch on<! w&itd ©hall always h# pxeaont
at the main enteranca of this office building during woxhing howra and
k««p watch over «u th® GlassIVfp «xoup Craployaea) about thair unveraont
and activities in th® Goyt»M«dical ^tosoat Fxorais®©# Ih»y shall
that
no packer loaves the premie®^ without th® written poralolon of th®
supervisory staffs ihoy shall maintain a register of dally ch^feh® end
report to tho Joint Diractor* They are xasponolblo for any lapse® or
lanlty in checking the packers end:th®lr official^ activities.
’ ■ •

*' ;

There shall be always .two or »ore cmterns 1 watch and
Ward at ths nain gate of GovtaMedltel Storea all the time during the
day and font watch and Ward furlhgnight* They shall throughly check
al! the CXas®»0» .employes® KQYlng out of.storoc during ly^h hour and
closing hours* It shall'be thiex* duty not to allow any <tentaln«r»vc>3cal«
bagae and other aj:tlcler:whi^hjaxe^ikely to tased for plloxage. They !
shall keep strict watch,.®V.the'.maln^g®^®
well us around ths pr^njlsas.?'*
Th® nigh watchman shall be rellgentthrough out the night and ©hall
make contlnouo rounds* They should boiesponclblo for any damage to the';
building or property duo to their-negligent or laxity. They shall not
allow any stranger within the premise® within out the psxMsslon of th® j
chief supervisors or Secretary during the absence of We Joint Director*^
They shall get enter the tlm® of «rriy®l'.and dopartuxe of ell th® yleltote
in the register - maintained.-..and yop««t;td-'.the?lolht Director any-lapses..Af;
notice* in this behalf*
■

Qm truck la ©noted w th# ^cvt.Medlcwl stwcae, or ;' '
the purpose of transportation packages from the Govt.Modlcal Store® to '• .-.!
the lorry booking offices or to tho railway booking office as the case ■■■■'[
may bo and in emergency this truck is being used for th® transportation
ef goods to the■phexiphexall.Institutions according to the needs* Ae a ;f.
matter of xPuUn£\.aW;:the drug®-waning, transported through a lorry^l^
agency whose xatt^contaMct Js'aratc^ipted. to'' all''the.medical and publichealth institute^ -One ambassador car ia alloted to th® Joint Director C'
for official use.r? The driver* of these vehicleo are responsible to ■
maintain log books, and also ths mUntalnence of vehicle,tool* and spare'.^S
parts. They cha|l attend to the work of get ting,renewal of registration <
and tax exemption .'certificate .and also, .the fitmew certificate, from tte ■<'
•T.Q office. They are responsible to maintain their driving licences In
currency. Ho 1* assisted by a Cleaner.

«U-

.'

-;W

.pointeDirector being the heed of institution is the
overall supervising andUontroUing authority of all tho acUyitei* of the
Government Medical fiteros*y The Joint Director ia also the Drawing and
M.tmr.ln, office^ AllJbHl. put w by th8 Amount. ».eU.n
he!ln, ''t

» io >

•

•ignad by the Joint DiwcUr

pxownUng to th«

Ih.

•

x.::;V2sx“,xk--,‘““™ —
. 4? ! • .-

““
ln.txm.nto «nd linen'
....„> te ^11" ;
th. «.p.xtrnnui Xn.tltMUw. thw^h out th, .tot. o.
th. budo.t
- *; "/C
proviHon provided fox o«ch inaUtutlons. '
In addition
X U«1S^‘ ,'^**i*> —u.1 xn.ututtono
---- j ^int^lnud
t“>vi'I,,,d1’* ilk« ««P0Mtl.n. hooxu, .to; «ti
on h. 1, °h°“:
y funoW™la» “<*« «>°
or th. Ooy.xLnt

.tt.„„
tS. L\" ™*aUng
x‘"u‘’‘to
L’V
f ‘',1:r1,w,ntj“i"t«»««
Bnn„i , te .
proparaUon o£ SUU Contrm {ax
• PF yof dxug«»®quip^nu,ip8Uuams and Hnen

H’al“, *

r?h ’xmrt^

which tondeo

hsvo

Smlw aM ol.o ott.ndtnt

ot X„
p *
“n<l «**•.»*♦» =«»‘u,o in this b.h»lr tor procutTOort
of dx„q. „„d oqulpnont. OU. Ord„, „iU
ptocw t„ th,
or"r«xnt«kSltflh,,?e ? "’>.R«C
th, <sov.xnn.nt or Indio .nd ftv.xnn.nt
no”1U>1“ "'•POxox. .M nlm.v.x th. M„<>nc)ili

”au

x: "::x",,

>—- *-/

.
. . Th8 0”,’»"»nt Moaool stox.o Km toon pxovtdod with th.
omnlv r^n
"‘"'“““'•t or ttVJ.o.qulpmnt. „U( lor tntuxn '
loooiu
,1<’,,"ttiMBU1 Phoxiphoxoi inotltutlon, rox th. vMr '.
th.lr no.lnot ^w^1’82^3
“‘i
•«""Pltux. Inourxod

-

.V ; ?'''■■

1980-01
1981 *02
19!32>>*83

>Um2gBS’

".Z

3#77tr?»SOOmOO
»4>31 »30^M(M)0
7>896t07r782»00

■.

>

■.

3^1^54^108^00 '
3127 S5 |i 6^lexQ
S it 95* 41 r 274w0 0

'••' '■:''<7-:<V;'.•

'

'

■

■ '"' J/“. ' hi'ir'ItS'’?/
■■■■'■^:■:■■■

•
djiwgich,

I

;v.;

■

'

.

'

A

< •
r ? •:

No.j-ifm' 217 HPc 92.
.Hangalore, ^te3; 7.9t1^92>
..CIRCULAR .
. ■
’

\
■

Sub; Streamlining’the «v +
■
i
<Ws,’ chemicals/o^X 1°X- +supply
UP?ly Of
of
J0 Government Hospitals®1
G«Lts, Institutions, et’ 'Centre£;t<p
~ regarding.
*****

1 be Pirc ctor a U‘ °f
& Pan,Uy Ware Services with
its Government ;..cd iGel £torOP
chemicals and surgical. itetnE r s weaponsib le-tQ,, supply drugs,
Cover nme nt Hospitals, centres, .ery year for a/large number of
' ’
Present ;system of indpn+iM^ r unhand ..institutions. Tbe
ent mg, procureme'nt
supply needs to
- -J be. further streamlined, , quality control and
the system in detail mnA 4
Uover n ae nt h a s examined
-loil and issues this Circul
tine' the; system.
- —ar to further stream- '
INDENT-2
The f pl low inp
ING:
g ontogo^ of b0Bpltals —
.
aunupl indents Cdirectly
*
to
Prescribed format
~ on or w«e,isdi?ai st«- i-tbe
■ e- mentioned agalnet. them;
Major and Teaching .
Hospital
to covernment Medical
bi District Hospitals'
Stores, by jiet
March every yeax .
o) TB Hospital
-t-S
------ s.

■

■

3.

The District
ci. : Health .Offi
consolidate
below and iurnistj^thp’m ;to
before the datef? specified
gainst'them:
'
.X
8)
(bthe.
Difl+rIh! t?11 Officer to ■
b) Community
/v'.o/ - r y
c) Primary Healt h lagtA
; glsSpTt -SatlrMfioer to
^Va-a.
sdical Stores tv

:: / 0°

(’•

/i -

__

4.

;

'

■■' ■•■ "

‘

i.(

-

InR3 «,atexrai
es”cdd W
1
by a Committee of

Officers and HoctorsWt'hp'n
Centres:

••■■

■’

'I-'.>

a) Prinir
b) Health
th
Pomllj, .f 1Ia
c) ■Survey,
]Wucatloo’W - Su b-Ce.ntres'‘
f
.
for\“
arid Tr9at'Iient Centres
d) Urban;':W^osy Cebtre&
e) DcntalvUpits.
\

’

’

•

■

••'i. <t

1"'

\\

:’>7 ■

*

-

‘i

f-

•.’

.

4
‘

'f '-

“

• . .2.

j.

- 2.

The package indents to be' so determined shall be by
a Committee of Doctors with the following composition:

5-

a) Joint '.Director (Government •
Medical Stores,)
b) One District'He alt h Officer
c) One Doctor Incharge of
Pr i mar y Heal th Ce nt r e
d) One Doctor incharge of
Primary Health Unit
e) One Lady Medical Officer
\\ •
f) Chief Supervisor (Government
. hedicai Stores) ' ‘

\

Chairman'

Member
■ Convenor .

These doctors to‘be selected at' random,- one’ each from..each
of the four :Revenue Divisions. '
■ rV-' .
j

Package. Indents shall be determined whenever a fresh
6;
rate contract'fOr purchase of drugs , chemicals and surgical
items is fixed by Government. The package indents shall be
valid for the period of the rate contract.

A' / •'
c

'

1 • /•

/Al

The annual indents for the units and centres as per
( the package .indents. determined to be consolidated by the
b Government Medical Stores by 31ST MARCH every year.

7.
J • ■ - b■ 1’ xA

7/J
j" >

.

v -/Ac ,
• - V’ 1

t

'

The Unit Officers shall furnish the annual indents
as ner the calender determined in the format at Annexure-I

8.

1

to this circular.

\

•

i •

' The-Electionic Da-ta'rprocessing Unit of the Government
9.
Medical Stores shall be’responsible for inve nt ory • control
covering: -7?. .

imUTORY
COMROL: '

a ) Stores Management; :
b) Purchases
c) Accounting
d.) Rate Contract

'!•■'

/

./"-.p

■/’'' 'Mf'V'/.M. .
•

........................................

51'.'

The functions and responsibilities ,of. Electronic
10.
data pr ocesslng Unit shall be as per. Annexure-II to this
Cir cular This 'shall'<be--••sub'ject/to .mod if icatipns !;from
time to time, depending upon the • regu ire me nt s and the
modifications shall be made .by the Directorate of Health
and Family Welfare Services. ■
’

11.
The Electronic Data^Processing .Unit, needs to be
further strengthened in terms of trained personriel’and
equipment. The Director of Health 5: Family Welfare Services
shall/separate proposals in this regard-for sanction of.
Government. . ’

1

- 5 -

/ OCWElViENT. 12.
Government. Medical Stores’ shall be responsible
to s' Pply upto 60%; of the budget provisions availab le
ever?/ year for the following hospitals .& Centres:

•1

a) Major ^Teaching Hospitals
b) District Hospitals
c) Mi n or H os pit al s
d) Com'uunity Health Centres
e) Primvr:/ Health Centres

1 .
C over in c nt Medical Stores shall be responsible
t o sufi;’^/- upto J00% of the budget provisions available
every year for the following units and centres as per
the Packa&e Indents determined from time to time:
<i

a) .Eximaxy Health Units
. h) Health & Family V/elfaxe Sub-Centxes
c) Surve/y, Education and Treatment Centres
tor Leprosy
d) • Urban• Leprosy Centres
e) Eental Units

14. .
Government Medical Stores shall be responsible to
s.upply upto’ 100^Of the budget^provisions available every
year under National programmes like (a) National Family
Welfare .Programme, (b) I/ieternity .and • child Health. Programme
(c) ^^'tlbpal-.Progranime f or ^.Control: of ".B^ndnese and. . . .
(d) Other7/programmes : in which drugs , chemicals, etc. have . - ,

to be supplied., , 1

1

<

; /'/

15.
The Unit Officers of the following hospitals
shall be responsible to. procure'upto. 40^ of the budget
pr ovisione’.available every year depending upon local
' needs and requirements: .
.

' •

r

■

a): Ma j or^.andqTeaching Hospit als •

b): Bietric^;.Hospitals
'■/■/.

• : . \ . . :<■
ui

.///;./

11.
The Zillri* Parishads . shall be responsible to
procure upto’40%. of the .■ budget provisions available
.every year, lor t hp •-f olloydng? hospitals and centres:

r- - ts

... •

a) Minor ' Ho epi Vais '
b) Community Health, Centres
c) Primary Health Centres

1

,\

{

I

■

l

‘

•

■■

t

“

21

-

The Zilla 'Darisi]ads to constitute a purchase Committee.
with the follwoing composition:

a) Chairman, Health Standing
Committ eu/.Ad mi n istr at or
b) Chief Secretary of the
Zilla Par is had
c) District Surgeon
d) One fedic-’T Officer of a
hiir.or. lion nt al
c ) Or.c kedical Officer of
.?r imary I■ al th Centre
1} District lie ■■1th Officer

Chairman

- ke m b e r - C 0 nv e n or

17.
The Zilla Parishad shall note the following guideline
in px 0 cure me nt:
a) Requirements of the ■•interim.period before
-receipt of stocks from Government Medical
^Stores:
\

b) Emergent requirements depending upon local
needs and conditions;
c ) Items , not indented for supply from Government
Medical Stores;.
d) Anti-rabbi^s vaccine , ant i snake venom,
ADS/ATS/AGGS
e ) Disinfects nt s

c/

.

A

. V*.

. Is '/if '•

18.
The Unit Officers and the Zilla Parishads while
procuring supplies upto 40^’of.the b udget provisions
available every ye ar, shall pur chase^only under the valid
’ rate contract . issued by the Depart meat 5; of Health & Family
Welfare Services..
,
'''
. /
19.

,7A ...
/^/tr • • •'

1. t.

> \ Av ' * •

the Unit Officers and .arrange for consolidation.

^tc>

v ' ' ' reference to the
. ■. Pr.o.curet'icnt
l4 s.h^ll be
b®. made
niade only
only, with

‘ ' s'1

'
.
v-pKv
T-17" ir:;>.nU.d it^r-c. Hy.cach;ox the hospitals, centres, units 3Pd

/i*;
t \ I' • > A , C

»
■

Government I'.'eclStores shall be responsib le to
consolidate the indents received under para 12, 1? & 14 of
the Circular ,
every year. The Joint Director
^(Government hedical StoresJ shall obtain the? indents from

/:>

■

* \

institutions.lin'd 0 r no cifcunistsfnces items not indented for
'' '
.... .
-v
■ should be procured, and the quantity ':procured shall be only
. yy in accordance with'.the consolidation of indents received.

•h .

21 . .

purchase orders;on^the manufacturers/suppliers under the valid! rate contract to he placed as per the following
calendar:
'
/

.. .5.
\

/
/
/

- 5 -

a; .l ou nc i’lirchase
b) II I-ound purchase :
c) III Round■ pur ch as/
d)

j.\

Round purchase

by 15th May
by 15th July
by 15tb September

I

by, 15th November.

These purchase orders should ensure availability
of shocks to make supplies ns
per the supply schedule
deter;lined .

22/

fl' '^Q^d^pe wlt.h: the consolidated indents,

G over pm.e.nt
1 stores shall bold stocks of essential and emergency

diu/-.- required for J months to meet immediate and

urgent
requirements, lurchrse orders to be scheduled to
ensure tlx?
a^aiJ ■ tility of. such reserve stocks.

OVALITY
CONTROL:

23.
To ensure quality control, the stocks received
as per
t he orders shall be subjected to:
a. Vilification with reference to
specifications;
b. Vcrificatio/'with reference to
quality; '

c. Verification with reference to
expiry dates;

/ f A hjt'

d. Verificgt.ion^with reference to
quantity; ,1 ndentcd <• ud 'suppiled ;
e • Obtaining ::annlytic6l report from
t he manufact ufer/suppXier^for
each batch, of .supply; ■
a

' ' ‘

' ■'1 .

.<

<fi. Pur ni shlng. .samples of. ..each batch')
of stocks received to the’Drugs I
Controller in Karnataka for
A
nnalytical report;
J

f.. Obtaining replacement of stocks *1
which'are unearing .expiry dates;. Z
b. Action against'defaulting- manufacturer/
supplier: ,.f^or: co ntr-aye nt ion., of the
terms of theo rate, contract; /I'...' , ...
i • Do struction _of sub-standard items;

;j • Str ict enf or ceme nt of ’ terms and '
cond
.
ate - contract

j-

■ ■

The Joint Director ('Government Medical Stores)
and the Chief^Supervisor (Government Medical

Stores) shall be. responsible for quality '
control,.
.
f
. .
’ X'-< '

’

■

1-

...

■

■

■,

v/i

■■Hl/''1. ■

•

■

■'

■

• r-6 .

■ ‘*i

_ M'' "—
Oh iTbY
./Djhi/hLL

'•1. ■ ’ .'•red

c1
I Ik-

f - h; J •' ' i

•J I. J Ci! j :'T
r ■

d i-tr i huted

co I

'

■> L

f-’f- .• i I. ei/Gc 11/ • nit/

Do

I

1

.•Hi:’’

• i-| •1 ,

Chi

(; i! 1 !; • rt :

.... -i

n

h

f c.1.1 ow i i ."

the

Li or. t h

•■ • I

-•

/eitie m- July

11 oh pit ‘in

1 hi.’i;’nJ.uj. T)i:-i.r ic to .

• hi nr

:

-■•J i; • II

'■" J ■•1. ,

n

. iy

'I

i’u I kni

hint r. icl.r .

Bi ,j n pH i

Vf-ul'f. ?I.

Pee?lili'i;r ;

Disti ict c .

hnrsmi

1 •••ndy.'i .Die tl icte

'le
■■‘i on' i. I:

- • -I i mmI

I

-fl

I:

!?• I ■!., I’d ( - )

■' cP il'o i ni'i-nd •: ? ‘J 11 ni : i l< nnti'id n
c.; • Lolo ’hl b'-H niid Rural Dif’t i let o .

7

Ju I y

Sh il'K’/r ?|

niid

ni id

-s i r-

11. ict c .

Di

iLni chur

< I. 1 • .i ;/. Chita. •idHXf
i.’l :r into.

5

?vr

or

Oj.'

t •iu^iUH/jCint.x ict .

r:

2

-I

wit I:

•

A 11 . ; • J '.'X '■•: 'H -' • • w; hi i.p
•nd T. .llo-cit

■7

••ceerd ■inco

in

el;iHU;11 y

Cd Ml

d 1 r: 1.1 i I.:h t i ' n

c-11r.■ u j«.

ctoreu f’h'itl

i '.m (J: • •! • (.

I. hr.

1 no 1 i.id i 11.'

dctniJcd

1 i.(‘chI: ••.
CD .

! 111 i f

H)-- ' *

i c; • I ; i t < > i . ■ i

•Hid

he

I I--

Cm Uh ye.
ediD
eh mJ. I.
kolLl I-'1C7-

•' n i I:

'>■ i11.

i co i c

nud

••'d-iit ic

I ion

of

i ndcnti. <•,

iMtoc.l-n

nud

froi.i
• i H(!

tlr-

'■ ’Vf’ r II-

f'11 t hoi

co litres,

U H It H

io-d irtr ibu t:i on

Such

from t ho

d;;tc

’ihit;

i •

j

Di.etiict

.Health Officcxc

ol

receipt

t he

(J ''-vc r irec* nt

end

1 u r i i -. h

WcJ. .1 ' i ■■■

iri.i. el: or

ro.)
I'H
.!■

(

.

ficr v ic':

: or

1) Lr c ct ■ 'X

px i J

Director

of

one

to

II;'.

of ilcfitli
thie

oodico.L

.if e over iii-!c nt

by the

Chief

f t he*

rlinlJ

ct'-rcF

of

nix rnoritl-.sr
nnd

Forni.l.y

Circu'l nr .

B; mi 11 y V'(fl f nxe

Htockc

ofl icox

in

of ever;/

Ilin encl

Health • ’lid

m 'd

I. he CovciHivut

.-tocks

Annaxura-11 I.

••lid b,; y every ye nr

Dir. C t o I : 11. (

the

or vari.ntinii.

■>[

on

to tl.e

ver it ie.ni i oh

d.ntcs of

((I over nrne nt hcMicnl iitcj on )

ic'.-L Stun'.'.; nt

c

expiry
to

promptly

veri fi

c' J I i I ' cote

mH nil m!

c t ocks1 xece ived witli refei e lice

the

d i ncre Pe iicy

i|rl.

la: fn-OHir i ■ i e

the

qii’iJ ity avid

reoort

1

i I

<’f. I ho

dirtxict.

jf i

lt O h! • received

d III 111;'

on lend ax

coi":'11cd i^ithiuj? _days

r ic

to ti

eni.l He

ctocke

honpitnln,

to various

U'Miccic

Henitli

si.' uku •

i • ; I I

rd .’. .

the

I • It ii.f-

pox

"."t i tut i.orif- within the

:di;rl I
Of

the Dirtrict

end

Ioi.;t.niii
•

—! i " 1.1 i ji te 11’c

I

~

i I-

■: i: *

ric i' I

1’1 U N .

C.fl ic. r

cex v ice H

Ch'Ll i

iiedicn'l

H t ' i.r < . r

Acconntp

r n nk

f'f

Of f icer

nuxpcoH,

• . I •

- 7

29.
The PrograniL-o Joint Directors of Directorate of
Health c Family Welfare Ser--Ices’, and Joint Director (Medical \
Education) Directorate of Medical Educat ion, shall be
I
responsible for verification of stocks in various hospitals,
centres, units and infctitutions.as detailed below:

1. Joint Diiectcr (I'/iedioal Education) ...All teaching
hospitals.
2. Joint. Director (Health & Planning)
3. Joint Director(health &Edn.Training)
4. Joint Diroctcr(Communicable Diseases)
5. Joint Direct or (Leprosy)
6. Joint Direct or (Malar ia)
7. Joint Director (Medical)
8. Joint Direct or ( Ophthalmology)
9. Joint Director(Government Medical Stores)

4;

These Progranmes, the Joint Directors shall verify
the stocks at random in various hospitals, centres,
units anj institutions during their tours in the
districts, in addition to their normal duties and
furnish separate reports to the Joint Director
(C '*ver nme nt ■ Med ical St or e s)j asper. Annexure-IV t o this;Circular.
'
4 *
*•
/ C HNKRAL

>

30. The Director of Health & Family Welfare Services shall
ensure strict adherence to these Circular instur ct ions - The
Joint Director(Covernment Medical Stores) shall be directly
responsiblev to ensure compliance to these Circular instmuc.t ions.
■■

31 •

•

-W'

■

'

’

This circular shall come ■ into force with immediate effect.
L<-..

GUA-----GO..*--

^.4'

(B iPRASABNA KUiviAR)
;
■
'‘rj.
Under Secretary to-Government',
; 1 O ; OO^lth. & l-'amily Welf ar e Depart r:e nt .

'
100.: 00 '
To:
.1.00<:...
1 * The Dire’ct.or , • Ho r-.lt h ^Family Welf are Services , Bangalore
2. The Birecto.r , Medical Education, Bangalore.
3» The Joint Director • ’ Government Medical Stores, Bangalore •
4. The Chief .Secretary, All Zillapar ishads.
5. All DistrictWealth ^ FamilyjWelfaredOffi
YS^The. Ch ief ■ Supervisor ,'d‘Giyexn me nt Medical St ores , Bangalore
7. All District-Surgedns. J; :’’' <
WBW
8. All .Joint.:.W
9. All Superintendents, Districts
Likuxxcib auu
and iviajux
Major r.Hospitals*
10. Finan c?’ Department/' Planning iDe part me nt. '
11. P.S.to Hon,’ ble’.'Minister' for-Health & Family Welfare.
12. P.A.to' Secretary (H) d.' (p.W), Health & F .W.Department
13- The I »F .A., •heal t h’& F .W .Dep art me nt.'
14 . All Under-Secretaries in Health &/F.W .Departme nt .
15* All Section Officer*3 in
Department
in. hvw
hw'Be
part me nt 16. S .G .File/spareg.
'
.

.

*

.

•

■

•-

•... 1 \

•

jj

annexure-i
ANN'AUIR TO SCVERNMENT .CIRCULAR NC.HFW 217 HPC 92
DATED 7TH SEPTEiiiBER-1992.

1 .

... 6. H-lAD cf the institution
(251 CHARACTERS)

INSllTUT IlN CODE (

• •

7. INSTITUTION NAME

2.

.(25 CHARACTERS)

.L..U DG xJT i v -J» j--2’-' tiB

INSTITUTRN PLACE
(25 aiAEAGTEl)S)

b.

4 . jjXi J..NDI: jp- •<

E. BALANCE

9, TALUK & DISTRICT
10. PIN CODE

LRUG CODE

NAME OF THE
ITEM

LAST
,STOCK QTTY
FUR’-'ULA- YEAR « UN
REIRN
CCNSUM- HAND 'QUIRED
PT ICN'

■

/

--C ■ ■

;
.

-

•

■

,

SIGNATURE OF THE INDENTING

-

• ■■>e7iSAcai, .oiticbh W.ITH SEAL.-

.

..

Z; -ii

. .
.

■.

’

■

? PTO

EA.;
.■■■■■•■■■

-

MMS/**

AMCU NT

: ■■

NG. CF ■iT.J'S
to.

RATE

T.4P(J

•

.

\S.

QTTY
IN

' ; : R.'

w .

■ ■

' ' ' ’I'
/ -.j

A •

.
R. R ■

AO iXUBE TO ’ GOVT-.. jl.itUULaR'NC.IIFW 21? I-1PC 92,
; 7'191 SEPTEMBER 1992.

DATED
\

I'3r,CK.7S 'MANAGEMENT1 SYSTEM

A. RLC!._iI.ING J ilij-1.. rJv.-xS

TriD AND CODED INDENTS

u. DATr> lEiKY 'of THE l ND BL'IS

U. jjn.LA r 7«.b LD.-i 1J' ( N
i;'

‘

■ ■ ■

'

•

■

ACfeiyYSW RjJlOR'J?, REFLECTING TIE
iis.uluIxY. CF
cF THn
-CHn DRUGS 1>ND CcST CF THE INDENT
JII HILL
SENT.
TilE
Til-4
4 LL .'i.,1,
J[1 S
-L':'l±'' -Lt
'Ll 1113
Til JCIN1 DIR^CTGR(mEDICAL STORES)/
iIIE. ORIGINAL
CD
~.p
/"-f-iHCVAL. . 1HE.
INDENT AND I.A.RP ARE
0UBM-I1-J 1TR o CTUf INY AND ACCURACY OF THE DATA WHICH
OilCuldJ .jx.. D(N^ BY TIE I.P.O. FOR WHI JI H.,1 IS TULLY
n-AjoFChlo LjLjj.

Jj

'

.

. Ba.idD. cN INDiiNT ANALY-IS i iEPCRl’ FINAL ALLCOATICN AND
UTDiiEiCN IF STCCK FILl AND BUDGET ElLaLS AHN MADE IN
JCMfUTZti. ..
/

1

■

’’

•

F.

^CTE’PdIHIING. IN CCmPUTER AS PER THE QUaNTTIY
CF DIFtEneNT ITiMS ALLOCATED.

G.

J’'b
pjCOJKS ARE RECEIVED, THE STOCK FILES
ARB J1-D A TED. 1.. .v
■” -d j\.-1''-I

IL BuBJ ui Fib xS AkB

UiLA led as and when budget is released.
PURCHASE. SYSTEM

A. BAS.Jj CN ,iHE REQUIREMENT-.BCCKS',’’THE DATA ENTRY WILL BE
1 x/’r-r
cm,JK ljtOT '’/I-LL-B£. SUBMITTED: TO THEJCINT DIRECTOR
PaDIdaL STuttr-o) FOR VERIFICATION GF'THE DATA. B. iCN THE AERRCVaL IF THE PURCHASE. INDENT BY THE JOINT
D11<l.^(R(MEDICAL STORES) INDENT FOR CGUNrENSIGNATURE '
.JD li(i.U.O3SOD . PRINTED AND -SUBMITTED TO JOINT
CALCNGWITH CHECKLIST AND FLIPPY
llLj
Cd E' INFORM AT ION) FOR- SUBMISS 1C N 1’0
L li{01 Cii Qi H BbL i’H & • F. v/. 8 hitVI CLS .
Al’l hK^lt.fc.,CbIVlLVG TH.l CcUNIiJKSxGNBB INDENT, PURCHASE
SUBMITTED TO THEJCINT DIRECTOR
V M nJ u. A L u 1 (_ i\ j. 1) j
■.

v

■

'■

■■

'

;K. ■

.MO

f

Q

A JCCUl''T ING SYSTEM
A.

/iCCC’Ji-io RLOElv.'.uLES

B.

ROC (I, G:S R/iYRBL.J
lO'^DUiiji j?tR ThEASUKIES(BILLS GENERATION)

KAT.G DANTRACT SYSTEM
k.'-JFMIICED TO TH..RAPEUtic CCmmITTME
- V^a^CICNS WITH RTEERiJNCB to the’
.•d-mt •m~j,-tA1Lj NEEDS.
■

TO JCINT B Hl ECT CR( MED I CAL
SECRETARY er '1HE COMMITTEE

'r<;L'kl'YXnr^
■ l’" iJf’iPhH

- '• IV

1.L' 1

PJ,

C.

TENDER FCR-'S PRINTED i'CR THE ITEMS WHTGI-I Al?i?
^•iRCV.D BY THE TiiLNAPEUTIC COMMITTEE.

D.

,l"' ''b|1i’ :-;D:-,A ■I’CfiHS. WILL BE PRINTED AND SENT 1'0
i’l..l.uv;L'l.NAi.u FOR FLOATING- GF TLNDERS.

LJ .

R LiC
rdND-ais SS3

LVED AND CHECKLIST

S /’1E1A- nl - ™E J c™' ?m^CK(«BDIOlL S'l'CRBS) • . .■
4 ,
..

■■■

■

■

' a.

A:. IL

All " ■ Si'
KiINUNG- cE TrU-xwCPERTS COmITTEE. RECCmmENDAT IONS.

II.

FV^ER COMMITTEE RECOMMENDATIONS
--1«D DKLlriNG OF THE HIGH POWER COMMITTEE RECCMmENDAT LONS.'

I.

K/u’E

XNTKrCT. TO THE TENDERERS
•>

.L.I.i./f''l ’ ri J.O U ) •

/

i

' ■

\\

?'r\ '

/

.

■

i

■
■

I

'u.

•

■—

•

-.

.■

vr

■

I

aih^xure-tii

•

v"

.i

. If^re jo Gcvernirent.Circular NoLEZv_2.17_HPC_92 dated 7th SePtenber 1332
li81f_ye?rly
.yf?rlZ stock Verification
Verilio^ion..ccxtificatJoint
Certif ioa+^Wlrni n+ tDireAorlGovt.kAioal
^o r.+ ^
SA'

1 • Half Year ending.

h
Iteni

Unit

e) it L u Stores Injection
b) " A it Stores Tablets
c) ” Ep Stores
d) n C & B

Stocks
Stocks
Total
Total,
procured • stocks
st ocks
during
be
uU??’Jg -t
'tfae
Ji"
half ”
year.

Balancefron
4xe half
.
Year-fe;.
‘ ■■•Oh: -

■

'

;’r

Stores).
u. .: c, ;_.

■ f ’-'r o”

2. Dates/period of ver ii i cat ion :

3. Quantity of stocks;

.

.

..

■

'

, ■

.-

. . 4 ••

> .

-

' i; '‘ ■

'

Variation to
purchase orders
Excess Shortfall

-W--J .

• t-

St ere 3.
•' ■- I---.ry *V

(itemwise lists for each stores to be furnished & certified)

4- Nature of Stocks: -

Item

k:<’

Unit-

e) 'A' Stores Infection
b) 'A’ Stores Tablets
c ) 'B' St ores

...

:

•

Su "-standard

-Or '
/>’

v •

•;. : .- ■

. Bacaged

Bate expired

;W

'A:,: -

■

’■

■

J A'-i'A.-

■■

-

- ■

d) ’ C*D' Stores

(Itei:iv?ise 1 lets ‘as’ per. observation).
o • ■.■ r/l' c of Stocks
s . in lakbsf .Value' of: opening j ^Stock.
____ ~______ ' .b'; - purchased
’A’ Stores Infection
bj ■ /- *'>St or es Tablet s
-

c)
Stores
) !CdJ! Stcrso-

y -‘-

"■

.

.

'

-

’

Total
Value ■

-■

■■

-

- - - /jr-

Total:

(Value Storewise only)
6. General Observations.

■- ■■

.

' >

h

tCA<_KUjk,-+’

_>

rvx-icLci^I

? kc!A/\A,<C<-^'>^\

F b/A

(4^

S' b /A

S-4?

-Sts. w->i

^u^ iy- £

4 Sy

iludb ■
^Cck^jweU -

1

□' b

i

s
f }A C>
?^AA^<v...<j_b> '■]

t C.C tj<-1\

stLv^c-i
iV^x V'-Cx.a

— b

-

)

-'IS

\ 'S c

/!

Joint Di rec tor

(Government Medical Stores)

Duties and responsibi1ities

The Joint Director ( J . D . ) , Government Medical Stores, is the Head of
of
the
the
Department
of Med ic a 1 Stores and is in overall charge
department.

He/she
is
the
controlling authority of all
t he
Government Medical Stores.
The sections are

*
*
*
*
*
*

the

sec tions

of

the

Chie-F Supervisor section
Packing yard
Purchase section
Accounts Section
Stores (A,B,C and D) and
O-Ffice (administration)

comparative
tenders,
preparing
Floating
He/she
will
assist
in
Con trac t.
the
Rate
to work related to
statements
and
attending
and
He/she will also
a 1 so assist in the work of the Therapeutics, Expert
High Power Committees.
He/she is responsible for the purchase of the medicines.
and equipment as per rate contrac t.

instruments

He/she will ensure that reorder levels and economic order 1 eve1s are
orders
place
and
for
the items under rate
contract
worked
out
on
time
.
adequate
supplies
advance
to
ensure
su-f-F ic ient ly in

He/she will work out the ABC and MED analysis and practices of’
material management.

good

quotations

and

Rate Contract firm fails to supply when the purchase will
t he
m a d e at the risk and cost of the R.C.Firm, or
equi remen t.
emergency
there

be

He/she
will
make
local
purchases,
following store purchase rules, when

cal ling

for

will be 1 irni ted to Rs .
The financial powers for such local purchase
at
(the
purchase
for any item
25,000/- for any individual purchase
over
this
ceiling).
In
case
there
cei
1
ing
).
a time should not be split to get
obtained
is
need for exceeding the financial limit, orders must be
and
Family
Welfare
services
or
the
from
Director
of
Health
Hea1th
the
powers
of
the
Director
of
Health
and
Government
if it exceeds
Family Welfare services.

)

He/she will

wi 1 1
He/she
least
once
work .

ensure the smooth working of the department.

sections,
at
call periodical meetings of the heads of
future
the
and
plan
a month,
month, review progress of work

supplied
t hat the drugs purchased, in stock and
He/she
wi 1 1 ensure that
and
that
the
drugs
are
meets the needs for rational use of drugs.

safe and are not banned;
of good quality and according to specifications;
according to the rate contract.

and

The Joint Director wi 1 1

along

control ,

Joint Director will be responsible for quality
T he
with the Chief Supervisor.

investigate complaints about

short supplies received by the indentors,
substandard or spurious drugs, and
such other matters regarding supplies,
and take appropriate action.

stoc k
taking
and
The
Joint
Director will arrange for periodical
Di rec tor,
physical
verification and the report will be sent to the
Health and Family Welfare Services for further action.

The
annual stock verification will be conducted by the
of Health and Family Welfare Services.

Di rec torate

con f iJoint Director will maintain all performance
appraisal
T he
appropriate
dential reports of the staff in the Department and take
action for improvement of the Department.

resources
development
He/she
will take necessary action for human
and continuing education/training of the staff in the department.

The
Joint
Department.

Di rec tor i s the Drawing and Disbursing

of

t he

Services

and

Officer

The
Joint Director reports to the Director of Hea1th
Family We 1f a re.

DUTIES AND RESPONSIBILITIES OF THE CHIEF SUPERVISOR

1 .

to
the
The
Chief Supervisor is next in rank in Administration
shall
Joint
Director,
Government
Medical
Stores.
He/she
Di rec tor
discharge all the administrative duties when the Joint
is on leave or on other duties.

2.

is responsible to receive all supplies from the
various
He/she
with
whom
orders would have been placed
by
the
Joint
firm s
Di rec tor , Government Medical Stores or by the Director of Health
supplies
are
and
Family Welfare Ser ices*, he ensures that the
received on time and i n conformity with purchase the orders.

3.

of
the
He/she
will compare the quality and the specifications
approved
by
the Firms with
that
of
the
supplied
materia1s
any
Joint
Director,
and
bring to the notice of the
samples,
obta in
shortcomings
in the said
supplies
and
or
vari ations
for
The Chief Supervisor will be
responsible
his/her
orders,
quality control along with the Joint Director.

4.

of
"DAY
Chief
Supervisor
is responsible for maintenance
The
book
the
said
make
entries
in
of
purchases
day
to
day
and
BOOK"
Joint
of
the
initials
h is
signature
and
obtain the
under
for
each
transae
t
ion
.
Di rec tor

5.

ar t ic1es
of
the
for the safe custody
He/she
is
responsiblehim/her
to
by
they
are
handed
over
as
received
till such time
the concerned stores.

6.

of
is personally responsible also for the safe delivery
He/she
entries
necessary
to
the
concerned
stores.,
and
make
the
stock
the
full
obtain
signature to that effect and
own
under
his
(
Graduate
stores
the
receiving
officer
at
the
signature
of
Pharmaci st) .

7.

He/she
is responsi b1e
from various firms and
when
and
samples
as
and
Health
Di rec tor,
Commi t tee.

S.

wi 1 1
He
off.

9.

investigate
any short or
faulty
compliance
He
wi11
indenters and obtain the orders of the Joint Director.

10.

He is responsi b1e to maintain uptodate the following registers

maintain a

received
for the safe custody of samp1es
the
undertake
to
demonstrate
he/she will
GMS
or
Di
rec
tor
,
required by the Joint
Ex
pert
or
the
Family Welfare Services,

eg ister of samples received

and

di sposed

to

the

:

i )

fail
to
who
particulars of RO Firms
Register
providing
par tia1 1 y
comply
with the supply orders either in full or
of
drugs
indicating
orders
No.
and
date,
particulars
placed
t he
ordered
for supply, financial value of the
orders
for supply.

ii )

replaced
by
particulars of drugs not
Register
providing
Drug
Conwhen declared substandard by
the
fresh
stock
troller, indicating batch number, date of expiry. quantity,
financial value.

}UTap a'_|4

04

sq. jodaj

jqst Auadng

j- axqn

•AiaAxqsqx yenb pue
fo
saxiddns
aqenbape
buxunsua J04 'JJTq
,i saui dt pauj
X[aATqeqiquenb
qaxqw AqxAxqae uaqqo Aue qno Ajjea [IJM
an
oq
paqsnjqua aq Aetn

*02

• aqsem fo qesodsTp
j.o ssauixueaia uadoud aq+ JQf a 1 q Tsuodsa_4 st an

*6T

jOf uoiqoe
- quaojquedap aqq j-o Buiuoiqaunj- qq.QOUJS aqq.
aq
IITM
pue
waxAaj
oq ‘qquow e aouo ueqq ssa{ qou piaq
ut
X.iaATqoe
aqedTOTqued
utm
3H
‘ sSuxqaauj { eq uaiuq jedap aqq

*81

pue uoxqaas jaqndiioa oq Aep buppOM
sdnjp 40 qjodaj Ayrep puas ittm
an

*ZT

■ q jodaj leox-qAieue
eqeqeuje;4
ut janojquog sbrua aqq
oq
paAxaoau
uojPuTUie^qa
saidujes
buxqsxujnf
J04
apqxsuodsaj
st an
4-0 qaq.eq qoea j-o

*91

•pai{ddn5 sonup j-o qaqeq qaea uoj- sjajnqaepiueuj
squodau yeaTqA-ieue aqq DUTUTeqqo jqj- axqxsuodsau st an

•ST

pile

sasiwajd

a'-ieq.
q atqm

aq}

• A x snoaueq { ntuxs
Xue

aqi

uo

• uj
uj *• d

UJO J j-

j

oq d n

sauoqs

pa a x a aa j

•joqaajTQ quxop aqq oq quodau pue
suadaa>|
sauoqs
paujaauoa
aqq 40 sq uawadpa { mou>< ae
lq.aaj-j-a qaqq. 04
pa 1eas
a
Aep
qaea
40
pua
aqq
qe
aauasajd ^T’4 1JI
a>jeq.
pue
shot jeA
A
[
aunaas
pa>jao{
Afuadoud
aue
siuoqj
/
sa
joq
s
paso{a
pue
j-o />.q t 1 yq Tsuodsau aqq st qi
aq4 qeqq aas oq uosTAjadns 4aT4‘3 aLl4

4^
aqi

-qoueu qsj£ pue jaqaiaoaG qsj£ ^uaqujaqdas
Suxpua
jaqjenb buxpaaoajd qaea
40
pua
aqq
“aunp
qqo£
J04
sdnjp
aqq
40
qaea
40
quaujau
t
nba
j
‘JeaX uaquenb qxau aqq
him
oq
sqjodaj
qpuqns
pue
qno
;jUOM
utm
an
uoqaauTQ
quxop aqq

* VI

*£I

* uot q. ae

s fi n j p
Xue
J-Q
oof Outm -jaqndiuoo aqq oq
pue
buipjoaaj
6u t qeq
{qisuodsaj
st
an
40 aaueqsux aqq A yaqex pawuJT ujuofux oq a
buiuueq

•suauxequoa aqq wajjA>jea{
punojj-x
syeoTtuaqa
pue
s5n.jp
‘ paqeuoxuaqap
pue
pauaj- t yd
‘
pjepueqsqns
pajepap
s5njp
‘
Auxdxa
40
aqep
sdnu p
aue
qaxqw
pa{xe4
oqw
swjtj
snoxueA
wqji
sdnup
j-u
sdnup aaeqdaj oq
&ut J.eau
apqxsuodsaj
aq
IIJM
aqs/an
jaA.oaaj oq uoTqae buT^eq JOJqsoa aqq

•pua jxaqq qe uDTq.oe
pue
a^eq
04 pue dn ijaaqa oq uoiqaas _jaq.ndujOD aq4
jaqqjnjJ-O
J° Aauaqod
aqq oq >|Ooqs ut aSrup aq4 j.o
paujaduoa
sauoqs
uaqqi
um
aq.ou
AiaqTi aqq j-o aaueApe ut sqquoo aauqq
Ajidxa
uaqst day
J-Q
I Itm
pue ‘■aqep Z.JTdxa duT-jeau sdnup
e
puas

-sonup pxes aqq 40
an { eA {eT3ueuT4 ‘sSnup 40 Aqxquenb - jaqunu qaqeq buxqeDTpux
aqq Aq •J04 pa^se uaqw paaeydau qou aue qaxqw Auxdxa
siuu T jaqep
buxjeau sbrup 40 sue1naTqaed
buxpxAOud
jaqsibay
J-o

<ttt

*21

* I I

Medical O-f-Ficer in charge of Packaging, Yard (M.O.P.Y.)

He will
The Medi c a 1
Officer is in charge of the Packaging Yard.
discharge the duties of the Joint Director, when both Joint Director
and Chief Supervisor are not available.
respon sible for the cor rec t despa tc h of
The Medical
Officer
is responsible
af ter
them ,
pass
articles.
He/she will receive the indents and
■For
t he
1 eve1s of
scrutinizing
them for
levels
supply appropriate
institution and availability of budget.

M,O,P.Y. will exercise proper supervision over the packing yard
during the actual packaging of the materials.

and

He/she i b responsib1e for getting the compiled indent entered in t he
to the
gate pass book under his/her signature and submit the same
J O i n t Di rec tor,
c e r t i Fy the delivery note that the packing was under
He/she will
that
His/her assistants
assi s tan ts will
certify
d
i
r
ec
t su per v i s i on.
his/her
( s)
done
in
his/her
presence.
The
packers'
name
the packing was
the
columns
in
used
,
with
the
number
of
boxes
shall
be noted,
provided,

M.O.P.Y, is e spon sible f o the correct delivery of t he goods to the
1 o r r y d r i v e r or clerk, in the presence of the watch and ward .

He/she is responsible to obtain the indents for packing mater ia1s on
t he
time,
ensure supplies and maintain the correct accounts of
shou
1d
Packing
work
packing materials received from the contractor,
not suffer From want of packing materials.
He/she is
section.
M,

e s pon sidle f c< r the strict discipline of the staff in

, P , y. w i 1 1 report to the Joint Director.

t he

DUTIES AND RESPONSIBILITIES OF THE GRADUATE PHARMACISTS

1 .

per sona11y
The Graduate Pharmacists in charge of stores will be
under
their
the
articles
responsible
for
the safe custody of
in
safe
and
proper
thei r
charge
and shall exercise proper care
storage.

They ■will receive the stores f r cm the Chief Supervisor
w he n
he
calls for them to do so and make proper entry
s toe k ledgers and keep an account for them.
"T

They
p r o m p 11 y i s s u e s t o r e s
wi 1 1
i n dent s are placed for the same.

t o t h e pac k i r< g

ya r d

as
in

and
the

wherever

4.

m a i n t e n a n c e o F all stock
They will be responsible for the props
ledgers day-to-day and see that both the receipts and issues are
entered under their initials.

5,

They will submit a list of drugs which
stuck
every
fifteen days without fail
ever y
Government Medical Stores.

6.

The Graduate Pharmacists will

i r<
equ ire rep1en ishment
to the
Joint
Director,

be watchful

o -t

the drugs:

necessary

i }

to become time barred and take action as
1ikely
under the advice of JD,GflS;

ii )

drugs coming under cold chain system are properly stored at
n o other items
the
low temperatures as required and no
other
than drugs are kept in the refrigerators;

i ii )

watch narcotic and addictive drugs;

)

find
drugs banned by Drug Controller
do
not
t ha t
wa tc h
on
way in
into
to the stores; in the evert such drugs are
the i r
and
they
are
a
r e immediately identified and destroyed
stoek ,
d iscounted from stock under the orders of Joint Director;
whether
longevity of drugs as at the point of supply;
t he
RC;
if
have 75 per cent of life if supplied through
they
Di rec tor
immediately bring it to the notice of Joint
not
and s e e k h i s o r d e r s .

7w

a

maintairing
The Graduate Pharmacists will be res pon s i b1e f o r
first
batchwise stock and issue drugs batchwise., on first in
out basis.

b)

are
ref rigerators
is his/her responsibi 1ity to see that
a
day
and
inside temperature measured twice
and
examined
report
It is his duty to immediately
twice a day.
recorded
to Joint Director if be f i n d s any refrigerator faulty or goes
out of order.

8.

The
Graduate Pharmacists
are- personally
responsible
f or
furnishing annual requirements of the respective stores for
the
preparation of
the consolidated annual
medical
indent
of
twelve
Government Medical
Stores,
keeping in view the past
months stock expenditure and balance.

9.

They will be responsible for strict discipline amongst the sta-F-F
working under their control.

10. They will
promptly report to the Joint Director when
they
suspect that any of the staff is not discharging his/her duties
proper1y or when he/sFse may be involved in any irregular ac t.

1 1 . They will be respon s i b 1 e for the correct entries in the delivery
notes and for getting the ledgers and delivery notes verified by
the internal auditor ( one of the FDA to function as internal
audi tor) .

12 . They will see that the doors, windows and other possible entry
points of the stores are closed securely and sealed in his/her
presence at the end of the day's work and certify to that effect
in the register maintained by the Chief Supervisor.
The Graduate Pharmacists report to the Joint Director.

0

2?

S-1
2 S'-----S

0

B

?<n
m

I

•X>

S S.

£ 5’
uO

era

a"
an
C3

r>

a>

tl O1
CT ?

JX

T

a
~i

g3
ra

cu

i

3

tn

tn

a

g=>

HU

!
ex

<-►-

Is

an

5

on

n
CM

an

cn
a

ro
in

n.n

if
m
rn

1

in

CT

a>
-r,

xr
rti

I

on
rrj
rn

3

•— •

S"

rq

r-<-

S

5 s

an
CT

i-•

g.
5

5

•1
tel

g

£

i

Joint Director

(Government Medical

Stores)

71

Duties and resoonsibi1ities

The Joint Director (J -D. ) , G o ■/ e r n it< e n t M e d i c a 1 S t o r" e s ;l
t h e D e n a r t m eh t o F M e d i c a 1 51 e r e s a i i d i s i n o v e r a 11
depar tmert»

H e / s i "f e i s t if e >::: o n t r c 11 i n g a u. t h o r' i t / o -F a 11 t he
Government Medical Stores»
The sections are

is the Head of
barge oF thss

sec tiers

the

qf

i C i “i i e F S u. p e r / o sec t ion
$ Packing yard
F’ u r c h a s e s e c t i o ra
% A c c o u i ■» t s S e c 11 o h
■t Stores <A?B?C and D) and
t OF -fie e ( a d m i n i s t r a t .1 o i "s
prepari
nq
ass ist in
F I o a t i. n q
t e n d e r s,
p
rep a r i n
q c s m p a r a t ;i. v e
He/she wil 1
statements and attending to work relates! to the Rate Cor tract. z ?he
w i 11
a 1 s {■::« a s s i s t i " "I the work oF the Therapeutics? Expert and High
F‘ o w e r C o m m i 11 e e a .

H e / s h e i s r e s p c? n s i b 1 e t o r t he p u r c h a s e o F t. h e
a n d e q u i. p m e r< t a s p e ■ r a t e c <") n t r a «

ed i c i n es

instruments

He/she will ensure? that reorder levels and economic: order levels are
p 1 ace order s.
worked out for the items under rate contract and
s u F F i c i e n 11 y i n a d v a n c e t o e n s u r e a d e q u a t e s u. p p 1 i e s o n time..

He/she will wprk out the ABC a n d V E D a n a 1 y s i s a h d p r a c t i c e s o f
m a t e r i a 1. m a r: a q e r>’ • e n t..
purchases
e / s hi e w i 11
rn a k e 1 o c a 1
•F o 1 1 o w ;i. n g s t o r- e p u r■ c h a s e t- 1 os when

ca11ing
J?!.'' -I'

good

quotations
'(i- e‘'' hrJ-'

and

'b’. At't:

h s E a t e C o n t r a c t F i m •;/ i 1 s t o su p p 1 y z o r
111 e r e .i r e ■■. e r ’ g *u e " ’ e □ u. i r e m e n t..

we r e w i 1 1 b e I - f > i t e d t. © F:
2 5 000 /.
T he fn an s .1 a 3. pow e ■ - s F o r •:>
•For ■ any ind w idue j pure ns ;• e z-; ths purchase For anv i tem at a time
I n c a s t h e r e is
should not be so :.
to get over t. h i s c e i 1 i n q )
n s ■ d F o ;■ • e ■ s e e "i .i ;• i q t fa e f i;• - r- c i a 1 11 m i t, a r d e r s m s t. b e c< b t a i n e d f r o tt.
/ Mel Fare services or the Government
iF
D ,i
t o r o -f He a 111; a n d F a r
e e e s k h e n:j w e r s o F the Di-ector o-F Health and Family Mel -f are
serv

i

4 -

He/she will ensure the smooth working of the department.

He/she wi 11
1 east once
work .

cal 1 periodical meetings of the
a month. review progress of work

heads of sec t i ortf,
at
and
p 1 an the future

S

He/she will ensure that the drugs purchased, in stock and supplied
meets the needs for rational use of drugs,
drugs that the drugs are
A.

— safe and are not banned;
- of good quality and according to specifications; and
a c c o r d i n g t o t h e r a t e c o n t r a c t.
The Joint Director will be responsible for quality controlfy
The Joint Director will investigate comp1aints about

- short su pp1ies received by the indentors?
-- s u b s t a n d a r d o r s p u r i o u s d r u g s , a n d
- s u c h o t h e r m a 11 e r s r e g a r d i n g s u p p 1 i e s j
The Joint** Director will arrange for periodical
stock
taking and
p h y s i c a 1 v e r i f i c a t i o n a n d t h e r e p o r t w ill b e s e n t t o t h e Di rector
H e a11 h an d Fa mi1y We1f a re Ser v i c es f o r f urt he r ac t i on„
The annual stock verification will be conducted by the
of Health and Family Welfare Services.

Directorate

Hci?/-*H-*e w i 1.1 m a i n t a i n a 11 p e r f o r m a n c e a p p r a i sal c o n f .1. d e n t i a 1
r e p o r tS
and take appropriate action for improvement of the Department.
He/she will take necessary action for human resources development
and continuing education/training of the staff in the department.

The Joint Director is the Drawing and Disbursing
Departmen t.

0 f F ic er

The Jc<in t Di rec tor reports to the Di rec tor of Hea 11h
F a m i 1 y We 1 f a r e .

of

the

Services

and

u-

AlLv\/\A^

DUTIES AND RESPONSIBILITIES OF THE CHIEF SUPERVISOR

1.

The Chief Supervisor is next in rank in Administration
to the
He^shal
J o i n t D i r e c t o r , 0 o v e r n m e n t M e d i c a 1 S t o r e s»
H
s h a 111
d i sc harg e
.is on leave or on
administrative duties when the Joint Director is
other duties.

2.

He/xs responsible to receive all supplies from the various firms
J o i n t Director,,
whom orders would have been placed by the Joint
Government Medical Stores or by the Director of Health and
Fami1y We1fare Services; he ensures that the supp1ies are^ in
c o n f o r m i t y w i t hi p u r c h a s e o r d e r s.

y/Zryt-C.

/i^~

3-

He will compa re t he qua1i ty an d the specifi c a t i on s o f the mate.
r i a 1 s s u p p 1 i e d b y t h e F i r m s w i t h t h a t o f t hi e a p p r o v e d s a m p 1 e s ?
and bring to the notice of the Joint Director., an/^variations or
shortcomings in the said supplies and obtain hisy^irders.
The
along
Chief Supervisor will be responsible for quality control
w i t h t h e J o i n t D i r e c to r .

4.

•Me-^is responsible for maintenance of "DAY BOOK" of purchases day
to day and make entries in the said book under his signature and
obtain the initials of the Joint Director for each transaction.

5.

He- is responsible for the safe custody of the articles received
till, such time as they are handed over by hiy/'t.d the concerned
stores »

<S»

Hy

7„

He/is
from
IS responsible for the safe custody of samples received
various firms and he/Vi 11 undertake to demonstrate the samples
a s a n d w h e n r e q u i r e d b y t he J o i n t D i r e c t o r ., G M S o r D i r e c t o r ,
H e a11 h and F ami1y We1fa r e Service s, o r t he E x pe r t Comm i t tee.

8„

He will
of f .

9U

ty
He wi 11
investigate any short or fan
fau11
y comp1iance
indenters and obtain the orders of the Joint. Director.

10

H e i s r e s p o n s i b 1 e t o m a i n t a i n u p t o d a t e t bi e f o 11 o w i n g r e g i s t e r s :

s

A

is personally responsible also for the safe delivery of the
s/ock to the concerned stores., and make necessary entries under
stoc
his own signature to that effect and obtain the full
signature
o f the receiving of f icer atAstores (Graduate Pharmacist).

maintain a register of samples received

and

disposed

to

t he

i)

to
Register providing particulars of RC Firms who fail
comply with the supply orders either in full or partially
i n d i c a t i n g o r d e r s N o . a n d d a t e., p a r t i. c u 1 a r s o f drugs o r -■
for
dered for supply, financial value of the orders placed
supp1y«

ii )

by
Register providing particulars of drugs not replaced
f r e s h s t o c w hi e n d e c 1 a r e ci s u b s t a n d a r d b y t h e Drug Control
guan ti ty ?
1 er
indicating batch number ? date of expi ry
•f i n a n c i a 1 v a 1 u e .

z^

i i i) Reg i s te r pr ov i d i n g par t i c u1 a rs of drugs n ea ring date of
f i rms
expiry which are not replaced when asked for, by the
indicating batch number, quantity of drugs, financial va 1 ue
o f t he sa i d d r ug s .

')

send a
Register of drugs nearing expiry date, and will
written r i o t e t h r e e m o n t h s i n a d v a n c e o f t h e 1 i k e 1 y expiry
potency of the drugs in stock to the concerned stores
of
the computer section to check up and to take f u r t he r
and
a c t i on a t t he i r en d .
AXx
11 „ He/wil 1 be responsible for taking action to recover the cost of
•f rom var ious f i rms who failed to rep 1 acej d rugs nearing
drugs
date of expiry, drugs declared substandard
substandard,,
drugs which aredeteriorated,
drugs and chemicals if found 1eaky and pi 1 -fered
fro m t h e c o n t a i n e r s .
i v)

e>

/

banning
12. He is responsible to inform immediately the instance of
taking
of any drugs to the computer wing for recording and
ac tion.
13. He will work out and submit reports to the Joint Director t he
at
requirement of each of the drugs for the next quarter year.
the end of each preceding quarter ending 301h June, 30 th Septernberh 31st December and 31st March.
14.

the
Chief
Supervisor
11 i s t h e r e s p o n s i b i 1 i t y C3 f t
he C
hi i e f S
u per v i s o r tto
o see tthat
|-f a t t h e
osed
v a r i o u s S t o r e s / r o o m s a r e p!" o p e r 1 y 1locked
o c k e d sec u.
ure 1 y ,
cc11o
s e d ra n d
sealed in his presence at the end of each day's work and take
acknowledgements of the concerned stores keepers to that effect,
and report to the Joint Director.

15. He is responsible for obtaining the analytical reports -from
manu-facturers -for each batch of drugs supplied.

1

the

. He is responsible for furnishing samples of each batch of stoc k
received to the Drugs Controller in Karnataka for obtain inq
an a 1 y t i c a 1 r e po r t«

17. He wi11 sen d d ai1y r e por t o f d r u g s received u pto 1 p.m. on
wo r ki ng d ay to c om pu te r s ec t i on an d store s s imu11an eously.

any

18. He will participate actively in the departmental meetings, which
will
be held not less than once a month., to review and take
act i on f o r t h e s m o o t h f u n c t i o n i n g o f t. h e d e p a r t m e n t „

19. He i s r es pon s i b 1 e -f or 11"!e p r ope r c 1 ean 1 i. ness o f the pre m i ses and
dis pos a1 o f wa s te»
20. He will carry out any other activity which may be entrusted
•f o r e n s u r i n g a d e q u a t e s u p p 1 i e s o f m e ci i c i n e s , q u a n t i t a t i v e 1 y
q ua 1 i ta t i ve 1 y .
The Chief Supervisor reports- to the Joint Director.

him
and

Medical Officer incharqe of Packaging Yard (M.O.P.Y.)

r

7

.h

//

The Medical Of f icery irlc. harge of the Packing
'v' j Yard.
He will discharge
both
Joint
Director
and Chief
the duties of the Joint Director;, when L-L:.
S u p e r v i s o r a r e n o t a v a i 1 a b 1 e.

The Medica 1 0
fficer is responsib 1 e for the correct
correc-l.: despateh o f
Officer
after
articles.
He/she will
receive
the
indents
and
pass thej/.,
wi 11
the
scrutinizing
them for
levels o
off supply
, ,
appropriate for
r-»c;
o f budget.
bu d g e t. // M.O.P.
M.
institution and availability of
y.
will
proper supervision over the packing yard
yaro and during the actua1
packing of the materials.

He/she is responsible for getting the compiled indent entered in the
gate pass book under his/her- signature and submit the same to the
J o i n t D i r ec t o r »

certify the delivery note that the packing was under
He/she wil 1
that
certify
d
i
r
ec
t su pe r v i s i on .
H i s / he r a ss i s tan ‘I.s w i 11
his/her
( s)
name
The
packers'
i
was
done
in
his/her
presence,
the packing
•
columns
usedn
in
the
with the number of boxes
shall
be noted.,
provided»

M.O.P.Y. is responsible for the correct delivery of the goods to the
1 o r r y d i- i v e r o r c 1 e r k , i n t h e p r e s e n c e o f t h e w a t c h a n d w a r d ..
He/she is responsible to obtain the indents for packing materials on
the
time,
ensure supplies and maintain the correct accounts of
s hou1d
packing materials received from the contractor^#Packing work
n o t su f f e r f r o m w a n t o f p a c k i n g m a t e r i a 1 s .

<a

M . 0 . P . Y . wi 11 report to the Joint Director.
fi

Ar

DUTIES fiND RESPONSIBILITIES OF THE GRADUATE PHARMACISTS

1 ..

'J

The Graduate P h a r m a c i s t s i rl c h a r g e o f s t o r e s w i 1 1 b e personally
their
re spons i b1e •for the safe Custody of the articles under
c h arg e and sha11 exercise proper care in their safe and proper
storage.

T hey will receive the stores from the Chief Supervisor
h e calls f o r t h e rn to do so and make proper entry
when
stock ledgers and keep an a c c o u n t f o r t h e m .
yard

as
in

and
the

whenever

3.

promptly issue stores to the packing
They will
indents are p 1 a c e d f o r t h e s a m e .

4.

They will be responsible for the proper m a i n t e n a n c e o f a 11 s t o c k
that both the receipts and issues are
ledgers day-to-day and^ere^e- tna
e n t e r ed u n d e r t he i r i n i t i a 1 s .

err

They will submit a list of drugs which require replenishment in
stock every
fifteen days without fail to the Joint Director.,
G ov e r n m en t M e d i c a 1 S t o r e s «

6j «

T h e G r a d u a t e P h a r m a c i s t s w i 11

A

b e w £11 c I" r -f ti 1 o f t h e d rugs ::

i)

likely to become time barred and take action -M-m® as sxs?
necessary under the advice of
? GrMSj

;i. i )

drugs coming under cold chain system are p r oper1y s to red a t
the
low temperatures as required and no o t bi e r i t e m s o t h e r
than drugs are kept in the refrigerator^,

i i i ) watch narcotic and addictive drugs.

iv)

watc h that d r u g s b a n n e d b y D r u g C o n t r o 1 1 g r d o n o t f i n d
t he i r w a y i n t o t h e s t o r s ; in the event such drugs are on
destroyed
a r e immediately identified and
stoc k ,IAif bannod-T are
f rom stock under the orders of Joint
and discounted from
Direc tor.

v>

whether
longevity of drugs as at the point of supply;
the
if
they have 75 per cent of life if supplie^ through RC;
Director
immediately
bring
it
to
the
notice
of
'Joint
not .<
and seek his orders.

A

T

"1 be responsible for
a) jf:.. bi e G r a d u a t e P h a r m a c i s t s w ill
on
is
sue d rug s b a tc hw i se .
batchiwise stock
and :
--firs t— Borved ba si s.

main tainincj

•f i r s t — c ome ix_,

b) i t i s h i s A r e s p o n s i. b i 1 i t y• to see that r e f r i. g e r a t o r s a r e
measured twice a day^recorded
e x a m i n e d a n d ‘inside
: ~ temperature
.. .......
It is his duty to immediately report to J o i n t
twice a day..
Director if be finds any refrigerator faulty or goes out of
order.

8.

Th«*Z'A are
personally responsible
for
furnishing
annual
requirements of the respective stores for the preparation of the
consolidated annual medical indent of Government Medical Stores,
keeping in view the past twelve
xuhck

9.

They will be responsible for strict discipline among s t the staff
working under their control.

10.

They
will
promptly report to the Joint Director when they
suspect. that any of, the staff is not d i sc. ha rq i ng
his/ ^Ltties
properly or when h/^mf'y be involved in a n y i r r e g u 1 a r a c t'.

.1.1 .

They will be responsible for the correct entries in the delivery
notes and for getting the ledgers and delivery notes verified by
the internal auditor ( one of the FDA to function as internal
audi tor).

12. They wil 1 see t hat ±he doors,Kof the stores are c losed secure 1 y
1ed
and sea
sealed
in his/pr‘esence at the end of the day's work and
certify to that effect in the register maintained by the Chi^f
Supervisor„

/y4it
s

The Graduate Pharmacists report^ to the Joint Director.

□

i... ”1

s

IX'

I §■
tn

T>
i

§ =r __
<

Hi

.in.-

.

f—1
X»

I

S’:
If
”1

• . I

.s s

S’
'JX>

CJ------------

s. S'

g ■

-i

~CI

£

S'
v-i

X"

co

3-’

cn s; s?
£

O

’ g S.

:=i

"S. a g —
1.0
—-

r-4rp

in
i-iin

g
2.

-------- c.3

S'
S’

I

If

I?
1-3

I.

£

g

? I

ru

x 51

1

I '•
■ £

S'

g..
5

> r-f

:

rt
n:»

___

;

k

aj

41

s
I

I?i
i ■t>

• E«

fXi

§

C3 ■

X3
rHrti

S'
in

rV

s__
§
S’

i

3

CM
=3

g

g

o’

oi

ex
n
DU

icn

jo
|in

SL.
NO.

ITEM CODE

ITEN

CLASSFICATION

PACKING

UNIT RATE

QUANTITY

AHGurr

100100-

Akflinium Hydroxide - 500®q Tab.

B

1000

5,000.00

143.00

- 740,000.00

2

100200

Magnesias Trisilicate - SOOsg Tab.

A

1000

12,000.00

144.00

X 1,723,000. oO

3

100600

Atropine Sulphate - O.Sag/al Inj.

B

1 as?

900,000.00

1.05

945,000.00

4

101000

Paraffin Liquid

C

450®l

700.00

40.50

28,350.0V

5.

101401

Loperamide - 2fflg Tab.

A

100

35,000.00

39.50

^1,332,500 .JOJ J

6.

101600

Digoxin - 0,25sg

C

500

1,000.00

93.50

■' 98,500Jj-.''

7.

103000

Mephenterffiine - 30mg/aI

c

lOffll

12,000.00

34.46

413,520.00

3.

103001

Mephentersine - ISsg/sI

C

Isl

2,000.00

2.72

5,440.00

103455

Spironolactone - 25mg Tab.

C

100

200.00

113.40

22,630.00

10.

103500

Adrenaline - 1 in 1000/

E

Is!

66,000.00

1.60

105,600.00

11.

104300

Acetylsalyclic Acid - 300sg

A

1000

35,000.00

30.00

2,800,000.00

12.

104900

Paracetoffiol - 125®g/5sl

A

450®l

30,000.00

61.65

4,932,000.00

13.

105000

Paracetamol - SOOsg

A

1000

30,000.00

172.50

5,175,000.00

13a. 105101

Pentazocine - 25ag IP Tab.

C

13b.

Pentazocane - 30sg/sl

14.

105300

Phenobarbitone - 30®g

B

1000

4,000.00 .

130.00

720,000.00

15.

105400

Phenobarbitone - 60ag

8

1000

3,000.00

330.00

990,000.00

16.

105200

Phenobarbitone - 200sg

C

1ml

2,500.00

2.15

5,375.00

17.

105500

Chlorpromazine - 25®g/sl

C

2d

13,000.00

4.31

77,530.00

13.

105700

Chiorprosazine - 25sg

C

IODO

275.00

172.12

47,333.00

19.

105800

Chlarproisazine - SOsg

c

1000

250.00

307.44

76,360.00

20.

106500

Prosethazine - 10sg

A

Promethazine - 25sg
Promethazine - 25ing/d
Promethazine - Ssg/Sd
20,293,733.00

)

8L.
NG.

ITEM CODE

I TEH

CLASSFICATION

PACKING

QUANTITY

UNIT RATE

AMOUNT
20,293.733.00

21

106700

Phenytoin Sodius - lOOso

L

1000

350.00

1,419.00

496,650.00

?2

106710

Carbamazepine - 200sq

B

100

3,300,00

190.60

628,980.00

23

107200

I bu pro ten - 400irig

A

1000

4,500,00

563.00

2,533,500.00

24

107201

Ibuprofen - 200fflg

A

1000

4,000.00

323.00

1,292,000.00

25

103400

Dexamethazone- 4®g/®l

A

2a 1

250,000.00

7.90

1,975,000.00

26

108500

Hydrocotisone sodium succinate - 134m.eq.

C

1 vial

7,500.00

10.75

80,625.00

108600

Prednisolone - Sag Tab.

A

1000

5,000.00

460.00

2,300,000.00

27

28

108601

Prednisolone - lOag Tab.

C

100

5,000.00

83.00

415,000.00

2q

109100

Glibencismids - Sag

C

1000

1,500.00

161.00

241,500.00

30

109800

Frusemide - 20mg/2sl

C

2®i

180,000.00

1.98

356,400.00

31

110600

Methyl E^qometyne - 0.2mg/ml

A

Is!

600,000.00

8.92

5,350,000.00 •

32

110700

Nethyl Ergoset/ne - 0.125mg

A

500

1,000.00

1,100.00

1,100,000.00

33

111000

Oxytocin - 10 lU/ial

C

l.OOffll

300,000.00

1.08

325,000.00

34

111300

Tetracycline - 250ffiq

A

1000

13,000.00

345.00

4,485,000.00

35

111500

Ampicillin - 250s»q

250ing

330,000.00

6.70

2,211,000.00

1,676.88

12,576,562.50

36.

111800

100 vials in CB8B

A

Ampicillin - 250ag Cap.

A

38.

112000

Chloramphenicol - 250fflg IP Cap.

39.

112001

Chloramphenicol - 1g vial

7,500.00

9.43

40:1)1

Ampicillin - 125sig Syr.

37.

1000

A

1000

4,000.00

2,000.00

8,000,000.00

A

60sl

50,000.00

22.93

1,146,500.00

Chloramphenicol - I50/5al

40.
41.
42.
43.

112300

Erythromycin
estolate i25mg/5ml
Erythromycin
oral 250mg

65,807,455.50

SL.
NO.

ITEM CODE

ITEM

CLASSFICATION

PACKING

B

1.00 via!

150.000.00

4.10

65,807,455.50
615,000.00

QUANTITY

UNIT RATE

AMOUNT

44.

112700

Benzyl Percillin - 5 lac IU (100 vials)

45.

112800

Benzyl Pencillin - 10 lac IU

A

1.00 vial

300,000.00

3.02

2.406,000.00

46.

112900

Procaine PenciIIiff - 4 lac IU

A

1.00 via!

500,000.00

6.38

3,190,000.00

47.

113000

Procaine Pencillin - 20 lac IU

A

1 vial

600,000.00

12.50

7,500,000.00

48.

113100

Benzathine Pencillm - 6 lac IU

C

1 vial

40,000.00

6.25

250,000.00

49.

113200

Benzathine Pencillin - 12 lac IU

B

1 vial

50,000.00

10.25

512,500.00

19.65

0.00

1 via!

Benzathine Pencillin - 24 lac IU

50.

51.

113900

Ethanbutol - 200inc IP

A

1000

6,500.00

470.00

3,055,000.00

52.

113901

Ethanbutol - 400sq IP

A

1000

1,300.00

877.00

1,140,100.00

53.

114000

Isoniazid - lOOmq

C

1000

4,000.00

74.00

296,000.00

54.

114300

Refaspic in - ISOag

A

1000

3,000.00

1,386.00

4,158,000.00

55.

114400

Refaspicin - SOOsg

A

1000

2,000.00

2,338.70

4,677,400.00

56.

114500

Streptomycin - 1g IP Inj.

A

1000

15,000.00

5,160.00

77,400,000.00

57.

115100

Clnfazisine - lOOmg Cap.

C

100

2,000.00

179.48

358,960.00

58.

115101

Clofazimine - SOmg

C

1000

130.00

864.00

15=.^0.00

59.

116500

Mebendazole - lOOmg/Sm!

C

30ml

1,750.00

8.19

14,332.50

60.

116600

Mebendazole - lOOmg IP

A

1000

10,000.00

1,103.33

11,033,333.33

61.

Metronidazole - 200ijg

A

62.

Metronidazole - 400ag

63.

Ferrous Fumarate - !50mg
t Folic Acid - 2.5mg

A

1000

25,000.00

105.10

2,627,500.00

64.

Ferrous Sulphate - 200mg
t Folic Acid - b.5ag

A

65.

Folic Acid - 5rag

C

66.

118900

1.7. Dextrose « 5Z IP

A

540$ 1

200,000.00

67.

119100

I.v. Dextrose - 252

C

25ml

25,000.00

185,197,101.33

SL.
NG.

ITEM CODE

ITEK

68.

119200

69.

119800

CLASSFICATION

PACKING

I.V. Dextrose - SOX

C

25a I

5,000.00

Godina Bicarbonate - 7.5X

B

25a 1

25,000.00

Sodiua Bicarbonate - 7.57.

B

10® 1

A

540®!

125,000.00

540®!

300,000.00

QUANTITY

UNIT RATE

AMOUNT
185,197,101.3:

70.
71.

119900

Sodiua Chloride - 0.9X IP

72.

120000

I.V. Dextrose 0.57. 4 Saline 0.971

73.

120200

Molar Lactate

B

540a!

40,000.00

74.

121000

Vitaain A in aquous base - 50000 lU/al Ini.

C

2a!

100,000.00

75.

Vitaain A Syr.

B

50000 IU

76.

Vitaain A Tab./Cap.

C

2.90

290,000.CC

77.

121200

Vitaain E Ccaplex NFI Inj. 100 via!

C

!0al

50,000.00

78.

121300

Vitaain B Complex Therapeutic Tab. NFI

A

1000

50,000.00

700.00

35,000,000.00

79.

121800

Vitaain C Tab. - lOOsg

C

1000

1,000.00

276.00

276,000.00

80.

122202

Salbutamol - 2®g/5sl Syr.

C

120®!

500.00

11.86

5,930.36

Salbutamol - 2®g Tab.

C

1000

1,000.00

193.00

193,000.00

Terbutalin - 2.5®g Tab.

A

1000

5,000.00

245.00

1,225,000.00

10ml

175,000.00

3.08

539,000.00

Chlorasphiniccd - 0.5X Eye Drops

5®!

50,000.00

4.77

233,500.00

Chloraaphinicoi - 171 B.P, ointment (Aplicaps) C

(for 1 cap)

50,000.00

0.29

14,280.00

Pilocarpine - 2Z Eye drops NFI

5®1

4,000.00

12.04

43,160.00

5®1

500.00

19.98

9,990.00

31.
82.

122400

83.

Terbutalin - 0.5®g/al Syr.

34.

Aminophyiline - 2.571 IV IF 10®!

B

85.

Deriphylline - lOOag Tab.

A

•36.

Deriphylline - 110®g/®l Inj.

87.

Deriphylline - 60®g/5®i Syr.

88.

12320!

89.
90.

124300

91.

C

Pilocarpine - 47. Eye drops NFI

92.

124600

Chlorpheniramins maleate I? - 4®g Tab.

c

1000

15,000.00

21.26

318,900.00

93.

124900

Benzyl Benzoate - 257, Emulsion

A

450®i

100,000,00

60.93

6,093,000.00
229,448,861.69

SL.
NC.

ITEM CODE

•?4.

125400

95.

126901

96.

ITEM

CLASSFICATION

PACKING

Chlorhendirft Gluconate - 7.57, liquid

C

1000®!

500.00

460.00

229,448,861.69
230,000.00

Whitfield Ointment Benzine Acid - 67.

C

15g

50,000.00

6.00

300,000.00

Whitfield Ointment Benzine Acid - 67

C

450g

1,000.00

150.00

150,000.00

QUANTITY

UNIT RATE

AMOUNT,

97.

127300

Zinc Oxide - 27 IP (skin)

C

20g

5,000.00

4.25

21,250.00

98.

127600

Miconazole Nitrate - 27 (skin) BP

C

5g

100.000.00

4.18

419,000.00

99.

128000

Dusting Powder (absorbable glove powder)

C

450g

2,500.00

100. 128301

Gentian Violet topical - 27. VSP

C

450®!

5,000.00

101. 12-3400

Hydrogen Peroxideiunbreakable dark bottle) IP B

1 It.

5,000.00

102. 129600

Pyridine Aldoxine Methiodide Inj.

C

20131

5,000.00

120.00

600,000.00

103.

Ether anaesthetic(in ambered coloured bottle) B

500ml

5,000.00

104. 131900

Mannitol - 207. infusion

A

100m!

50,000.00

25.71

1,285,714.29

105. 132300

Water for injection
(in sachine made ampules)

A

5sl

4,500,000.00

106. 143600

- Ranitidine - 150mg IP Tab.

A

1000

2,000.00

1,886.00

3,772,000.00

107. 143603

Ranitidine - SOmg/Zml Inj,

C

2.00

30,000.00

2.80

84,000.00

108. 144303

Etophylline - 46.5njg with
Throphylline Umg/Sim! Syr.

C

lOOml

12,500.00

9.91

123,875.00

109. 148100

Dopamine Hydrochloride - 40sig/nil IV BP/USP

C

5d

5,000.00

22,90

114,500.00-

110.

Metoclopramide HCL - Sisg/m! Inj.

C

2m!

50,000.00

2.10

105,000.00

111.

Metoclopramide HCL - ICmg Tab.

C

100

5,000.00

42,60

213,000.00

112,

Metoclopramide HCL - Ssig/Sml

C

30ml

50,000.00

5.79

289,500.00

113.

Diazepam Tab.

A

114.

Diazepam Inj.

115.

Diazepam Syr.

116.

Indoffiethscin - 25®g Cap.

C

117.

Pethidine - SOmg/s! Inj,

B

129700

149700

237,155,700.98

SL.
NO.

ITEM CODE

iteh

CLASSFICATION

118.
119.

Halothane liquid, anaesthetic

A

Thiopentai sodiuia - 0.5g aap.

A

120.

Nitrous Oxide liquid, anaesthetic

A

121.

Oxygen cylinder on trolleys with
flowmeter 2 mark

A

122.

Nagnesiuffi Sulphate powder - 10g/4al

C

123.

Doxycyclin - lOOag Cap.

E

124.

Co-trimoxazole Tab.

A

125.

Co-trifloxazole Syr.

126.

Dapsone - 25ifig Tab

127.

Dapsone - SOmg Tab

128.

Dapsone - lOOmg Tab

129.

Thiacetazone - ISOag Tab.

3

130.

Diethyl Carbaaazine - 50ag Tab.

3

131.

Diethyl Carbaaazine - 125ffig/5iRl Syr.

3

PACKING

QUANTITY

UNIT RATE

AMOUNT

LIST or- ESSENTIAL DROSS

Sno.

Med i c i n e

Dosage

AMIKACIN SULPHATE VIAL

250 MG

AMIKACIN SULPHATE VIAL

500 MG

3

AMIKACIN SULPHATE VIAL

100 MG

4

AM I NOPH¥ I... 1.1N AMP a

250M8/10ML

5

AMOXYCILLIN CAP„

250 MG

6

AMOXYCILLIN CAP-

500 MG

7

AMPICILLIN CAP.

500 MG

0

AMPICILLIN INJ.

500 MS

9

ATENOLOL TAB

50 MG

10

ATROPINE. SULPHATE AMP.

0.. 85 MB /I ML

11

BENZYL PENICILLIN VIAL

10 LAC

u. L

CALCIUM GLUCONATE AMP.

10 ML

13

CALCIUM, VITAMIN TAB.

14

CARBAMAZIPINE

200 MG

15

CEF A ZO I... IN SOD I UM VIAL

1 GM

16

CEFAZOLIN SODIUM VIAL

250 MB

17

CEFAZOLIN SODIUM VIAL

5 00 MG

18

CEFOTAXIME SODIUM VIAL

1 GM

19

CEFOTAXIME SODIUM VIAL

250 MG

20

CEFUB.OXIME I NJ.

750 MG

1.

Monthly Qty.
Required

I

|

j

I

I
l

LIST OF ESSENTIAL DRUGS

IT
IIh

Sno.

Medicine

L

Das e.y e

21

CEPHALEXIN CAP.

250 GM

Z.

CEPHALEXIN CAP.

500 MG

I

Monthly Qty.
Requ. i red

i

i

o~r

CIPROFLOXACIN I„V„

100 ML

24

CIP ROF I..OX AC IN TA B .

500 MG

25

CIPROFLOXACIN TAB.

750 MG

26

CLOXACILLIN CAP.

250 MG

27

CLOXACILLIN CAP.

500 MG

28

CLOXACILLIN VIAL

250 MG

29

CLOXACILLIN VIAL

500 MG

30

C 0 T RIM A X A Z 0 L E T A B ,

S. S.

31

COTRIMAXAZOLE TAB.

D „ S.

32

COTRIMOXAZOLE SYP

50 ML

33

CREMAFFIN LIQUID

210 ML

34

DEXAMETHASONE VIAL

8 MG72 ML

35

DEXTROPROPOXYPHENE ?T. ACETAMINOPHEN

350-400 MG

36

DEXTROSE

5%, 5 40 ML

37

DEXTROSE 5%, SODIUM CHLORIDE 0.9%

540.ML

38

DEXTROSE AMP,.

50%, 25 ML

39

DEXTROSE AMP...

25%, 25 ML

40

DEXTROSE VIAL

50%, 100ML

I

I

I
i

I
i

I

I
I

i

I
i

i

LIST OF ESSENTIAL DRUGS
“•tI
I!

I

hii

Sno.

i

41

DIAZEPAM AMP

IO MS/ML

42

DIAZEPAM TABn

5 MB

43

DICLOFENAC SODIUM GEL

50 GMS

I

44

DICLOFENAC SODIUM TAB-

50 MG

I
I!

45

DISULFIRAM TAB.

250 MG

46

DOMPERIDONE TAB.

10 MG

47

DOPAMINE HCL AMP.

200 MG

48

DOXYCYCLINE CAP.

100 MG

49

ELECTROLYTE M

540 ML

50

ELECTROLYTE P

540 ML

51

ENALAPRIL MALEATE TAB

2.5 MG

52

ENALAPRIL MALEATE TAB

5 MG

Med icine

Dosage

IIh

Monthly Qty
Requ. i red

i

!

Ii
!i

I

I
|

l

!

I
Ii

I
i

53

ENALAPRIL MALEATE TAB

10 MG

54

ERYTHROMYCIN SYP.

60 ML

55

ERYTHROMYCIN TAB.

250 MG

i

56

ETHAMBUTOL TAB.

800 MG

I

i

I

57

ETOFYL LINE & THEOPHYL LINE AMP.

2 ML

58

ETOFYLLINE SL THEOPHYLLINE RETARD TAB.

300 MG

59

ETOFY L L I NE ?>'. THEOP HY L L I ME TAB .

100 MG

60

FRUSEMI DE TAB.

40 MG

I
I
(

LIST OF ESSENTIAL. DRUGS

L

Sno „

61

j

I
I
I

M edi cine

FRUSMT.DE AMP..

Dcj-s -3.Q e

Monthly Qty.
R.equ.1 red

20 MB/2 ML.

62

BENTAMYCIN E DROPS

3 ML

Ii
!i

63

BENTAMYCIN VIAL

80 MG

Ij
I
i

64

GL I DENOL. AM IDE

5 MG

65

HEPARIN VIAL.

5000 IV

66/

HYDROCORTISONE SOD. SUCCINATE VIAL

100 MG

67'

IBUPROFEN

200 MG

68

IBUPROFEN

400 MG

69

IMIPRAMINE HCL

25 MG

I

I!
I
I

I

I
i

j

j

70

IMIPRAMINE HCL

75 MG

71

INSULIN VIAL.

40IV/ML. 10

72

INTRAVEL. SODIUM VIAL

500 MG

73

LIGNOCAINE I NJ.

1 %, 30 ML

74

LIGNOCAINE INJ. VIAL

2%, 30 ML

75

LIGNOCAINE JELLY

2%, 30 GM

76

LIGNOCAINE WI TH ADRENAL IME IN J . VIAL

27., 30 ML

77

MANNITOL

207 , 350ML.

78

MEBENDAZOLE TAB.

100 MG

79

MEGLUMINE IOTHALMATE/DIATRIZOATE

767 , 20 ML

80

METRONI DA Z0LE TAB.

200 MG

i

I

I

I

!i

I

I

LIST OF ESSENTIAL DRUBS

Medicine

DD-=5age

81

ME-TRONI DAZ01. EZ TAB B

400 MB

82

ME TRONI DA Z OI. E VIA I...

100 ML

83

MULTIVITAMIN DROPS

15 ML

84

NEUROBION TAB.

85

NIFEDIPINE CAP.

5 MB

86

NIFEDIPINE CAP.

10 MB

87

NIFEDIPINE TAB.

20 MB

Sno»
i

Monthly Qty.
R e q u. i r e d

IJ:

I

i

88

NORFLOXACIN CAP.

400 MB

89

P ANCURONI UM BROM I DE.

4MG/2ML

90

PARACETAMOL AMP.

150 MB/ML

91

PARACETAMOL SYP.

60 ML

92

PARACETAMOL TAB.

500 MB

93

PARACETAMOL/IBUPROFEN

94

PENTAZOCINE LACTATE AMP.

30 MB/ML

95

PENTOXYFYLLINE TAB.

400 MB

96

POTASSIUM CHLORIDE AMP.

150MG/10ML

97

PREDNISO LONE TAB.

5 MG

98

PROCA INE PENICIL LIN VIAL

4 LAC

99

PROSTIBMIN AMP.

0.5 MB/ML

100

PYRAZINAMIDE TAB.

500 MB

LIST OF” ESSENTIAL. DRUGS
H

IIII

Sno.

Medic ine

Dosage

101

FW4ITIDINE HCL AMP „

50 MG

102

RANITIDINE HCL TAB.

150 MS

L.

Monthly Qty.
Required

1

II

!
>

I

I

103

RIFAMPICIN CAP.

150 MG

104

RIFAMPICIN CAP.

450 MS

105

RIFAMPICIN CAP.

600 MS

106

RINGER LACTATE

540 ML

107

SALBUTAMOL RESP. SOLN

15 ML

10S

SALBUTAMOL TAB.

2 MS

109

SALBUTAMOL TAB.

4 MB

i

I

I

|

I
i

I

iI

110

SODIUM CHLORIDE SOLN.

540 ML

111

SUCCINYL CHOLINE INJ.

50 MG/10 M

112

terbutaline: sulphate amp.

0.5MG/IML

113

VITAMINS AMD MINERALS CAP.

i
I

i

7 7
f
V

GOVERNMENT MEDICAL STORES, BANGALORE■

Formu1 ation
(2)

I tern Name
( 1)
1.

Levels *
(3)

ANTACIDS

Aluminium Hydroxide 500 mg

Tablets

1 ,

Magnesium trisilicate 500 mg

Tablets

1 , 2

Cisapride 10 mg

Tablets

1 « 2, 3

Ranitidine 150 mg IP

Tablets

1 ,

Injection

1 , 2, 3

Diptheria Antitoxin (ADS)
10,000 IU/AMP IP

In j ec t i on

1 .<

Tetanus Antitoxin 10,000 IU/VIAL
IP (100 VIAL IN CBB WITH HCP) BP.

Inject ion

Polyvalent Anti-snake venom serum.
Lyophylised Ative 0.27. Phenol Before

Inj ec tion
with distilled water
Lyphi1isation

1 , 2, 3

Pyridine Aldoxime Methiodide
(PAM) Antidote for Organo Phosphorus
Poisoning (10 AMPS IN CBB)

Injection

1 f

2, 3

•n

3

3

ANTEDOTES
Atropine Sulphate 0.5 mg/ml
(100 AMPS IN CBB WITH HCP)

3.

IP

2, 3

ANTI-SPASMODICS
Valathamate Bromide Smg/ml
(25 AMPS IN CBB WITH HCP.)

1ml AMP

Injection

1

2, 3

Valathamate Bromide lOmg

Tablet

1 ,

Hyoscine Butyl Bromide 20 mg/ml BP.
(100 AMPS In CBB WITH HCP)

I nj ec tion

1 , 2

* 1. District Hospital

2. 30

100 beds hospital

3

3. Primary Health Centre-

1

I

I tern Name
( 1)
4.

Formu 1 ation
(2)

LAXATIVE

Paraffin-Liquid (20 BOTS PKG IM CBS
WITH HCP) IP/BP

5.

6.

Levels
(3)

Liquid

1 , 2., 3

Purozolidone 27. Suspension

Suspension

1

Loperamide 2mg

Tablet

1 , 2, 3

Digoxin 0.25 mg/ml IP
(25 AMPS IN CBS WITH HCP)

Injection

1

Digoxin 0.25 mg IP

Tablet

1 , 2

Diltiazem 30 mg

Tablet

1, 2

Injection

1 <2

Propranolol 40 mg IP

Tablet

1

Verapamil Hydrochloride 40 mg IP

Tablet

1 , o

Verapamil HCL 5mg/2ml

Injection

1,

Di 1sopyramide 150mg

Capsule

1

Mefedipine lOmg

Tablet

1, 2

Nefedipine Retard 20 mg USP

Tablet

1, 2

Dihydra 11 az ine 25mg USP

Tablet

1 , 2

Metoprolol 50mg

Tablet

1,

"Enalapril Maleate 5mg (Strip.)

Tablet

1 , 2

3

Glyceryl Trinitrate 0.. 5mg IP

Tablet

1

“7

3

Isosorbide

Tablet

1 , 2

3

ANTI-DIARRHOEAL

2, 3

CARDIAC

Procainamide lOOmg/ml

IP

IP

2, 3

2

3

3

“7

6.1 ANTI-ANOINAL

5 Mono Nitrate 20 mg

2

I tern Name
(1 )
6.2

Levels
(3 >

EMERGENCY
Mephentermine 30mg/ml

IP.

I r< j ec t i on

1 , 2. 3

Mephentermine ISmg/ml

IP.

Ini ec tion

1 , 2, 3

Injection

1 5

2, 3

Inj ec tion-1V

1 ,

3

InJ ec tion

1, 2

Methyldopa 250mg IP/BP

Tablet

1 , 2, 3

Reserpine Img/ml USP.
(100 AMPS In CBB WITH HCP)

I n j ec t i on

1

“7

'2

Adrenaline 1

I n 1O0Q BP

Dopamine Hydrochloride 40mq/ml IV
BS/USP (25 AMPS IN CBB WITH HCP).

Bupivacaine Hydrochloride
lOOmg/ml BP/USP (100 AMPS IN CBB WITH HCP)
6.3

Formu1 ation
(2)

ANTI-HYPERTENSIVE

Dihydral lazine 25mg LISP
7.

DIURETIC
Frusemide 40mg Amiloride HCL 5mg

Tablet

Frusemide 20mg/ml IP.
(100 AMPS IN CBB WITH HCP)

I n j ec t i on

1 ,

Chlorthalidone lOOmg USP

Tablet

1 , 2, 3

Spironolactone 25mg

Tablet

1

Phen formin HCL 50mg IP
(IN TIMED DISINTEGRATION FORM)

Capsu1e

1 , 2, 3

Insulin 40 lU/ml IP
IP(100 VIAL IN CBB WITH HCP)

I n i ec t i on

1 , 2, 3

Insul in-protamin Zinc 40 IIJ/ml
IP (100 VIAL IN CBB WITH HCP)

Injection

1 , 2, 3

Insulin Zinc Suspension (Lente)
40 lU/ml (100 VIAL IN CBB WITH HCP)

Injection

1 ,

•7>

3

3

ANTI-DIABETIC

3

3

Item Name
(1)

9.

Formu1 ation
(2)

Purified Insulin 40 Units/ml
Pork Monocomponent

Injection

1,

Purified Insulin 40 Units/ml
I sophane

Injection

1 ,

Puri-f ied Insulin 40 Units/ml
zinc suspension

Inj ec tion

1 , 2.,

Purified Insulin 40 Units/ml
Mixture of Neutral and Isophane

Injec tion

1,

Purified Insulin 40 Units/ml
Monqcomponent
Human

Inj ec tion

1 ,

G1ybene 1 amide 5mg IP

Tablet

1 , 2,

Tolbutamide 0.5mg IP/BP

Tablet

1 , 2, 3

Tablet

1

Injec tion

1 ,

•“7

Adrenochrome Monosemi Carbazone 0.75mq/ml
(100 AMPS IN CBB WITH HCP)

In j ec t i on

1 ,

2,

3

Adrenochrome Monosemicarbazone 0.5mg

Tab1et

1, 2

3

11 .

Suspension

1 , 2

3

Paracetamol SOOmg BP/IP.

Tablet

1 , 2, 3

Ketorolac Tromethamine 30mg/ml

Inj ec tion

1 , 2

Pentazocine Lactate 30mg/ml
(25 AMPS IN CBS WITH HCP)

Inj ec tion

1 ,

3

ANTI-COAGULANT

Heparin 5000 IU/ML IP
(100 VIALS IN CBB WITH HCP)
10.1

”7

ANTI—VERTIGO
Cinnarizine 25mg

10.

Levels
(3)

COAGULANT

ANALGESIC/ANTIPYRETIC

Paracetamol 125mg/5ml

IP/BP.

4

IP.

'*7

3

I tern Name
<1 >

12.

Pormu1 ation
(2)

Buprenorphine HCL 0.3mg/ml

I njection

1 , 2

Buprenorphine 0.2mg

Tablet

1

Ketamine lOmg/ml USP

I n j ec t i on

1,

Ketamine 50mg/ml USP

Inj ec tion

1 , 2

Ibuprofen 400mg BP.

Tablet

1 , 2, 3

Ibuprofen 200mg IP

Tablet

1,

n

Diclofenac Sodium 50mg

Tablet

1

2, 3

Diclofenac Sodium lOOmg S.P

T ablet

1 ,

2,

Diclofenac Sodium 25mg/ml

Tablet

1 , 2, 3

Diclofenac Sodium SOmg

Injec tion

1, 2

Diclofenac Diethylammonium
EQ to Diclofenac Sodium 17. W/V

GEL
GEL

1 , 2, 3

Indomethacin 25mg

Tablet

1 ,

3

3

3

2, 3

DENTAL

Clove Oil
IP
(25 BOT IN CBB WITH HCP)
13.

Levels
(3)

' Oil

1 , 2, 3

Phenobarbitone 200mg/lml IP
(100 AMPS in CBB WITH HCP)

Injection

1 , 2, 3

Phenobarbi tone 30mg IP

Tablet

1 , 2, 3

Phenobarbi tone 60mg IP

Tablet

1,

Phenytoin Sodium lOOmg/ IP

Tablet

1 , 2, 3

Phenytoin Sodium 100mg/2ml

Tablet

1 , 2, 3

Carbamazepine 200 MG IP

Tablet

1 , 2

Sodium Valproate 200mg

Tablet

1, 2

Trihexy Phenidyl Hydroch1oride 2mg USP

Tablet

1

ANTI-EPILEPTIC

5

2

3

14.

PSYCHDTHERAPEUTIC
Chlorpromazine 25mg/ml
IP
(100 AMPS IN CBB WITH HCP)

15.

Levels
(3)

Formal ation
(2>

Item Name
(1>

Inj ection

1,
rr

Chlorpromazine 25 mg/ml

IP

Tablet

1.

Chlorpromazine IQOmg/ml

IP

Tablet

1,

^7

3

Diazepam 10mg/2ml IP
(100 AMPS IN'CBB WITH HCP)

Inj ect i on

1 !. 2

3

Diazepam 5mg IP

Tablet

1, 2

3

Fluzetine HCL 20 mg

Capsu1e

1,

Ami trypty1ine Hydrochl oride
25mg
IP/BP

Tablet

1,

Trif1 operazine 5mg IP

Tablet

1, 2

Fluphenazine Decanoze 25mg/ml
BPCIOO VIALS IN CBB WITH HCP)

Injectian

1

Lithium Carbonate 300mg IP

Tablet

1

Promethazine 2.57. W/V USP
(100 AMPS IN CBB WITH HCP)

I njec tion

1 , 2., 3

Promethazine 25 mg

Tablet

1 , 2, 3,

Oxymetazoline 0.057. Aquoves Solution
(Nasal Drops)LlSP (50 BOT IN CBB)sterile

Drops

1 , 2, 3

Hydrocortisone Nasal NF I
(50 BOT IN CBB)Sterile

Drops

1 , 2

Chlorpheniramine Maleate IQmg/ml IP

Injection

1

3

Ch1 orpheniramine Maleate 4/mg IP

Tablet

1 , 2

3

Astemi zo1e 10 mg

Tablet

1 ,

Terfenadine 60 mg

Tablet

1

Embramine 25 mg
(PKG IN CBB)

Tablet

1 , 2, 3

•“7?

3

ANTI-ALLERGIC

IP

6

16.

ANTI-GOUT
2

Ta b 1 et

1

Gal lamine 40mg/ml IP
(100 AMPS IN CBB WITH HCP)

Injection

1 , 2

Suzamethonium Chloride 50mg/ml

Inj ec tion

1 ,

Pancuronium Bromide 2mg/ml
(100 AMPS IN CBB WITH HCP)

Injection

1 , 2

Tubocurarine 1Omg/ml IP
(100 AMPS IN CBB WITH HCP)

I n j ec t i on

1, 2

I n j ec t i on

1, 2

Ether-Anaesthetic IP
(IN AMBER COLOURED BOTTLES)

Liquid

1 , 2, 3

Hyaluronidaze 1 SOO lU/ml
(100 AMPS IN CBB WITH HCP)

I n j ec t i on

1

Ethyl Chloride-spray with leak proof
valve IP. (25 BOT.IN CBB)

Liquid

1 , 2, 3

Halothane BP

Liquid

1 , 2

Lignocaine 17. W/V IP
(25 VIAL IN CBB)

Inj ec tion

1

Lignocaine 27. with Adrenaline
(25 VIAL IN CBB)

Inj ec tion

1 , 2, 3

Lignocaine 27. W/V PLAIN BP.
(25 VIAL IN CBB)

Injection

1 , 2,

Lignocaine 47. W/V (Topical)
(25 BOT. IN CBB) USP.

Liquid

1, 2

Lignocaine 57. W/V (Heavy)
(25 AMPS IN CBB WITH HCP)

Injec tion

1, 2

Lignocaine Dental cartride
(25 AMPS IN CBB WITH HCP)

Inj ec tion

1

Allopurinol

17 .

Levels
(3)

Formu1 stion
(2)

I tern Name
(1)

100 mg

ANAESTHETIC

Neostigmine 0.5 mg/ml
IP
(100 AMPS IN CBB WITH HCP)

7

2, 3

3

Item Name
(1)

IS.

Formu1 ation
(2)

Levels
(3)

Lignocaine - Viscous 27.
(25 VIAL IN CBB)

Liquid

1

Lignocaine 27. Jelly USP.
(100 tubes in CBB)

Jel ly

1 , 2, 3

Thiapentone Sodium 500mg IP
(25 AMPS in CBB)

Inj ection

1, 2

Thiapentone Sodium Img BP
(25 AMP/VIAL IN CBB)

Injection

1

Hamycin (vaginal) 4LAC IV (Strips)

Ovu1es

1 , 2, 3

Nystatin 1LAC IV Vaginal
(Aluminium Foils in CBB)

Tablet

1 , 2

ANTI-INFECTIVE

18.1 ANTI-FUNGAL

Gr i seo-f u Ivin

IP.

250mq

Tablet

Griseofu1vin 125mg

Tablet

Micenazole Nitrate 27. (Skin )
(100 Tubes in CBB) BP/USP.

Ointment

1 , 2

Micenazole Nitrate 27. (EAR)

Drops

1 , 2

Tetracyc1ine-Oxy 50mg/ml IP
(100 VIAL IN CBB WITH HCP)

Injection

1 , 2, 3

Tetracycline 250mg IP

Capsu1e

1 , 2, 3

Cetotazime 1 mg

Injection

1 , 2

Doxycycline HCL lOOmg

Capsu1e

1 , 2, 3

Gentamicin 40mg/ml
(100 VIAL in CBB)

Inj ec t ion

1

'"J

Injection

1 ,

2, 3

18.2 ANTI-BACTERIAL

Ampicillin 250mg
(100 VIAL IN CBB)

IP/BP.

IP/BP

8

Formulation
(2)

I tern Name
(1>

Levels
(3)

Inj ection

1, 2

3

Ampicillin 250mq IP/BP

Capsu1e

1, 2

3

Amoxicillin 250mg BP/IP.

Capsu1e

1, 2

Amoxycillin SOOmg

InJ ec tion

1 , 2,

Norfloxacin 400mg

Tab1et

1 , 2

Nalidixic Acid 500mg

Tablet

1 ,

Nalidixic Acid 200mg/5ml

Syrup

1, 2

Ciprofloxacin 5Q0mg

Tablet

1, 2

Ciprof 1oxacin 2mg/ml

Injection

1

Injection

1, 2

Ampicillin 500mg
(100 VIAL in CBB)

IP/BP.

Chloramphenicol Succinate Img Vial
(100 VIAL In CBB)

IP.

2

Chloramphenicol 250mg
(100 VIAL In CBB)

IP.

Capsu1e

1 , 2, 3

Chioramphenicol 500mg
(100 VIAL In CBB)

IP

Injection

1 , 2

Cioxacillin 500mg/VIAL IP/BP.
(100 VIAL in CBB WITH HCP>

I n j ec t i on

1* 2

Cloxacillin 250mg
IP/BP.
(Aluminium Foil Packing.)

Capsu1e

1, 2

Erythromycin estolate 100mg/5ml USP.

Suspension

1

Erythromycin estolate 250mg

Tablet

1 , 2, 3

Kanamycin Sulphate Img IP
(100 VIAL IN CBB WITh’hCP)

Inj ection

1

Penci 11in-Benzy1 5 LACS IV IP
(100 VIAL IN CBB WITH HCP)

Inj ection

1, 2

Benzyl Pencil 1 in lOLAcs IV IP
(100 VIAL IN CBB WITH HCP)

Injection

1 , 2., 3

P

IP/BSP

2

3

3

3

Leve1s
( 3)

Formu 1 at ion
<2)

I ten Name
< 1 >

• Penn i 1 1 in Procaine 20 LACS
(100 VIAL IN CBB WITH HCP)

IP .

IV

Benzathene Pencillin 6 LACS
(100 VIAL IN CBB WITH HCP)

t i on

1,

Injsction

1 ?

Injection

1 5

In j

Fortitied Procaine Pencillin
4LACS I
IV
V IF,
(100 VI AL IN CBB WITH HCP >

IV

IP .

2,

-T

-n

rr

Benzathene Pencillin 12 LACS IV
(100 VIAL IN CBB WITH HCP)

IP .

Injection

1 , 2,

3

IV

IP ,

Inj ec tion

1 , 2

3

Tablet

1 ,

’7

Tablet.

1 ,

2

3

Trimethroprim SOmq
400
400v-^
Su1phamethoxazo1eA Bp/IP.

Tab!et

1 ,

Trimethoprim 40mg
Su1p ha me t ho xa zo1e 200mg

Tablet

1

2

3

Trimethoprim 40mg
Sul p h a. m e t h o x azole 200m g / 5 m 1

Suspension

1 , 2?

3

Methenamine mandalate 0.5mg USP.

Tablet

1 ,

■"7

“T

3

Benzathene Pencillin 24 LACS
(100 VIAL IN CBB WITH HCP)
S'j 1 phadiazine 5Q0mg

IP.

Sulphadimidine 500mg

IP.

IS.3 ANTI-TB
Pthambutol

200ng

IP

Tab 1 et

1 ,

"7

Ethambuto1

40 Ong

IP

Tablet

1 ,

25

E thambuto1

60 Ong

IP

Tablet

1 5

Ethanbuto1

SOOrng

TP

Tablet

1 ,

2

I son i a z i d

1 00 mg

IP

Tablet

1 ,

“n

I soni a z i d

30 Ong

IP

Tablet

1 ,

2,

Pi tampic in

1 50 mg

IP

Capsu1e

1,

10

3
-T

“T

I tern Name
(1)

Formu1 at i on
(2)

Leve1s
(3)

Ri fample in 300mg

IP

Capsule

1,

■*7

Rifampicin 4S0mg

IP

Capsu1e

1

2, 3

Rifampicin lOOmg/ml IP

Syrup

1 , 2, 3

Streptomycin 1 mg IP
(100 VIAL IN CBB WITH HCP).

Injec tian

1 ,

Clofazimine lOOmg IP.

Capsu1e

1 ,

Clofazimine 50mg

Capsu1e

1 , 2

Injectione/IV

1 , 2

Metronidazole Benzoloxy1 ate
Suspension Equivalent to 200mg/5ml
Metron idazo1e

Suspension

1 , 2, 3

Metronidazole 200mg BP/IP

Tab1et

1

Metronidazole 400mg BP/IP

Tablet

1 , 2., 3

Trinidazole

Inj ec tion

Tinidazole 300mg

Tablet

1, 2

Tinidazole 500mq

Tablet

1

Metochlorpramide HCL lOmg BP

Tablet

1 , 2

Metochlopramide HCL 5mg/5ml

Liquid

1

2

Metochlopramide HCL 5mg/ml
(25 AMPS IN CBB WITH HCP)

Injection

1 ,

—j

Domperidon lOmg

Tablet

1

3

3

ANTI-LEPROSY
•7

3

ANTI—AMOEBIC

Metronidazole 5MG/ML 1OOML in
Aqueous Base
BP.
(100 BOTTLES IN CBB WITH HCP)

11

3

2

3

Zl

Z

I

UQ T4 DSf uI

‘ I

UO T 4 Z5.3 f U J

‘ I

UQT^aafui

(spT>aja4.s oaiqjuj) •dsn iw/bdo-t?
141 apiuoqaay a uo pa u t ad e t j 1

(dZH HlIN 883 NI S3VIA 001)
‘jl
pd/bdt au»aseq4 ade xsq
dSH

I

0 £ Z 5 u G a 4 = a & o j d A ■< o J p A h
S3NOWHOH

1

£

i~

ua t4 aaf uJ

(dZH HUM aaZ '->T SdNtf 001)
‘di
ld/Al £ UTOO4.AXQ

T

de a-4

(aSZ GT saqnj.
*dSM JoqeaTiddt) q41M M/M 7.10*0)
(aseg deaJ3) deaJ3 pajqaouaTQ

t T

' I

“+Giq*i

‘Z

fc’ I

uQT4aa Cui

‘Z

‘ I

di

di

6dgrj*fj auT_4^ado5_43

TAq^a^j

(d3H HUM SS3 NI Sdwy 001)
fd/bd^’O auTJ+su/o6J3 -[Aqqaw

□IH131SB0

■dsn/^a/di
2 kZ ‘ T

43iqei

‘ I

4-5 iqe±

■dsn/da/di
£

“Z

B^oo1

aqejqjs auyzedeqjea

{/.qqaiQ

suios

a4.ej4.T3 auizedueqjea TAq43TQ
~ltfI3U3I3~ I1NU £’

‘ I

4G iqe-l

bdc£ autweq4. ad t u ,<c{ 6d00£ auj xaped 1 ns

*■■ I

q^iq^i

di 5dc * 3 au tnbedt a s

i"

fcZ ‘ I

q^ipei

-dg bdg‘£ auynbedTJa

2

‘Z

'I

q-siq^i

■jg bdoez auinbajo{4'j

z

*■■ z

‘ 1

uorqaarui

£ lZ

(don hum aaz
'dB/dl

Sduy oon

dNy/bdO£Z auTnbojop_|3

ttHbU'WN-IlNU 9*

i £)
a [ a A.a

(Z)
□ope { nd jo j

( I )
adef'j da4 1

21 .

Trimacinolone Acetonoide
lOmg/ml USp (Intra Articular Cortico
Steroid)

Injbc tian

1

Prednisalane 5mg IP

Tablet

1

Prednisalone lOmq IP

Tablet

1 , 2

Prednisalone 20mq IP

Tablet

1

Thyroxine Sodium lOOmg IP

Tablet

1

Stilbesterol Diphosphate lOOmq

Capsu1e

1 ,

“7

Stilbesterol Diphosphate 250mg

In j ec t i on

1 j,

2

I n j ec t i on

2

3

1 , 2., 3

SERA
Anti "A" Sera IP

Sera

1 ?

Anti "B" Sera IP

Sera

1 , 2, 3

Anti "AB" Sera

Sera

1 ,

Anti "D" Sera (monoc1 ona 1)

Sera

1 , 2, 3

Coombs Sera

23.

3

VACCINES

Tetanus Toxoid 10 doses IP/BP
(100 VIAL IN CBB WITH HCP)

22.

Levels
(3)

For mu. 1 at ion
(2)

I tern Name
(1 )

1,

^5

“7

T1

3

3

3

Australia Antigen Kits for Elisa method

Antigen

1

Australia Antigen Kits for Slide Test

Antigen

1 9

2, 3

VDRL Kits of Slide Test

Diaqnosts

1 ,

3

ANTI-HELMINTHI CS
Mebendazole lOOmg

Tablet

Mebendazole 100mg/5ml

Suspension

13

Formu1 ation
(2)

Item Name
(1)

Levels
(3)

24 . ANTI-CANCER

Cyclophosphomide 50mg/VIAL

Injec tion

1

Cyclophosphomide lOOmg/VIAL

Injection

1

Cyc1ophosphomide 200 mg/VIAL

Inj ec tion

1

Cyc1ophosphomide SOOmg/VIAL

Inj ec tion

1

Tablet

1

Cyc1ophosphomide lOOmg

Tablet

1

Azathioprine 25 mg

Tab1et

1

Mercaptopurine 50mg BP.

Tablet

1

Vincristine Sulphate 1mg/VIAL

InJ ec tion

1

Doxurubicin HCL lOmg USP.

Inj ec tion

1

Mitomycin C 2mg/ VIAL USP.

Inj ec tion

1

Mitomycin c lOmg/ VIAL USP.

In j ec tion

1

Asperginase 1000 KU/VIAL
Containing Asperginase 10000 KU/VIAL

I n j ec t i on

1

In j ec t i on

1

Actinomycin 0 (containing Actinomycin
500 mcg and Mannitol 20mg USP.

In j ec t i on

1

Cisplatinum lOmg/VIAl

Injec tion

1

Fl urouracil 250gm

Capsu1e.

1

Inj ec tion

1

Methotrexate 2.5mg Tabs. BP.

T ablets

1

Methotrexate 5mg/ml Intrethecal

I n j ec t i on

1

IP/USP.

Injec tion

1

5-F1urouraci1 250mg/5ml/ USP.

Injec tion

1

IP

Cyc1ophosphomide 50mg

B1eomyc in

15mg

Usp.

Methotrexate 50mg/2ml

Flurouracil 50mg/ml

BP.

14

I tern Name
(1 )

Formu1 a t i on
(2)

Chlorambucil 2mg BP.

Tablet

1

Chlorambucil 5mg BP.

Tablet

1

Me1pha1 an

2mq

BP.

Tablet

1

Melpha1 an

5mg

BP.

Tablet

1

Thio-Tepa 1 Smg

USP.

Injection

1

Tablet

1

In J ec t ion

1

Calcium Leucovorin 50 mg

Tablet

1

Procarbazine 50 mg

Capsu1e

1

Hydroxy Urea 500 mg

Capsu1e

1

Tomox i -Fen

Tablet

1

Ferrous Sulphate 200mg IP
Sugar coated

Tablet

1 , 2, 3

Ferrous Fumarate 200mg IP

Tablet

1 , 2, 3

Iron-dextran 50mg/ml Im/IV
(100 AMPS in CBB WITH HCP) IP

Injec tion

1 , 2, 3

Iron-dextran 50mg/ml 10ml +1 m 1 dua 1 Pack

Injec tion

1 !. 2, 3

Calcium Gluconate 107. IV IP
(50 AMPS IN CBB WITH HCP)

Injection

1 j,

Calcium Gluconate 500mg IP/BP.

Tablet

1 , 2, 3

Vitamin-K lOmg/ml
IP.
(100 AMPS IN CBB WITH HCP)

Injection

1 , 2

Folic Acid Smg BP

Tablet

1 , 2, 3

Thioguanine 40mg

BP.

Calcium Leucovorin 3 mg/ml.

25.

6.

Levels
(3)

USP.

10 mg

HOEMOPOIETIC

VITAMINS AND MINERALS

15

^7

3

3

I tern Name
( 1)

27.

Formu1 ation
(2)

Levels
(3)

Vi tamin-A in Aqueous Base
- 50,000 lU/ml USP.
(100 AMPS IN CBB WITH HCP)

I njec tion

1, 2

Vitamin A 50,000 IU.

Tablet

1 , 2, 3

Vitamin A 50,000 lU/ml
in Aqueous Base

Drops

1, 2

Vitamin-B Complex NFI
(100 VIAL IN CBB WITH HCP)

Inj ec t ion

1 , 2, 3

Vitamin B Comp1ex-Therapeutic NF I

Tab1et

1 , 2, 3

Vitamin-B Complex Therapeutic NFI

Drops

1 , 2, 3

Vitamin-B1-33mg B6-33mg B12-33.3mcg/ml
(50 AMPS IN CBB WITH HCP)

Inj ection

1, 2

Riboflavin Vitamin B2 20mq

Tablet

1, 2

Vitamin C 500mg/5ml NFI
(50 AMPS IN CBB WITH HCP)

Inj ec ti on

1, 2

Vitamin C lOOmg/IP.

Tab1et

1 , 2, 3

Dextrose 57. IV IP
(Packing in CBB>

In j ec tion-1V

1 , 2, 3

Dextrose 107.IV IP
(Packing in CBB)

I nj ec tion-1V

1, 2

Dextrose 257.IV IP
(50 AMPS IN CBB WITH HCP)

Injec tion-IV

1, 2

Dextrose 507,IV IP
(50 AMPS IN CBB WITH HCP)

Inj ec tion-1V

1, 2

Electrolyte Gastric Replacement
Solution with 57. Dextrose

Inj ec tion-IV

1, 2

Electrolyte Maintenance Solution
with 57. Dextrose

Injection-IV

1, 2

Electrolyte Maintenance Paediatric
Solution with 57. Dextrose

I nj ec tion-1V

1, 2

3

3

IV FLUIDS

16

3

Item Name
(1)

Formu1 ation
(2)

Potassium Chloride 157. W/V USP/BP

I njec tion

1 , 2

Sodium Bicarbonate 7.57. W/V

I njec tion

1 ,

3

Sodium Chloride 0.97. IP

Injection-IV

1 .

3

Norma 1 Saline IP ;

Inj ec t ion-1V

1 , 2, 3

Sodium Chloride with Dextrose

I njec tion-1V

1 , 2

3

Sodium Lactate-Compound
(Mo1ar-Lactate) IP.

I n i ec t i on -1V

1 ,

3

Dextran 40 IN Normal Sa1ine IP.

Injection-IV

1 ,

Plasma Volume Substitute Containing
3.57. degraded Gelatine

Injection-IV

1 , 2

Low Molecular WT Destran 540ml

Injec tion-IV

1 , 2

Nanni to1

107. IV IP.

I njec tion-1V

1 , 2, 3

Nanni to1

107. IV IP

Inj ec tion-1V

1

Mannitol 207. IV IP.

Injection-IV

1 , 2, 3

I njection

1 , 7

3

Salbutamol 4mg IP.

Tablet

1,

3

Salbutamol 2mg/5ml

Syrup

1 , 2

Salbutamol Sulphate lOOmcg/mt
(200 Metered Doses)

I nha1 er

1 ,

Terbutai in 1.5mg/zml

Syrup

1,

3

Terbutalin 2.5mg/ml USP.

Tablet

1 ,

3

Terbutalin 0.5mg/ml
(50 AMPS IN CBB WITH HCP)

Inj ec tion

1 , 2, 3

Aminophylline 2.57. IV IP,
(50 AMPS IN CBB WITH HCP)

I n j ec t i on

1 ,

T5

3

Theophylline lOOmg IP/BP.

Tablet

1 , 2

3

Water -For Injection
(in Machine made AMPS)
29.

Leve1s
(3)

7?

2, 3

IP.

ANTI-ASTHMATIC

17

—}

3

2

I tern Name
(1 )

29.

Formu1 ation
(2)

Levels
(3)

SKIN
Calamine Lotion

BP.

Liquid

1

Liquid

1, 2

Benzyl Benzoate Application 257.

Emu 1sion

1 , 2, 3

Gamma Benzene Hexachloride 17.

Liquid

1,

Certrimide Cream BP.

Ointmen t

1 , 2, 3

Silver Su 1 phad i az ine 17.

Cream

1 , 2, 3

Betamethasone 0.17. (Skin)

Ointment

1 ,

Betamethasone Valerate 0.127. with
chinoform 37. Base.

Cream

1,

Betamethansone with Neomycin Sulphate

Cream

1, 2

Dexamethasone Acetate 0.17. and
Framycetin Sulphate cream 17.

Cream

1 , 2

Clobetasol Butyrate

Ointmen t

1 ,

Nitrofurazone 0.27, water soluble
Base (skin) USP.

Cream

1 ,

Povidone iodine USP 57. W/W (0.57.
in cream base)

Cream

1, 2

Povidone Lotion USP 57.

Lotion

1 5

Paraf-Fin White Soft IP.
Ointment Base

Ointment

1 , 2, 3

Podophylum Resin IP.

Powde

1, 2

Potassium Permanganate IP.
(In Amber coloured bottle)

Crystals

1

Psoralen 5mg

Tablet

1, 2

WhitField Ointment with
Benzoic Acid 67.

Ointment

1 , 2? 3

Sulphur Skin Ointment 107. IP.

Ointment

1 , 2, 3

Glycerin

IP.

18

2, 3

3

*7

2,

3

3

3

2, 3

Item Name
(1 )

30.

Formu 1 ation
(2)

Levels
(3)

Coalter ointment USP.

Ointfnen t

1 , 2

Turpentine Liniment IP,

Liquid

1 ,

—

Zinc Oxide (skin)

Ointment

1

2, 3

Benzoin CO TP IP.

Liquid

1 , 2, 3

Gentian Violet 27. USP. Topics 1

So1ution

1 , 2, 3

Gentian Violet 17. USP. Topical
Hydrogen Peroxide (in unbreakable
dark Bottle) IP.

So1ution

1 , 2, 3

Liquid

1 , 2, 3

Iodine-Weak Solution TP-IP

Liquid

1 , 2, 3

Mythyl Salicylate IP. 4Z W/W
Mephensin IP 7.7. Iodine I0P 57. W/W

Ointment

1 , 2, 3

Polymyxin B Sulphate 5000 Unit with
Bacitracin 400 units and Neomycins
3400 Units/gm IP/BP.

Powder

1 , 2, 3

Framycetin Sulphate 17. W/W

Ointmen t

1 , 2., 3

Chi or a phen ic a 1 57. (Ear) BP.

Drops

1 , 2, 3

Su 1 phacetamide 207. EAR BP

Drops

1, 2

Oin tmen t

1 , 2, 3

Chioramphenico1 o.57. EYE DROPS

Drops

1

Framycetin Sulphate IP 5MG

Drops

1 , 2, 3

Dexamethasone Sod. Meta su1phoben zoate
0.1167. W/V Framycetin

Drops

1

Chi oraphenical Applicaps 17.
(EYE) Sterile

Ointment

1 , 2, 3

Gentamicin 0.37. W/V USP

Drops

1 , 2? 3

Gen tamic in 17. (EYE) USP

Oin tmen t

1„

157. IP.

IP.

3

EYE/EAR

Chi oramphenicol 17. (EYE)

IP

IP/BP

3

2, 3

3

Level
(3)

I-or mu 1 at ion
(2)

I tern Name
(1)
S u 1 □ h a c e t. a rn i d e 10 7. (E Y E) USF

D r o p *»

1

2

Phenyl Ephrine HCL 57

Drops

1 >i

2

Phenyl Ephrine HCL 107

Drops

1, 2

T e t r a c y 1 i n .1.7 (E Y E) USF

Oin tment

F1 u o res c: i n C o r n & a 1 s t a i n s t r i p s
(OFTH) USP.

□PTH Strips

H o m o trap i ri e H y d r o c h 1 o r i d e 2 7
Eye drops USP- Sterile

Eye Drops

Fluorescein Sodium 107 USF»

I n j ec t i on

1

C y c 1 o P n t o 1 a t e H C I... 17 E y e 8 P .

Eye Drops

1, 2

Betamethasone 0 K17 with Neomycine
(eye) Sterile

Ointment

1,

.B e t a m e t h a s o n e 0« 17 w i t h N e o m y c i r ’i e
0,57 (eye) NFI Sterile.

Drops

1, 2

Fhilocarpine 27 (eye) NFI/BP.Sterile

Drops

1 !.

Phi1ocarpine 47 (eye) BP.Steri1e

Drops

1,

h t ro p i n e

0intment

17 (e y e) IP ..

20

2,
1
2

X.

Z..

2

I.
11. ACCESSORIES

SI .
No.

I tern Name
(1 )

Formu1 ation
(2)

Levels
(3)

01 ,

Cotton wool, Absorbable IP, 500g.Nett

Dressing

1, 2

02.

Sterilised medicated paraffin gauze
containing Framycetin 500 Units/gm
and Neomycin Sulphate IP 0.357. W/W
lOcms X lOcms.

Dressing

1 , 2, 3

Dressing

1 ,

3

03.

Gelatin Sponge-Absorbable
10mm X 10mm X 10mm (Dental) LISP
Packing in CBB.

04.

Gelatin Sponge-Absorbable
70mm X 50mm X 1mm (nasal)
Packing in CBB

Dressing

1

Gelatin Sponge- Absorbable
SOmm X 25mm X 7mm (Gynec.)USP
Packing in CBB

Dressing

1 , 2

Gelatin Sponge-Absorbable
70mm X 50 mm (general) LISP
Packing in CBB

Dressing

1 , 2

P1aster-Adhesive Zinc Oxide
207. - 10cm X ION
LISP.

Dressing

1

Transparent Hypo Allergic Plaster
having Bi—directiona1 tear,
tear , size
5cms X 9.14MTS

Dressing

1 , 2

Porous elastic Adhesive Bandage
Sems X 4NTS

Dressing

1 , 2

Transparent Hypo Allergic
Plaster having Bi-directional tear
size 7.5cms X 9.14MTS

Dressing

1,

11.

Plaster of Paris

Powder

1 5

2, 3

12.

Drip set-polythene -for IV
administration- sterlised with
Gamma irradiation - Batch
certificate from B.A.R.C./K.H.I.0.

App1i ance

1,

3

Disposable Blood collection bags
(CPDA Solution) 350 ml capacity

Bags

1,

05.

06.

07.

08.

09.
10.

13.

IP.

21

•p

2

3

Formu1 ation
(2)

Levels
(3>

Disoosable Blood collection double
bags (CPDA Solution) 350 ml capacity

Bags

1 ? 2

15

Disposable Blood Lancets

Lancet

1 , 2,

16

Disposable Blood Drawing Sets

Drawing Set

1 „ 2

17

Hypodermic Needles SS ISI

1.5" X IS

Appliance

1 , 2,

IS

Hypodermic Needles SS ISI

1 .5" X 20

App1i ance

1 , 2,

19

Hypodermic Needles SS ISI

1.5”

X 22

App1i ance

1 , 2,

20

Hypodermic Needles SS ISI

1 .5” X 24

Appliance

1 ,

21

Hypodermic Needles SS ISI

1"

X IS

Appliance

1 , 2

22

Hypodermic Needles SS

1 ”

X

20

Appli ance

1 ,

■2?

23

Hypodermic Needles S.S.

X

22

Appliance

1 ,

2

24

Hypodermic Needles S.S.ISI 1

Appliance

1 , 2,

25

Disposable Needles 20G X 1 ”

Appliance

1 , 2

26

Disposable Needles 22 G X 1 "

Appliance

1 , 2

27

Disposable Needles 24 G X 1 "

Appli ance

1 , 2,

28

Disposable Needles 26G X 1 "

Appliance

1

29

Syringe 2CC All G lass
Interchangeable ISI .

Syringe

1 , 2.,

30

Disposable Syringe 2.5ml

Syringe

1 , 2

31

Syringe 5CC All Glass
Interchangeable ISI

Syringe

1 , 2,

32

Disposable Syringe

Syringe

1, 2

33

Syringe 10CC all glass
Interchangeable ISI

Syringe

1,

34

Disposable Syringe 10 ml

Syringe

1 , 2,

35

Syringe 20CC all glass
I nterchangeab1e ISI

Syringe

1 , 2,

SI
No
14

I tern Name
(1 >

ISI

22

ISI

1"

X 24

2,

SI .
No.

I tern Name
(1 )

Formu 1 ation
(2)

Levels

(3>

36.

Clinical Thermometer Centigrade ISI
Packing in plastic tube with cap.

App1i ance

1 , 2, 3

37 .

Rectal Thermometer Centigrade
Packing in plastic tube with cap.

Appliance

1 , 2

38.

Gloves Surgical 6 size ISI
Each Pair in Plastic cover and
25 pair in CBB

App1iance

1 , 2

39.

Disposable Gloves 6 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1, 2

40.

Gloves Surgical 6.5 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1 ,

41 .

Disposable Gloves 6.5 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1 , 2

42.

Gloves Surgical 7 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1, 2

43.

Disposable Gloves 7 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1 , 2

44 .

Gloves Surgical 7.5 size ISI
Each Pair in Plastic cover and
25 pair in CBB

App1iance

1,

45.

Examination Gloves Size 6
Not -For surgical procedures
25 pairs in plastic bag in carton

Appliance

1 , 2, 3

Examination Gloves Size 6.5
Not -For surgical procedures
25 pairs in plastic bag in carton

Appli ance

1 , 2, 3

Examination Gloves Size 7.5
Not For surgical procedures
25 pairs in plastic bag in carton

App1i ance

1 . 2

Disposable Gloves size 7.5 ISI
Each, pair in plastic cover and
25 pairs in CBB

Appli ance

1 , 2

46 .

47.

48.

23

3

"2

3

Formu 1 ation
(2>

SI .
No.

I tern Name
(1)

49 .

Sheeting waterproof mackintosh
36” width

Levels
(3)

Sheeting

1 , 2, 3

Powder

1 5

2, 3

50.

Acid Benzioc Powder IP 450gm
Bleaching Powder GR 2 337. Chlorine
ISI (Laminated HDPE Packing)

51 .

Chlorine tablet 2.5qm
Containing 300mq Chlorine

Tablet

1, 2

Denture Base Material
Heat curing ISI ADAS

Powder

1

Denture Base Material
Cold curing ISI ADAS

Powder

1

Denture Impression Material
ISI ADAS

Powder

1

Gum Paint-TRS Aconite, Belladonna,
lodimitis, Benzo in Methopip

Gum Paint

1

56.

Mercury Ip

Liquid

1

57.

Silicate Cement ISI/ADAS
Glass ionomer filling material powder
15 gms and Liquid 10 gms

Cement

1

58.

Dental Prophylaxis paste

Paste

1

59.

Sterile Absorbent Dental P o i n t s

Denta1-point

1

60.

Dental Restorative Universal and
Cata1yst.
Catalyst Paste-1, Universa 1 Paste-1,
Mixing stick-35

App1iance

1

Dental Restorative Acid Etch Bond
Technique catalyst and Universal Resins
Etching liquid 1 Brush Handle 100
disposable brushes and 100 disposable
mixing weIls.

Appliance

1

62.

Den ta1 F1 oss

String

1

63.

Den ta 1 Stone Plaster ADAS

Powder

1

64 .

Mercury triple Distil les for
Dental Use
ISI/ADAS

Mercury

1

52.
53.
54.
55.

61 .

24

3

SI .
No .

Item Name
(1 )

Formu1 ation
(2)

Levels
(3)

65.

Silver Amalgum Alloy with 607.
Silver ISI

Powder

1

66 .

Orthodontic Wire Dentauram 0.6
0.7, 0.8, and 0.9 mm gauge.
Plastic packing in CBB

Wire

1

67.

Arch Wire for Orthodontic purpose
gauge 0.014, 0.016, 0.018 & 0.20.
Plastic packing in CBB

Wire

1

Full Teeth sets
Complete Square Mould, Tapering
Mould avoid Mould (shade stellon
1, 2, 3, 4, 5, or equivalent

Mou 1 d

1

Anterior Teeth Sets (lower
and Lipper Square and Tapering
Mould Stellan Shades 1, 2, 3, 4, 5,
or equivalent

T eeth

1

70.

Posterior Teeth sets (Different
Shades and Sizes)

T eeth

1

71 .

Calcium Hydroxide - Dycal catalyst
13gm Base llgm 1 PAD in CBB Packing

Paste

1

72.

Dental Carving wax Block Acme X
1.5cms X 1.5cms

Wax

1

73.

Pumice Powder -For Polishing

Powder

1

74 .

Zinc Oxide euginol Impression
Paste.
Zinc Oxide Paste 125gm
Euginol Paste 85gms Mixing Pad 1 .

Paste

1

68.

69.

ISI .

75.

Intra Dental Wire Soft 16

Wire

1

76.

Zinc Oxi phosphate Cement ISI/ADAS

Cement

1

Dextrose Anhydrous (injectable Grade)
IP/BP free from physical impurities.
(PKD. in Double Poly B AG in KEG with
Painted Label on KEG.

Powder

1

Mannitol Powder for Injection in
Airtight Polybag IP/USP/BP Double
Polybag 0.2mm thickness, sealed,
painted label to be affixed v^ith batch No.

Powder

1 ,

78.

25

■

SI .
No.

Formu1ation
(2)

Item Name
( 1 )

Levels
(3)

Sodium chloride (INJ Grade) IP
free from physical impurities
PKD in airtight 0.2mm Polybag
sealed in carton.

Powder

1, 2

SO.

Sodium Citrate IP. (INJ Grade)
PKD in Ploybag in Plastic Bottles.

Powder

1 , —•

SI .

Bott1e—Approx 72 mm Dia 165mm
HT. 38.5mm Screw neck USP Type 1.

Glass Bottle

1 , 2

82.

Bott1e-Approx 79.5mm Dia 210mm
HT 38.5mm screw neck USP Typel.25
Bottle in CBB with HCP. Overflow
capacity 665ml USP.

Glass Bottle

1, 2

Cap Sc rew Aluminium with Centre open
-For manual srew sealing screw (Neck
Bottles to -Fixing the rubber plugs
USP (Packing in CBB>

Closure Screw

1, 2

Foil Seals Aluminium Assorted colours
for fixing and sealing over both screw
type and sealing Type Aluminium Caps
(Packing in CBB with Embosemen T
"Government of Karnataka".

C1osure

1 , 2

Rubber Plugs -For 540ml USP Type-1
Bottles o-F smooth surface alround with
one hole for infusion needle and other
for air inlet on top ISI packing in
polybag in corrugated CBB.

C1osure

1 , 2

Sodium Iodide 17. Solution W/V
(Disin-Feetant and Bactericidal
Packed in CBB)

Liquid

IV Cannula Set (made of Teflon) Hinge
Type biway connection at the top.
Sizes 14, 16, IS, 20, 22
Gammairradiation certificate ■From
B.A.R.C./K.M.I.0. Packing in CBB.

ftppliance

Autoe 1ave Indicator Labels
2.5cms X 5cms

Labels

79.

S3.

S4 .

85.

86.

87.

88.

26

SI .
No .

Formu1 ation
(2)

I tern Name
(1)

Levs1s
(3)

Jelly

1 , 2

Sterilised Surgical Suture
Plain Catgut 2/0 USP.

Suture

1 , 2

Sterilised Surgical Suture
Plain Catgut 1/0 USP.

Suture

1 y

Sterilised Surgical Suture
Plain Catgut 1 USP.

Suture

1 , 2

Sterilised Surgical Suture
Plain Catgut 2
USP.

Suture

1

2

Sterilised Surgical Suture
Plain Catgut 3
USP.

Suture

1,

•n

Sterilised Surgical Suture
Chromic Catgut 3/0 USP.

Suture

1, 2

Sterilised Surgical Suture
Chromic Catgut 2/0 USP.

Su ture

1 , 2

Sterilised Surgical Suture
Chromic Catgut 1/0 USP.

Suture

1

Sterilised Surgical Suture
Chromic Catgut 1 USP.

Suture

1 ,

Sterilised Surgical Suture
Chromic Catgut 2 USP.

Suture

1 ,

“7

100. Sterilised Surgical Suture
Straight Needle Chromic 2/0 USP.
Round Body 60mm.

Suture +Needle

1

2

101 . Sterilised Surgical Suture
Straight Needle Chromic 2/0
Round Body 45mm USP.

Suture + Needle

1, 2

102. Sterilised Surgical Suture
Straight Needle Chromic 2/0
Round Body 60mm USP.

Suture + Needle

1

103. Sterilised Surgical Suture
Straight Needle Chromic 1/0
Round Body 45mm USP.

Suture + Needle

1 , 2

39.

Skin Contact Jelly
Ultra Sound

90.
91 .

92.
93.

94 .

95.
96.
97.
98.
99.

27

2

2

2

SI .
No.

1 04 .

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

Formu 1ation
(2)

Item Name
(1 )

Leve1s
(3)

Sterilised Surgical Suture
Curved Needle Chromic 4/0
Round Body 16mm USP.

Suture + Needle

1 ,

2

Sterilised Surgical Suture
Curved Needle Chromic 3/0
Round Body 22mm USP.

Suture + Needle

1 ,

2

Sterilised Surgical SutureCurved Needle Chromic 2/0
Round Body 65mm USP.

Suture + Needle

1 ,

2

Sterilised Surgical Suture
Curved Needle Chromic 2/0
Round Body 45mm USP.

Suture + Needle

1 ,

Sterilised Surgical Suture
Curved Needle Chromic 2/0
Round Body 30mm USP.

Suture

Need 1e

1 ,

2

Sterilised Surgical Suture
Curved Needle Chromic 1/0
Round Body 45mm USP.

Suture + Needle

1

2

Sterilised Surgical Suture
Curved Needle Chromic 1/0
Round Body 30mm USP.

Suture + Needle

1

2

Sterilised Surgical Suture
Curved Needle Chromic 1
Round Body 45mm USP.

Suture + Needle

1 ,

2

1

Suture + Needle

1 ,

2

Sterilised Surgical Suture
Curved Cutting Needle Plain 4/0
16mm USP.

Suture + Needle

1 ,

Sterilised Surgical Suture
Curved Cutting Needle Plain 3/0
16mm USP.

Suture + Needle

1 ,

2

Sterilised Surgical Suture
Curved Rev. Cutting Needle Chromic 6/0
Round Body 8mm USP.

Suture + Needle

1 ,

2

Sterilised Surgical Suture
Curved Cutting Needle Chromic
60mm USP.

28

SI .
No.

116.

Formu1 ation
(2)

I tern Name
(1 >

Sterilised Surgical Suture
Curved Blunt Needle Chromic
Round Body 63mm USP.

Levels
(3>

1

Suture

Need 1e

Suture
1/2 Circle Chromic 1
Heavy 45mm Needle USP.

Suture

+ Needle

Sterilised Surgical Suture
1/2 Circle Trocar Point 1
40mm Needle USP.

Suture + Needle

1, 2

Suture + Needle

1 , 2

120. Sterilised Surgical Suture
1/2 Circle Round Body 1/0 Chromic
40mm Heavy Needle USP.

Su tu re

Need 1 e

1 , 2

121 . Sterilised Surgical Suture
1/2 Circle Round Body 3/0 Chromic
25mm Needle USP.

Suture + Needle

1, 2

122. Sterilised Surgical Suture
1/2 Circle Round Body 2/0 Chromic
45mm Need 1e USP.

Suture + Needle

1, 2

123. Sterilised Surgical Suture
1/2 Circle Round Body 1/0 Chromic
45mm Needle USP.

Suture + Needle

1 ,

124. Sterilised Surgical Suture
1/2 Circle Round Body 1/0 Chromic
30mm USP.

Suture + Needle

1, 2

Sterilised Surgical Su ture
1/2 Circle Mayo's Chromic 1/0
45mm Heavy Needle USP.

Sutu re + Need 1e

1 , 2

126. Sterilised Surgical Suture
1/2 Circle Reverse Cutting Chromic
50mm Need 1e USP.

Suture + Needle

1,

Su tu re + Need 1e

1

1

117. Sterilised Surgical

1 18.

1 19. Sterilised Surgical Suture
1/2 Circle Trocar Point Cutting 2
Chromic 40mm Heavy Needle USP.

125.

127. Sterilised Surgical Suture
1/2 Circle Reverse Cutting and
Round Body 2/0 Chromic 36mm Needle USP.

29

1 ,

2

2

SI .
No.

129.

129.

1 30.

I tern Name
( 1 )

Formu1 ation
(2)

Levels
(3)

Sterilised Surgical Suture
5/9 Circle Round Body Chromic
55mm Need 1e USP.

1/0

Su. tu re + Need 1 e

1 ,

Sterilised Surgical Suture
3/9 Circle Round Body Chromic
45mm Needle
USP.

1/0

Suture + Needle

1 ,

Suture + Needle

1

Su ture + Need 1e

1

Sterilised Surgical Suture
9/0 60mm Curved Micro Point USP.
Round Body 45mm USP.

2

131 .

Black Virgin Silk, Spatulated
9/0 60mm Curved Micro Point Double
Needle USP.

132.

Black Virgin Slik, Spatulated
9/0 60mm Curved Micro Point Double
Needle USP.

Suture

Needle

1

Mersilk Black Braided Silk
4/0 16mm Curved Round Body Needle USP.

Suture + Needle

1 ,

Virgin Black Braided Silk
9/0 9mm 1/2 Circle Reverse Cutting
Micro Point Needle USP.

Suture + Needle

1 , 2

Mersilk Bick Braided Silk
6/0 9mm 1/4 Circle Spatulated Micro
Point Needle USP.

Suture + Needle

1 ,

Mersilk Black Braided Silk
4/0 20mm 1/2 Circle Round Body Need 1e
USP.

Suture + Needle

1 ,

2

Mersilk Black; Braided Silk
3/0 25mm 1/2 Circle Round Body Needle
USP .

Suture + Needle

1 ,

2

Mersi1k Black Braided Silk
2/0 30mm 1/.2 Circle Round Body Needle
USP.

Suture

Need 1e

1 ,

2

Mersilk Black Braided Silk
1/0 30mm 1/2 Circle Round Body Needle
USP.

Suture-

Need 1 e

1 ,

Mersilk Black Braided Silk
2/0 50mm 1/2 Straight Round Body Needle
USP.

Suture + Needle

133.

134.

13S.

136.

137.

139.

139.

140.

30

1 , 2

2

I tern Name
( 1)

Formu 1 ation
(2)

Leve1s
(3)

141 . Green Size 2, Coated Braided
Polyester with 45mm Heavy Tapercut
Need 1e USP.

Suture + Need 1e

1, 2

142. Sutupak Pre Cut Suture in Sterile
over wrap packs 2/0 X 2 X 75cms USP.

Sutu re + Need 1e

1 , 2

143. Sutupak Pre Cut Suture in Sterile
over wrap packs 1 X 2 X 75cms USP.

Suture + Needle

1

144 . Sutupak Pre Cut Suture in Sterile
over wrap packs 3/0 10 X 75cms USP.

Suture + Needle

1 , 2

145. Braided Nersilelne Suture
5/0 8mm 1/4 Circle micro Point
Spatulated Double Needle USP-

Su tu re + Need 1e

1 ,

146. Braided Coated Nersilelne Suture
4/0 8mm 1/4 Circle Micro Point
Spatulated Needle USP.

Suture

147. Braided mersilelne Suture
2/0 30mm 1/2 Circle Round Body
Needle USP.

Suture + Needle

1 ,

148. Synthetic Absorbable Suture
4/0 16mm 1/’2 Circle Tapercut Heavy
Needle USP.

Su t u. re + Need 1 e

1„ 2

149. Synthetic Absorbable Suture
2/0 40mm 1/2 Circle Round Body
Needle USP.

Suture + Need 1e

1, 2

150. Synthetic Absorbable Suture
1/0 40mm 1/2 Circle Round Body
Needle LISP.

Suture

Need 1e

1 , 2

151 . Synthetic Absorbab1e Suture
1 40mm 1/2 Circle Round Body Heavy
Needle USP.

Su tu. re + Need 1 e

1 . 2

152. Synthetic Absorbable Suture
3/0 36mm 1/2 Circle Taper Cut
Needle USP.

Su t u r e + Need 1 e

1,

153. Synthetic Absorbable Suture
3/0 17mm 1/2 Circle Taper Cut
Need 1e USP.

Su tu re + Need 1e

1, 2

SI .
No .

31

Need 1e

■n

1 , 2

2

•n

r-.

ID ■-•
> I- '•
Qi -J

I
I
Qi

n
Qi

Hi

T3
Qi
Qi
Z

•S'

'6

iU

Qi

Hi

’0

T.I
QLU

Qi
Qi
Z

111

Hi

1'

Z1

U'

3 -E:
k
CI
11

Qi

□

Qi
L.
3

3
4-'

Ci
LG

Qi

Qi
L.
3

5

I:

J.'

4-1

Q:

Qi

3
4'
3
Li

"i

111
L
3

IT!

I

4-'

T1

>

I
I
I

i •

cr

LJ 23
GJ k
k. -h Qi
3 U
LrJ

44 f.'
3
LO

0!

Qi

li'

=N zi

ID
ID
E
iti

Z

(fl
£

£> r~.
I'D 1!
£ k.

.0
03 u
£ O
0
If!
£

Lfi
£ r-j

<1
L.I

Ci
LG

.4 3

Qj Q IB
£
-n

4-'
XI
E O Qi
>
IB

t

>
iH

m
k- O' ±

6 L

E
Qj ■-•

si i

4?

IB U
k
3 k
ID
3 Ci
LG 03

Qj

im
Li ■-J
•h tn

4-'

3
u
k
ID

ci
03
44 1-

id
£ Qi
44 -i

ID
k U
3

n

QI

I’D

J1J O

'D

k. O
O
ID
.Ci
E
<[ ID E
r< LCj
H H M

1’

•H LG

ID 44
£

O’
C

GJ

LG -< Z

E C 44
> -H 3
LG > U
<■

LI’J

U9
U9

tn

Ci
L.
U

U

Li

D

ST.

ill
E
LJ

l.i

T3
ID
4-'

O'

III

4-J

3 r-i

3 —
LG ID
£
ID U _
ci..

£ P
r- zi
iD
£

Qi

k O
Ci '■■.

Hi •S'
£

X3
ID
Qi

<r in z

N
U 'H £
•H LG £
+•■
<i
ID 4-.’
£ IB

c

Cl
L.

LU

£

E 0 E
> H o
LG > ct

0
L

Cl
CL

LJ
*
k. Cl
•H I..G
ID U 13
k
4-'

1.13 Z
£
U >

03
k.
4-'

•r4

Cl
Cl.

u
k.
ID Li
k
3 r-J

LG

GJ

r.

ID <1
k r-3

ID

44

ill
111 XJ
£ Qi

U ID
£ LCi Z.
X' cr
£
k G
£
•3
in in -j
£
D
<1 Qi O
M
U 'H e
•h to e

&

44

<1

x ID

3 O CL
19 •••■-. LG

r -i z

QJ
ID

Qi

£

M r~l
03 -H X'
£ LG Qi
kID
C X3 z
Ul Qi
£ XJ E
C -H £
03 O
u k. -O
•H El
O'
GJ X E
£ Q' ■H

44
0 X)
h O

b? > ra

0 X
H Cl
LG > LQ

C

co
U9

Qi

11'

T.i
Q'

TO
Qi
U«
cZ

4

4

4

4

Qi
L
3
4-'
~i
LT'

GJ
L
3
4-'

Qi
3

Qi
k
3

Qi
L.
3

1:

5

Zi
in

id

ji1

n
G.I

4 J Et
3 LG
LG

>- XI

z QJ
c

3
•
LJ CL
LG
E
X £ Z
-< E
h <1 Qi
!?

>■ P

19 23 W
O
U9

E • ••-

ID

£' ° *

s

lb
c
c*

Ch

Ch
C

ID 4-'
L
3 J
U

Qi 4-'
k 4-'
3 3

"i

U

in
Qi

z xi

Qi

Qi

44 CG
E •■•-. Xi
ID I-"' ID
£
~
il:
X £ Z

£

Qi

0 C £
E -- 3

Qi
Q

c

3

E
CJ LJ CL.
-- k LG
> -H Z
Z LJ

■h <1

i!

QI

■£

LG

Qi
Qi

GJ
•D
Tj
£

1.

Qi

Qi

0 o xi

C TJ 4-'

Qi
L
3

3 Hi

3 3
l. 9 £
03
E Ci
Ci LG

Ill

c

CJ 3
k 4-'

k. 4-'
3 03
4-' r~;

g

Qi

c:

■H

Qi
flj

3

£
CT'
•H

c
h

3
D
•ct:

O'

(D
13

4-'

c

ID
Ifi
k.
ID

Qi

Ti
Qi
_Qi

d.

4

Hi
r-H r-i

I
I
I
I
I
I
I

Hi
T3
111

Qi
K

Qi
111
Li:.

Cl X
Ci ID

k.
Qi _3
F'-r
E Qj LG
E

4-i
C

k.
...

■4 '

Q.i
ID
Q: k.
XI ID
■13

>

E

111

Li X

0.

IB

£

£

E !li
CO 0
X

Cl

£
LTi

c c- a.-

£

O

.9
0 Lf0
£_

z co z

E O Cl.
IJ
LI
Z 13 Z)

<i

-o

K‘
<1

Ci

O'

ID Ci
k IXi

3
LG

3
-1.9

O'

Qi
TJ
T.'
E

::i

>■ (I

r1

03

-

U

3
LG

E 3
IB L.j
E
•r- £

05

Q'

k n.

■rr
D
E O Q.
CJ -x LG

z cj z
'■0

X3
C CL
3 LG
Ci Zi
U.« Ct
X?
11'
03 111
E
Xi
> U 111
k Qi

0 T.1
Ci ff.

E M
Cl (3

J.J

44 r-J
C

Qi
k.

ID

3

E 3
GJ L
E
03 E
r- £

<*

■4- fJ
0
E C
d '•■•

E

03 £- 3
r-, £ CG

o

■u- q

C
C G

SC tin
<j

<
-CJ

i:i

c0

SI .
Nc.

I tern Name
( 1 >

Formu 1 ation
(2)

1 67 . Mono f i1 amen t Po1ymade Su ture
1
50mm 1/2 Circle Pound Body Heavy
U_oop Suture) Needle USP,

Level 5
(3)

5u tu re

Need 1 e

1 .*

2

Mono-F i 1 aiTi&p. t Polymade Suture
1/0 40fT«Ti 1/2 Circle Heavy Needle USP,

SU tu »■'e

Need 1 e

1 ,

2

Mono fi1 amen t Po1ymade Su ture
1 40mm 1/2 Circle Heavy Needle USP,

5u tu.re

Need 1 e

1 ,

2

Monofi1 ament Polymade Black Size 1.
lOOcms 1/2 Circle ReversE, Cutting.,
500m m H e a v y N e e d 1 e U S P .

Suture

Needle

1 ,

■7

Po1ypropy10n e Mes n
Size 6cm # 11cm

Meeh

1 5

172, Pol y p t- o p y 1 e n e M a s h
S ize 15c m $ 15 c m

Me s H

1 ,

173. Po1ypropy1ene Mesh
Size 30cm # 30cm

Meeh

1

Monoti1 ament Prolene Suture
6/0 13m m C u r v e d Pound Bod y Dou b1e
Need 1e USP.

a u t o. r e -r- N e e d 1 e

1 ,

T5

MonoFi1 ament Prolene Suture
3/0 22mm curved Cutting Needle USP.

Su tu

e

* Needle

1 ,

•p

MonoFi1 ament Prolene Sutu e
2/0 25mm Taper Cut Needle
Need 1
(90cms Sutore)
USP .

au.tu re

Need 1 e

1 ,

2

Mor.ofi 1 ament Prolene Mesh
17.-.-s X llcms USP,

Mesh

1

2

MonoF i1 ament Prolene Mesh
8.5cms X 11 cms
USP,

Mesh

1 ,

•“7

Mono-F i 1 amen t Prolen e S u t u r e
2/0 17mm 1/2 Circle Taper Cut
Needle USP.

□u t’j.re

x Needle

1 .

2

M o n o F i. 1 a m e n t p r ■ o 1 e n e S u t u r e
1/0 25mm 1/2 Circle Taper Cut
Needle USP,

5 tj t u r e

4- N e- e d 1 e

1

2

168.

169.

170.

1 74 .

175.

176.

173 ,

179.

1 SO .

“T -T

"7

Leve1s
(3)

Formu 1 ation
(2)

I tern Name
( 1 )

SI .
No .

X-RAY
Powder

1 ,

132. Barium Sulphate Suspension 75’4
W/V ( M i c r opaque Sus pen s i on -F or
Double Contrast -For Gastro
Intestinal Tract) IP/BP.

Suspension

1 ,

133. Sodium Meglumine Amidotrizoate
(Iodine Content 60’4 USP)
(10 AMPS IN CBB)

In j ec t i on

1 ,

•y

134 . Sodium meglumine Amidotrizoate
(Iodine Content 76’4 USP)
(10 AMPS IN CBB)

Inj ec tion

1 ,

—•

Iohe xo1 10ml 180mg/ml
(25 AMPS IN CBS WITH HCP)

In jec t i on

1 ,

•“7>

Ichexol 10ml 240mg/ml
(25 AMPS IN CBS WITH HCP)

Inj ec t ion

1 ,

2

Iohexo1 10 m 1 300m g / m 1
(25 AMPS IN CBB WITH HCP)

In j ec Li on

1 ,

-j

1-31 .

185.

186 .

187.

Bari u ir S u 1 p h a t e

Compound IP,

NOTE
1 .
“•

I terns Mo,

52

to 76. will he in use where Dental Surgeon i s avai1able.

I terns No. 77 to 87 will he in u s cs where Intravenous -Fluid preparation -Facilit
is available.

■Fac i 1 i t i e s

3.

I terns No. T30 to 140 will he in u s e w h e r e E y e / E N T / P 1 a s t i c S u r g e r y
are ava i 1 ab 1 e .

4,

All suture material i-f a v e e x p i r y dates.
Checl For some on indenting and on regular basis,

5.

h e n b o u g h t s e p a r a t e 1 y are more
s ut ur e mat er i a 1
and
Need les
use Fu1 to the s ur geon s w ho can use without wasting.

6.

ihere
are other
Indian Companies
ape t
manufacture and market suture material,

7t

synthetic suture material are rarely used and very expensive and need
Al 1
to individual surgeon who use them -For accounting.
They
are
be given
econc-m is a 1 to be purchased and stored.
Q _ Q __ 0 _ 0 _ 0 _ 0 _

34

•From

Johnson

and

econnmi c a1

Johnson

WU:

Ill. LABORATORY CHEMICALS

01 . Acetic Acid 1% IP
02 . Benedict's qualitative reagent
(20 Bats, in a CB box with Honeycomb partition MFI
03 . Benedict/ s quantative solution reagent

04. Xylene

pure .

05 . Chloroform A.B.
06 . A c e t o n e E x t r a P u r e

07 . Paraffin Wax MP 58 degree C to 60 degree C
08. F o' t a s s i u m A1 u rn i n i u m S u 1 p h a t e p u rifled

0 9 . H a e m a t o xy 11 i n
10. Mercuric Chloride purified

11 . Eosin
12. Bis mac k Brown

13 . Light Green
14. P o t a s s i um Iodi ne IP.

15 . F o r m a 1 d e hy d e

16

Go1d Ch1oride 1gm

17 . A c t i v a t e d C h a r c o a 1
18. S o d i u m B i c a r b o n a t e
19. G1 a c i a 1 A c e t i c A c i d

20. M e t hy 1 e n e B1 ue

21 . G e n t i a n V i o 1 e t
22 . S o d i u m C h 1 o r i d e
■ 7 -I
ij -J .

C a r bo 1 - F u s c h i n

J 4 . Glycerine

25. 3od i urn Me ta- Bi s u Iphate
26. Potassium Hydrogen Ortho Phosphate
27. Sodium Hydrogen Ortho Phosphate

28 . Potassium Di-chromate

29. 0 o n c e 111 r a t e d 3 u 1 p h u r i c A c i d
30. C o n c e n t r a t e d N i t r i c A c i d
31 . Tri-Sodium Citrate

32. Orange-0
33. Schiff Reagent

34. bl ent r al. Red
35. Sudan III

36. M e r c u r i c 0 x i d e
37. Sodium Thiosulphate
.38 . Iodine

39. Alcian Slue
40. Phospho-tungstic Ac id
41 . Liquid Paraffin
42 . DPX Mountant

43. L i qu id Ammoni a
44. C o n c e n t r a t e d H y d r o c h 1 o r i c A c- i d
45 . 3 u 1 p h o 3 a 1 i c y 1 i c A c i d
46 . Sodium Nitro Prusside
47 . Thrombokinase 10 mg Tablet
48 . Silver Nitrate
49 . Egg Album in Flake s

50 . P o t a s s i urn H y d r o x i d e

•^■3 7

51. Calcium Chloride
c r>

Sc ho r r ' s S o 1 u. 11 on

r <?
-J .

Drabkin's Solution

54. Glycol Methacrylate
55. S odi am Ethox1de

56 . Sodium Methoxide
57 . Para-formaldehyde
58. C a 1 c i urn A-.j etate
59 . Sodium Acetate

60. Sodium Borohydride

61. Acid Fuchcin

62 . Ba sic F uc hc i n
63 . Ether AR
64. Glacial Acetic Acid AR

65. Sodium Tongstate AR
66. Molybdic Acid AR

67. Copper Sulphate AR.
68 . Sodium Carbonate AR

6'9. Sodium Hydroxide AR
70. T^taric Acid AR

71. F o t a s s i u m 0 x a 1 a t e A R
72. Sodium Citrate

73. Ammoniurn Oxa1ate
74. A mmo ni um Sulphate

75. Picric Acid AR
76. Ferric Chloride AR

77. Perchloric Acid AR.
73. Trichlo.ro Acetic Acid AR

CMFlDkNri^L
Table 17.2.1 Essential Dmg List for 30 to 100 Bed Hospitals
SI.No. item Name
___ 1 Atropine sulphate 0.5 mg/ml ip, 1 nil
____ 2 Valatliamatc Bromide 8 mg/ml 1 ml

?

Formulation

__ini_____

__ ini_____

____ 3 Mephentermine 30 mg/ml IP, 10 m!
__ !lu______
____ 4 Adrenaline I IN 1000 BP, I ml
__ Ini______
____ 5 Heparin 5000 lU/inf IP, 5ml
__ !ni_____
____ 5 Pentazocine Lactate 30 mg/ml, 1 ml
__ Ini______
_____6 Diazepam 10 mg/ 2 ml IP, 2 ml_________ __ Ill!_______
____ Z Suxamethonium Chloride 50 mg/ml, 10 ml __ Ini______
____ 8 Dexamethasone 4 mg/ml IP, 2nd______ __ ini______
____ ? Ilydrocortisone Sodium Succinate_____
__ ini______
____ 10 Insulin 40 iu/ml IP, 10 ml
______
__ ini______
H Frusemidc 20 mg/ml IP, 2 ml ______
__ ini______
____12 Mcthyld Ergometrine 0.2 tng/ml IP, 1 ml __ ini______
___ 13 Oxytocin 5 iu/ml IP, I nd___________
14 Gentamicin 40 mg/ml IP/BP, 2 nd

»

I
o .

I?.

J

•

___ 15 Pencillin - Benzyl 5 lacs ID IP
___ 16 Benzyl Pencillin lOlacs ID IP________
17 Polyvalent anti-snake venom________
18 Dextrose 5 % INJ. IV IP
___ !2 Aminophyllinc 2.5 % INJ. IV IP, 10 ml
___ 20 Ketamine 50 mg/ml DSP, 10 1111
___ 2] Pyridine Aldoxime Methiodide, 20 nd
22 Lignocaine 2 % W/V plain BP, 30 nd
___ 23 U>»npcn(oiic Sodiuni 500 nig IP
B111 w*4h-Benznphen; 2 ml
Kanilidinc 50 mg, 2 ml
26 Dopamine Hydrochloride 40 mg, 5 ml
27 Metoclopramide HCL 5 mg/ml, 2 nd
28 Aqueous solution of Hcmocoagul, 1 nd
29 Aluminium Hydroxide 500mg
30 Furozolidone 100 mg
j^4- Iodo Gldcmjhydroxy Qumolino32 Propranolol 40 mg IP
33 Spironol Aelone 25 mg
34 Acetyl/ Salicyclic Acid 200 mg
34 -Analgin 500 mg4R
37 Paracetamol 500 mg BP/IP ______
38 Phenobarbitone 30 mg IP
39 Phenobarbitone 60 mg IP
___ 40 Diazepam 5 mg IP
___ 4 I Phenytion Sodium 100 mg IP
___ 42 Ibuprofen 400 mg IP
43 Diclofenac Sodium 50 mg
44 Indotnctliacin 25 mg
___ 45 Hudro.xy progesterone 250 mg/ml. 1 ml
___ 46 Prcdnisalonc 5 mg IP
___ 47 In
' sulin Zinc Suspension (Lente)
48 Glybcnclamidc 5 mg IP
49 Fnisemidc 40 mg IP
50| fctiacyclinc 250 mg IP

105

__ !ni______

__ ini_______ i

__ ini______ i
__ ini
__ ini_____
____ INJ. IV_____

__ ini______
Inj

__ ini______
__ ini______
__ iniL_
_ iBi__

INJ. IV

JlBl__

JlBi___
fab
la

I Jab
jjib
fab

. li’k
fab

bi’k.
lab
Tab
Tab^
fab
Tal^

fab

ll'L

Tab_
fab_
Caps

1

I able 17 2ssenlial I )iug Lis! Ibi 30 to IOt) Bed I lospilals (’onliniicd

SI. No.

I'oi nmlalion

Hem Name

Inj

51 Ampicillin 25<>d mg H7I[P__
52 Ampicillin 500 mg BP/IP
5 I Amoxicillin 100 mg

Ini
(ops
lab

__3j Not floxacin

lal^

55 CipioJHjxacin 500 mg

ZI
(J
_J7 Am] >ici 11 i 11 25 (Id mg II7IJP

lhllyZ
9'1^____

Cipiolloxacin 2 ing/ml

Lajis

58 Clilmamplicnicol 250 mg IP

jab_^

7759 f -ntlHomyciiHsstolalc 250 mg
Ld_____

60 Pcncillin Piocainc 20 Iacs 10
Pcncillin 12 lacs

Inj

___ 61

lab

___62 •<’!! 111!El*2ElHoxazolc 400 mg___
63 Metronidaz.olc 5 ing/ml, 100 nil
Mctkmikl:iz.oIcjU)0 nig BP/1P__

"

LNLjV—
Lab

Tai.7 ”

65 Mcbc^Lizolc 100 ing
~66 1 claims
'
Toxoid 10 doses 1P/BP

ipjZZZ
Vcc

2___ 67 A1 iti RabiogVaccinc, 30 nil
__68 CaIcimn Gluconate 500 11 ig BVBP

!

ban

69 Next ipse 25 % INJ. IV ]PI 5_ nd___________
JO I’o(assium Cli101 ide 15 % W/V USP

’~7I Sodium Bicarbonate 7.5 % W/P. 25 ml

_ 72 Sodii nnCI iloj klc_0.9_%_iP,_510 m|_________
73 Sodium Cbbride with Dcxltosc, 510 nil
71 S0(I i m 11 LacI a I c- co 11 ipo 11 ncL _5 10 m I

rzj!

_____

Salb 11 (a 1 ppMmg IP______________________

____ 7(j I c r b 111 a I i 11 2.5 11 igJJSP___________________
C111o 1 jj)hoilical A}yiI[caps_j %

1.2Z

___ 78 GcimunKciii 0.3 % W/V USP, 3 ml
79 C111o 1 p11 e 11 i 1 amino Mcleatc 10 mg, I nil
80 C111o 1 p11 cni 1 a 1 nine Mcleatc 4 11 ig■
81 C11101011 ex id inc G11 iconatc 7.5 %, 1 It
82
JJI 450 in*
83 IodincWeak Solution TR-1P, 450 ml

KJ Ijlici - Anaesthetic IP, 500 m;
^_85 Fla lol iianc _[J_i yjEWj’l’—_________________
86 Lignocaine 5 % W/V (Heavy), 2 mj

i

i

!

l_NJ_. I V
iNJ.jy’i''

inj. iy

INJ. iv7
Tab

DlLOinl__.____
Diops

lnj_______

Tab__

Lsil___
Letd

L(|d_ _77I.
Lqd

____

LlJ____
!l'j_______
iNJjy___

88 Vai al 11a 11 in Ic Bi omidc 10 mg_____________
*89 Ramlidinc 150 nig

I ab 7_
Tab

1 90

b»i777~ 1

Llopiiyljn I<29.4 mg 1 hco|)h\Hine, 2 ml____

_’’9931 I >ji gox i 1 >_0 J 5 n 1 g 11 ’

yinj__

Mclocliloioj)ianndc_^_____________________

lab

____________
91 Vi la mi n B Qaijncx-llici apciiijc__________

iab

95 Vitamin Bl -33 mg B6 - 33 m. 3 mlg
” 9f’ Benni Bcn/.oale applicalion 25 %,_4 5() n_il_

B.ml

r.?_
z
7 98

i

!’U_______

’’ 87 Mrtmiiloi 2^

2! l iainycctin Sulpluile I % W/W IP, 100 gm

<

i~Nj.~iv

ial)

Pichloioniclax) leno! 105 2<pBWL7.L_5 [I___

Lqd

I'oi 111:1 Idchyde II’. 500 ml

I .qd

99 Walci loi Injcclion. 5 ml

Ini

106

7

I able 17.2.2 Lisi of Dings for Distiicl Hospitals
I n joe I ions________
_lLJ?e[oiol

_ J ablets___________
J.________ 3(M) mg-

..Z^Ai’P’iophjJ line
3. A11 qpji i nc__________

_L

:_A tllZl’a H n c _________
5. Botropliasc
.!>• Bcnzcllicnc Pcnciliin 12 Lakhs
-j^-A Si V (Ami snake Venom Scrum)
A—betamethasone 4 nig./ml.
Jdlaralgan or Bnscopan
JO. Vit. V (500 mg)___________________ _
I L. Calcium Gluconate
12. Chloiomycclinc
i
JL-CiT,-, Id Lakhs (Crystalline Penicillin)
V <’
.-!.15
1DohbpaiW Lakhs___________________
M r ( JA_ Pupa in inc
16. Dcriphyllin
————-———_

V.

.. 11-- Dextrose 5%
JK. Dexamethasone
_______
J2i_Amj)icillin 500 mg.
7IP Fiuclodcx (10 Per cent)
_2_LJJcxlrosc Saline
_2j. 1 lacrnacccl (450 ml)
-JlJnsnlin - Plain 10 ml \ iai

5._ Atcnalol 25 mg, 50 ing_________
__ 6.
lab. Buscopan
__ *7.“ Biufut^K/ing. ‘IjMjnfl*

------ !L

P•’£1ex 1j■ ipeutic and JTio|>h> lacb

— JL__ Ll’l’LY'JaiaijlJJienyjcun^
------ llL£aj)^j:]dpionuccHnc_^
_ H- lab. COM 4 mg____
‘

"

.1^ Ciprofloxacin 500 nig^jjj mj>_
! 1 t_l?jfioxin 0.25 _ing___________

__ J C-I^iazepiiai 5 mg
___ 15. Diiodohydioxy Quinoline
l!LJ?en|)l^|j2ijclaicb_
— .J.L_ fJiclonac Sodiimi
___ !LJiLV;Die.91L5jJJfJI_2-5jlig
----- *2:_C\?JL;rchacyclinc_2^
- ^LLJ.aJL_LLluimbj
_ -Suipiiatc (JOO mg)
__ 72.

I

lab. Lasix:J0_nig_

_ ^^l^ hiiiuqijdmj^i^^

-llJnsulin - Lente 10 ml vial
25. Lasix

26. _Mclaclopiopainidc_ _
. 2 7. Meti(Hiid;i/.qlc________

Asj2i 0 n 15() ing. JO0 mg

__ J. Paracclamal SlMHajJ
__ A__LajX-Ainpiciilin - 250mg,500 mg

|

_ -Zl^J'ab. Lobe Acid (5 mg)
I
2.\ Tai) hJiI 300 mg____

■

. 7R_Nqnnal Saline__
-7*2. I hJ loco [Ozone _Sod ii 11 n Succinate
-3(JLl^lfI)RinlN) 100 mg

-2i-_Alaani_lo£7(]_2i

2b:_J('P;H amide
- - j-7-. J ab Nlcbcndazaic

.
_
.

A+mitii -

K• Magiicsiniii jj isHicale _
7^- d al). .M.clL,lLy.PPa_25O nig
-3(). Cap. NilcdajijjicL5 JO? 20 mg~

.. ^l^^T’LHedmsqlonc^, HHng

J7._ Prtx pcnicillinc (4 Lakhs)
JJ. Ranitidine
2 L..L’2 a’n (2-Pyriidinc Aldoxinic Meth-odidej5
J5, Ri!’/;er lactate___________

J7•.Jlab.. Phenobar£iik)_n_c_Sodinni_JOjtijg, 60 ing
3J. Tab. <<«?LyjHcijijc_X5(nn/>^00 ing_
J 'L_Cap_. IP /a in pi c in £50 j ng, 45 0 nig ~

35. lab. Salbnlaiiiol 2 nig, 4 mg
J 6 ■ ’I ab. J \Yiiz i 11 a ini d cJ7 50 nig
.27. Tab Septiaii |J._S.
J^-^'alL VJIa^nhiJCJOf) mg.
. 3 (2_ J'aL-. Nj>Lllaxan4.(2O_nig

Jf’:J.I.,.cl’L(mjyjjnc (IG)__
JJ. <d vacai n |xh i I c (0.5 cc)
3"8^ Sltcplo penieillotJ/rgt!! iinulc tkiSrt*-?.__

-P7. I..V^’jpjoj]oxacm IQO nil
-■!d P9:J,r052-75//o, 50 %
JI ■_ _.(2 LS' IpCc nac_ Sodimn

nig

.3 LL. MlIIO.II* (ja z:o£c _
41. Chloioyline

12. Dninatax 5tm mj;. 1000 mg
•13. (hiiamvcin 80 mg
4 I. Imfcjon I 12

'17 •_ J 0 v 11 ii o 11 ly ci I ic I is I co I a I c 2 5 0 11 ig

J-L ! !ll,’,an_iusulin„-J
hi.inan
rJl'.
’U’an adia])id_
acfiapid
J (2 ! .hl i umi. j nsjil m__-J hi ma n JHixlaid__
J4 7.
7i.JPlmivobaidilone
,,.,.c,.lo[’mcliJqnc Sodi
Sodium (Lmninal)i 200 mg
J_'l
ampoules

107

Spin *:Slh
1 (liniments
j
healer coil
2
I ’’’’jnsone__
! Lennvalc
_______
I. Diprov ale

5 p e 111; ilenc
_6.__ 12?1 ho vale Ml-'_____
_L._LL'J.,25*l!i£_______
_L

Miliicoitin-viofoim

9. Uctagel___________
.Jlb_P’pi ovate RD______

_LL.J2j 11! Pile_________
J j . -Re h i be sob_________
_L] • SI c I idci in _______

I

J4-_LxcJ___________
_JJL_L.P idcini
II An(iJjiiiKal Ointment

_LUbtoiol___________
_L__ Ni/.nil____
_ Ca ncsl on___________

.J-__ Ll>111L lop__________
.5._ Ijimm____________
6.
I incdciin__________
_7.__ Ciindid____________
8. Candid B lotion

9.

Stu [az_____________

PJJimP io < men t.<\_____
_J_.__ C<)_t:nv1_____________
2.__ A lode rm _________
.1. GAB '
4. Siloderm
._L__ Ayur calamine
_6.__ Dcrmical _________
7Z__ Moi st 11 !c>j__________
8. CI i n a de___________
_9^ ijylop_____________
.!O:_Llicklin
Jh_ Lltsamjcm_________
12. Genlamycin_________
13 •_ S11 vc i ex _________ _

_lL_AimI___________

I able 17.2.2

Conti ..

______

.

|

----------- jzLdj!LC»!»!.9.R ( Inlar Conipunv). Ampoute'1- Ahacinhim_(1jacmhim). A11ijmtilc
________ C__ A^F3?’il^i_LlL9,J2L£..7_ L2 I'll via] _
________ 1-__ luLLLdlklilLQx-Al!!! >0111 e_
8.__ Morphine, Ampoule__________ ~
------------- ___ I nJ 12ia^J2anL__A£npoiilc_________
------------- ! 1L_ Illi £c L’llliy c i i k\A.in poulc_____
------------- 1L_Jlli.Lbamadal Hydiocldoi_idcj_’11aiilazac). 51)

LL_I’• L Cb £0])jrrola£c. Ainjjgu

_______
15. 1 nj. Jlicncr/ym, Ampoi11e_______
______ _l^!’’i^:ijoii‘Myk.AE,i,oi’!?_________
_______ 12:—Illi DphcdiiiijJydiocliloiidc, Ampoule______
J.!L_1 nJ .CL<ll»onqla[J\ nijxmlc__
______.___ JJa b>tj»aZL^l'jll’pt I les
_______ 2L_PJetii}I ctlici. 500 ml bo(lics__
JL-UlLLbllocajneJJjihgdi^
_____
_____ JLJni Lil'nocajncXblhoelj^
_______
______ 21_1 lli.Li/Oine^iilie Heavy, 5 % ampoule
■
______ 24. Inj Scnsoracainc, 0.5 % anipoulc/yial______
25. Inj Scnsoiacaino Heavy, 0.5 % 4 ml_______
______ 26. lia/inpuldlrvijdHy,_ tubes
_____ _27^_Lp;nocainc viscous, bottles _________
_____ Enie_i r,cncyj)ru^s_
_______
__ _
_____ _L !1 ’.I AlLLcllll!I*1 g,_J>nifnile
_____ 2._ Inj Lasi.v ampoule
____________ L
" "
’ ”
’
- :i’Ai Mcilicn(hic^_JO.ny;/c^
_____ < _!'1 f Lbl’‘JHol 10 %. 250 mi boUlcs___

___

5.

„!^_Retino_____________
JC I’er sol forte

.
J.
Z
C

s

L_ (iiiso\in_bP
_______ 2_ Nizial
______
]-._..C3ncslcn_\'aj; _
J„.!'ox’(l
________ 5. Ncopsoia H n__
________ 6.__ R cc o I i_i i a_________
____ __ Anaesthetics_____
________ L__ IniLLbiojJCJItone sodium. 0.5 j;m7vnd
—_____ 2.__Ini SjicchiJj^

A * * V. ’ Ji ’c 1 ablets
I]js no hl________
Ze I op________
Aiciicl

'l-.J.^'Cinc _________
5. lai is (a I jo nlabs_
_ rolaianiine rcpclabs
,7^_ JI jcxsl .OhJllJl_____

108

Inj Dopamine. Ani|ionics

. _.CAV.^
■

-

• V.
•"■

v

■

'

.

•

'

.

V s<';^
GOVERNMENT MEDICAL STORES, BANGALORE.

1 tern Name
(1 )

>- c r mu 1 a t i on
(2)

Leve]5
(3)

ANTACIDS
A1uminiu m Hyd r0xide SOO mg

Tablets

1 ,

Magnesium trisilicate 500 mg

Tablets

1 ,

3

Cisapride 10 mg

Tab1ets

1 , 2

3

Ranitidine 1 0 mg IP

Tablets

1 , 2, 3

Atropine Sulphate 0.5 mg/ml IP
(100 AMPS IM CSE WITH HCP)

I nJection

1 , 2, 3

Diptheria Antitoxin (ADS)
10,000 IU/AMP IP

Inj ec tion

Tetanus Antitoxin 10,000 IU/VIAL
IF (100 VIAL IN CBB WITH HCP) BF.

Injection

Polyvalent Anti-snake venom serum.
Lyophy 1 ised Ative 0.27. Phenol Before

Injection
with d i s t i11ed water
L y p hi 1 i s t i on

Pyridine Aldoxime Methiodide
(PAM) Antidote -For Crgano Phosphorus
,iscning (10 AMPS IN CBS)

Inj ec ticn

—i

—<

ANTIDOTES

7

1, 2, 3

2, 5

ANTI-SPASMODICS
Vs I .a thamate Bromide Smg/mi 1ml AMP
(25 AMRS IM CEB WITH HOP.)

I nJ ec tion

Va1 athamate Bromide lOmg

-r _ t_ i — j-

Hyoscine Butyl Bromide 20 mg/ml BP.
(100 AMPS In CBS WITH HCP)

I n j ec t i on

1 . District Hospital

’■

1 ,

2,
7

f ci u 1 e <_

3

1, 2

Primary Health Centre. ■o;<7

I

Name

Forma 1 a t ion

Leve1s
(3)

LAXATIVE
Paratrin-Liquid (20 30;3
WITH HCP) IF/BP

IN C5E

Liquid

1,

Furozolidone 27. Suspension

Suspension

i, 2, 3

Lose amide 2mg

Tablet

1 , 2, 3

D i g c x i in 0.25 mg/ml IP
(25 A NFS IN CBS WITH HCP)

In jeez tion

1 , 2>

D i g o x in 0.25 mg IF

Tablet

1 „ 2, 3

DiItiazem 30 mg

I ablet

1, 2

Injec tion

1 ,2

Propranolol 40 mg IF

Tablet

1

Verap<amil Hydrocnl oride 40 mg IP

Tablet

3

ANTI- DIARRHOEAL

CARDIAC

Proca i n am i d e 1OOmg/m1

IP

r~y

I n j ec t i on

*

Di 1sopyramide 150mg

Caosu1e

1

Neredipine lOmg

Tablet

1 ,

Ne-Fed pine Retard 20 mg USF

Tablet

1 ,

Di hvd ra11 a z ine 25mg US-

Tablet

1,

Ne t e r■ c 1 o 1 5 0 mg

Tablet

1 , 2

Enalapri1 Na 1ea te 5mg (Strip)

iablet

1 , 2

G1 y c e r y 1 Tr in i trate 0.5mg IP

Tablet

1 , 2, 3

Isosor bide

Tablet

1 , 2, 3

Ve-raoamil

HCL 5mg/zml

IF

-“ 7

1 ANT I-ANGINAL

5 Mono Nitrate 20 mg

2

3

eve 1
■ 3 :

j=c tier,

■^= r r = t e r! i r- e
j1 ire

1 ,

■T

’~ j sz tier

3

Ir. jec tier

, 2,3

~ z? ~ ~ i

"?

1 ,
.'j: ~

'-1 te
^MPE

—

—

HZ“

'•: CEE

HCr)

I n i =c t i er.

1 , 2

AMT I-HYPERTENSIVE

Me thy 1 dope. Z5Qn-tg

IP/.EP

R e e a - z i/-' a
Cl?'- AM-E

•' 1 > WITH

■ ablet

T

**

1,

z^ = l1 a z ir =
DIURETir

iz=

■ at'. ■= t

r a-

>i I

Tablet

ANTT-nrceetIC

EC

3 1 MT

3P-

I

I n j sz t i or

x i

2

Ir. jec ticn

1 ,

•"T

ZEE MI”In = u I in
A Z IU / Ti 1

■.-‘
•jsz-er. eior. ’• Lente}
VIAL IM C E WITH HCP*

3

h

■

•

- • ■ '--W^

sr'-^

r

Item Name

1 at ion

Levels
(3}

'■ 1 = ‘

9.

Purified Insulin 40 Un its / ti 1
Pork Monocomccnent

In j ect ion

1 ,

Purified Insulin 40 Units/mi
I sophane

Injection

1 ,

Purified Insulin 4Q’ Un its / m 1
zinc suspension

Inj sc tion

1 , 2,

Puri tied I ns u1i n 4Q Units/m1
3 n d Isophane
Mixture or Neutral and

In jec tion

1 , 2,

4Q Units/ml
Purified In^uli
Mcnocomoonent - Human

InjEC tion

1,

Glybene lamide 5mg IP ’

Tablet

1 , 2

Tolbutamide 0.5mg Ir/SF

Tablet ■

1 , 2, 3

Tablet

1

Injection

1

^7

Adrenochrome Mon oee m1 uar b a z on e 0.75mg/m1
(100 AMRS IN CEE WITH HCP)

Inj = ctier

1 ,

-7

3

Adrencchrome Non semic a-r ba zone 0. omg

Tablet

1

-7?

3

Suspension

1 , 2, 3

Tablet

1 ,

Inj ec tion

1 , 2

-n

ANTI-VERTIGO
Cinnarizine 25mg

10.

ANTI-COAGULANT
Heoarin 5000 IU/T1L IP
(100 VIALS IN CEE‘WITH HCF)

10.1 COAGULANT

ANALGE5IC/ANTIPYRETIC
Paracetamol

IZSmg/zml

IF/EP.

Paracetamol SCOmg EF/’P
Ketore lac Trometnamine

■11Omg /m 1

Pentazocine Lactate 30mg/ml
(25 AMPS IN CEE WITH HCP)

■...

,

•

■■■.

..i

...... '■

IF.

............... ......

I n j* ec t i on
■

■-

..

1
■

’

;

•7

3

• 2 . .3

UT.U
’

■’"

■

'

-

•i-

1
4

' tern Name
(1 )

12.

Levels
(3)

BciDrenorphine HCL Q.3ma/ml

In j ec ticn

1 , 2

Buprenorphine 0.2mg

Tablet

1

Ketamine lOmg/ml USP

Injection

1 , 2

Ketamine 50mg/ml UEP

Injection

1? 2

Ibupro-Fen 4Q0mg BP.

Tablet

1, 2, 3

Ibupro-Fen 200mg IP

Tablet

1 , 2, 3

Diclofenac Sodium 5Qmg

Tablet

1 ,

3

Diclofenac Sodium lOOmg S.P

Tablet

1 , 2

3

Die lo-Fenac Sodium 25mg/ml

Tablet

1, 2

3

Diclotenac Sodium SQmg

Inj'ection

1,

3

Diclofenac Die thy 1ammonium
EQ to Diclofenac Sodium 17. W /V

GEL
GEL

1 , 2, 3

Indomethacin 25mg

Tablet

1, 2

3

Gil

1 ,

3

7^

DENTAL

Clove Oil
IP
(25 BOT IN CBB WITH HCP)

13,

r o r mu 1 a t i on
(2)

ANTI-EPILEPTIC

L

Phenobarbitone 20Qffig/lml IF
(100 AMPS in CBB WITH HCP.)

Injection

1 , 2

3

Phenobarbitone 30mc IP

Tablet

-»

3

Phenobarbitone 6Qmg IP

“ablet

1,

Phenytoin Sodium lOOmg/ IP

Tablet

1

Phenytoin Sodium 10Qmg/2ml

Tablet

1,

Carbamazepine 200 MG IP

Tablet

1,

Sodium Valproate 2Q0mg

Tablet

•J

3

2

3
-?

1< 2
€k-

Trihexy Phenidyl Hydrochloride 2mq LISP

3

Tablet

■

.

1
...... ...
■

■

.

•If|

•

--^77

-

I

;iane

■

Levels
(3)

( 2)

PSYCHOTHERAPEUTIC

Chlorpromazine 25mg/ml
fp
(100 AMPS IN CBB WITH HCP)

InJection

1, 2

Chlorpromazine 25 mg/ml

IP

Tablet

1 , 2, 3

Chlorpromazine lOQmg/ml

IF

Tablet

1 , 2, 3

4

Diazepam 10mg/2ml IP
(100 AMPS IN CBB WITH HCP)

Injec tion

Diazepam 5mg IP

Tablet

1 , 2, 3

Fluzetine HCL 20 mg

Capsu 1 e

1,

Amitrypty 1ine Hydrochi oride
25mg
IP/BP

Tablet

1, 2

Tri-Fluperazine 5mg IP

Tablet

1 , 2

Fluphenazine Decanoze 25mq/ml
BPdOO VIALS IN CHS WITH HCP>

Inj ection

1

Lithium Carbonate 300mg IP

Tablet

1

Promethazine 2.57. W/V USP
(100 AMPS IN CBB WITH HCP)

Injection

1,

Promethazine 25 mq

Tablet

1, 2

Oxymetazoline 0.05X Aquoves Solution
(Nasal DrooslUSP C50 BCT IN C8E)sterile

Drops

1 , 2, 3

Hydrocortisone Nasal NFI
‘.50 EOT IN CBB) Sterile

Drops

1, 2

InJ sc tion

1 , 2, 3

I

2, 3

3

ANTI-ALLERGIC

IP

Chlorphen iramine N a1e a t e 1Omg/m1

IP

3,

Chlorpheniramine Maleate 4/mq IF

Tablet

Astemizole 10 mg

Tablet

1 , 2,

Ter-Fen ad ine 60 mg

Tablet

1

Embramine 25 mg
CPKG IN CBB)

Tablet

1, 2, 3

1

6

.. ,

3

.. . ,

^1

- y"’ ’’ "

-

,

_____________

r ormu1 a tion
(2)

I tern Name
(1 )

Level

:

________

?:S
16 .

ANTI-GOUT
Allopurinol

17.

Tablet

100 mg

I

ANAESTHETIC
Gallamine 40mg/ml IP
(100 AMPS IN CBB WITH HCP)

Injection

1, 2

Suzamethonium Chloride 50mg/ml

Injection

1, 2

Pancuronium Bromide 2mg/ml
(100 AMPS IN CEB WITH HOP)

Inj ec tion

1, 2

Tubocurarine lOmg/ml IP
(100 AMPS IN CBB WITH HCP)

Inj ec tion

b

Inj ec tion

1 , 2

Liquid

1 , 2,.

Neostigmine 0.-5 mg/ml
IP
(100 AMPS IN CBB WITH HCP)

Ether-Anaesthetic IP
(IN AMBER COLOURED BOTTLES)

t

1, '2

!

2

Hya1uronidaze 1500 lU/ml
(100 AMPS IN CBB WITH HCP)

Injection

Ethy1 Chloride-spray with leak proof
valve
IP. (25 EOT.IN CBB)

Liquid

1 5 2,

Halothane BP

Liquid

1, 2

Lignocaine 17. . W/V IP
(25 VIAL IN CBB)

Inj ec tion

1 , 2,

Lignocaine 27. with Adrenaline
(25 VIAL IN CBB)

Inj ec tion

1 , 2,

Lignocaine 27. W/V PLAIN BP.
(25 VIAL IN CBB)

Injection

1, 2

Lignocaine 47. W/V (Topical)
(25 BGT. IN CBB) USF.

Liquid

1 , 2,

Lignocaine 57 W/V (Heavy)
(25 AMPS IN CBB WITH HCP)

Inj ec tion

1,

Lignocaine Dental cartride
(25 AMPS IN CBB WITH HCP)

Inj ec tion

1

2,

f

s

■

J

Item Name
( 1 )

IS.

rormu1 ation
(2)

Levels
(3)
A '^5-

Lignocaine - Viscous
(25 VIAL IN CBB)

L i qu i d

1

Lignocaine 27. Jelly DSP.
(100 tubes in CBB)

Jelly

1 j

Thiapentone Sodium 500mg IP
(25 ANPS in CBB)

Inject ion

ihiapentone Sodium Img BP
(25 ANF/VIAL IN CBS)

Inj ection

3

2
■■

1,

PNTI-INFECTIVE

IS. 1 fiNTI-FUNGflL
Hamycin

(vaginal) 4LAC IV (Strips)

Nystatin 1LAC IV Vaginal
(Aluminium Foils in CEB)

IP.

Ovules

1, 2, 3

Tablet

1, 2

Griseofulvin

25Qmg

Tablet

Griseofulvin

125mg

Tablet

2

Nicenazcle Nitrate 27 (Skin)
(100 Tubes in CBB) DP/USF.

Ointment

1 ,

Nicerazo1e Nitrate 27. (EAR)

Drops

1, 2

Injec ticn

1 ,

Capsule

1, 2, 3

Cefotazime Img

Injection

1, 2

Doxycycline HCL 1OOmg

Capsu1e

1 , 2, 3

Injection

1, 2

Injection

1, 2, 3

IS.2 ANTI-BACTERIAL

Tetracyc1ine-Cxy 50mg/ml IF
(100 VIAL IN CBB WITH HCP)
Tetracycline 25.0mg

Gentamicin 40mg/ml
(100 VIAL in CEB)

IP

IP/BP.

■

Ampicillin 250mq
(100 .VIAL IN CBS)

IP/BF

' '

■

• ■

;

7

: <:7 .

r

3

.

j?

'‘K,

S

■
.

..

J ' k <'7

Formulation .
(2;

Item Name
' 1 <

Level 5
<3)

Injection

1 ,

Capsu1e

1 , 2, 3

Amoxicillin 250mg EP/IP.

Capsci 1 e

1, 2,

Amoxycillin 500mg

Inj ec tion

1

Norfloxacin AOQmq

Tablet

1 , 2

Nalidixic Ac i d SOOmg

Tablet

1 , 2

Nalidixic Acid 200mg/5fnl

Syrup

1, 2

Cipro-f loxacin 500mg

Tablet

1 , 2

Ciprofloxacin 2mg/ml

Injection

1,

Injection

1 , 2

Amo ic i11i
■100 VIAL

oOCmg

Ampicillin 2S0mg

I=/SF.

IP/EP

Chloramphenicol Succinate Img Vial
(100 VIAL In CBB)

IP.

2.

I

■n

Chloramphenicol 250mg
(100 VIAL In CBB)

IP.

Capsui 1 e

1 , 2, 3

Ch1 cramphenico1 SOOmg
(100 VIAL In CEE)

IP

I n j‘ ec tion

1 , 2, 3

Cloxacillin SOOmg/VIAL IP/SF.
(100 VIAL in CEB WITH HCP)

Injection

1 , 2

Cloxacillin 250mg
IP/BP.
.(Aluminium Foil Packing.)

Capsu1e

1

Erythromycin estolate 100mg/5ml USP.

Suspension

1 , 2

3

i ablet

1 , 2

—

[Kanamycin Sulphate Img IP
-<100 VIAL IM CBB WITH HCP)

In j ec tion

1

Panei11in-Benzy1 S LACS IV IP
<100 VIAL IN CBB WITH HCP)

Inj ection

1, 2

E-enzyl Penci 11 in lOLAcs IV IP
• ICO VIAL IN CEE WITH HCP)

Inj ec tion

1, 2

IP/BSP

Erythromycin estolate 250mg

9

-2

’ .

7

.

.:;7

3

.

■■ w

, ||

.I

______ _____
I
I

I tern Name
( 1 '

pormu I a11on

Fortizied -•^ccaine Pencil 1 in
IV IP.
I 4LSC3
IN CSS WITH HCP)
(100
VIAL
I

I

V •<
■■

|

(2

Level(3)

I n j ec 11

x?

Pencillin Procaine 20 LACS IV IP.
(100 VIAL IN CBB WITH HCP)

Injection

1 , 2’ '

Benzathene Pencillin 6 LACS IV IP.
(100 VIAL IN CBB WITH HCP)

Injection

i, 2, :

Benzathene Pencillin 12 LACS IV IP.
(100 VIAL IN CBB WITH HCP)

InJ ec ticn

i,2,:

Benzathene Penci 11 in 24 LACSZ IV IP.
(100 VIAL IN CBB WITH HCP) ■'

Inj ecticn

1 ,

Su1phadiazine SOOmg IP.

Tablet

1 ,

Tablet

1 , 2

Trimethreprim SOmg
Su1phamethoxazcle Bp/IP.

Tab1et

1 , 2

Trimethoprim 40mg
Sulphamethoxazole 200mg

Tablet

1,

Trimethoprim 40mg
3u1phamethoxazole 200mg/5m1

Suspension

Methenamine mandalate O.omg USP.

Tab1et

1 , 2, 3

I
I
Su 1 phadiTiidine SOOmg

I
I

I
i
i
I
I
i

IP.

IS.3 6NTI-TB
3

Ethambutol

2C0mg

IP

Tablet

1

Ethanbuto1

400mq

IP

Tablet

1 ,

Ethambutol

600mg

IP

" a b I e tl

1

Ethambutoi

SOO mg

IP

Tablet

2

2, 3
•-'tl
■' ■ 4

Isoniazid

1 OOmg

IP

Tablet

1

2, 3

I seniaz id

300mg

IP

Tablet

1 , 2, 3

Rifampicin 150mq

IP

Capsu1e

1 !» 2 ’ y

’

■n

3

2. I

J
10
■

:.vvi *

#1
______
I tern Name
1>

Pormula t ion
(2>

Levels
(3)

Hi + ampic in

IP

uapsu 1 =■

1 , 2, 3

Ri-Fampicin 450mq

IP

Capsu1e

1 , 2, 3

Syrup

1, 2,

injection

1 .» 2, 3

Clofazimine lOOmg IP.

Capsu1e

1 , 2

Clofazimine 50mg

Capsu1e

1,

Inj ec tione/1V

1, 2

Metronidazole Benzoloxylate
Suspension Equivalent to 200mg/5fnl
Metronidazole

Suspension

•<

Metronidazole 20Qmg BP/'IP

Tablet

1 , 2, 3

Metronidazole 4Q0mg BP/IP

Tablet

1 , 2

Trlnidezc1e

Injection

Ri-Fampicin

lOQmq/ml

IP

Streptomycin imq IF
(100 VIAL IN,CBS WITH HCP).

IS.4 ANTI-LEPROSY

IS.5 ANTI-AMOEBIC

Metronidazole 3MG/ML 100ML in
Aqueous Base
BP.
(100 BOTTLES IN CEB WITH HCP)

2, 3

7

n i c a zcia 300mq

> ab1et

1,

'inidazole oOOmg

I ablet

4

Metochlorpramide HCL IQmq BP

Tablet

1 ,

Metochlopramide HCL Smg/Smi

Liquid

1, 2

Metochlopramide HCL 5mg/ml
(2c AMPS IN CEB WITh'hCP)

Injec tion

1,

Dem pe r i d on 1 Omg

Tablet

1

■•7

3

■5WT ■

■O^
•

■

■

w ■ '

.

Formu I ation
(2)

——------------ Level ’
<3 ):

Chloroquine 250mq/ANP. IP/BP.
(100 AMPS in CEB WITH HCP)

In jec tier,

1, 2, :

Chloroquine Z50mq BP.

Tablet

1 , 2, '

I Item Name
( 1 )

IS. 6 ANTI-MfiL^F?I^L

I

Primaquine /’.□mg BP.

Tablet

1, 2, Z

Primaquine Z.Smg IF'

Tablet

1 , 2, 3

Sulpadoxine SOOmg Fyrimethamine 3omg

Tablet

1 , 2, C

Diethyl carbanmazine Citrate
50mg
IP/BP/USP.

Tabl-et

1 , 2, 3

Diethyl carbamazine Citrate
lOOmg
IP/Bp/USP.

Tablet

1,

Inj ec tion

1,

IF

Tablet

1 ,

Dienestro1 Crsam (Cream BaseX
(0.01Z W/W wi t h Applicator USF,
25 Tubes in CBS?

Cream

1

Oxytocin 5 IV/ml
IF,
(100 AMPS in CBB WITH HCP;

Injec tion

1 ,

Hydroxy progesterone 250mg/ml USP

Injection

1 , 2

Dexamethasone £mg/ml
IP .
(100 VIALS IM CES WITH HCP’

In j ec t i on

1 , 2,

I n j ec tier.

1

IS.7 fiNTI-FILfiRIAL

IP. OBSTETRIC

Methyl Ergometrine 0.2mg/mi
(100 AMPS IM CEB WITH HCP)
Methy! Erg ometri e 0,125mg

IF

T

20. HORMONES

Triamcinolone Acetonide IM
40mg/ml USP. (Cortico Steroids)

.

_•

it
>■

12

■

■

..

-t:’-

S as ■

ATI ■

-I'’..

•

’• •-

w.
- *.

.

I tern Name

.

■■■

'

Fc^.tiu 1 at ion

-

■

bevels
(3)

( 1 }

Trimacino1 one AcStcncide
lOmg/mJ USp (Intra Articular Cc-rtico
Steroid >

Injec tion

Precnisalcne 5mg

IP

Tablet

1 , 2, 3

P^sdnisalcne IQmg IP

Tablet

1, 2

Predni = a 1 one 20mg IP.

Tablet

1

Tablet

1 , 2

Stilbesterol Diphosphate IQOmg

Capsule

1 ,

Stilbesterol Diphosphate 25Qmg

Injec tion

1, 2

Injection

1 , 2, 3

Thyroxine Sodium 1QOmg

21 .

.

IP

3

VACCINES

Fetanus Toxoid 10 doses IP/EP
(100 VIAL IN CBS WITH HCP> •

■

i

SERA
An t £

"A" Sera

An ti

'’S”

Anti

"AB” Sera-.

Sera.

1

2

”»

Sera

1, 2

3

Sera

1 , 2

3

Sers

1

o •

3

Coombs Sera

Sera

1 , 2, 3

Australia Antigen Kits •Per Elisa method

An tiqen

1

Australia Antigen Kits for Slide Test

Antigen

2, 3

VDRL Kits of Slide Test

Diagnosts

'7?

An t i

23,

S e a IP

Sera

(monoc1 ona 1>

3

ANTI-HELMINTHICS

Nekendazcle 1 OOmg

Tablet

Mekendazo1e 1OOmg/Sml

Suspension
■

■

--

7

■■ s

^crmu 1 -s t icn

I tern Name.

Levels
(3)

24. ANT I-CANCER

Cyc1ophosphomide 50mg/VIAL

Injection

1

CycIcphcsphcmide lOQmg/VIAL

Injection

1

Cyc1ophosphomide 200 mg/VIAL

Inj ection

1

Cyclophos phorn ide COOmq/VIAL

Inj ec tion

1

Tablet

1

Cyc1ophosphomide lOOmg

Tablet

1

Azathioprine 25 mg'

Tablet

1

Mercaptopurine 50mg EP.

Tablet

1

Vincristine Sulphate Img/VIAL

Injec tion

1

Doxurubicin HCL lOmg USP.

Injection

Mitomycin C 2mg./ VIAL US".

Inj ec tion

1

Mitomycin c 10mg/ VIAL USP.

In j ec tion

1

Asperg inase’ 1000 KU/VI AL
Containing Asperginase 10000 KU/VIAL

Injection

1

Inj ection

1

Actinomycin D (containing Actinomycin
5-bo mcg and Mannitol 20mg USP.

Inj ec tion

1

C i e p 1 a t i n u m 10 m g / VIA1

Inj ec tion

1

F1urouraci1 25Cgm

Capsu1e.

1

Injec tion

1

I ablets

1

IF

Cyclop hos p hem ide SOmg
■'

Bleomycin

15mg

Methotrexate SQmg•-ml
Me t hot rex a te

BP.

, 5mg ; abs.

Methotrexate omc'ml

t-e theca 1

Injection

1

F1urou rac i1 50mg/m1

IF/USP.

Injection

1

5-Flurouraci1 250mg/oml/ USP.

Injection

.1

■

4

14

-

........

.

■......................................

■

..............

:

j--

J

|P

I tern Name
( 1 )

For.mu I a tion
2 '

Tablet

1

Chlorambucil 5mq BP.

Tablet

1

Melpha1 an

2m g

BP.

Tablet

1

Melpha1 an

5mq

BP.

Tablet

1

Thio-Tepa 15mq

USP.

InJection

1

Tablet

1

Injection

1

Calcium Leucovorin 50 mq

Tablet

1

Procarbazine 50 mq

CapeuIe

1

H y d r o xy Urea 50 0 mq

Capsule

1

Tomcx i -fen

Tablet

1

BP.

Calcium Leucovorin 3 mg/ml.

26.

Levels
(3)

Chlorambua11 Zmg BP.

Thioquanine 40mq

25.

................. fwwiFW

USP.

10 mq

HOEMOPOIETIC
Ferrous Sulphate 2Q0mq
Sugar coated

IP

• ablet

1 , 2, 3

Ferrous Fumarate 200mg

IP

Tablet

1 , 2

Iron-dex tran SOmg/m1 Im/IV
(100 AMPS in CBS WITH HCP) IP

Injectinn

1 , 2? 3

Inon-de x t an 50mc/m1

In j ec tion

1,

Calcium Gluconate 10’4 IV IP
(50 AMPS IN CBB WITH HCP)

Injaction

1 ,

3

Calcium Gluconate 500mq

Tab 1et

1 ,

2, 3

Injection

1 ,

2,

10m 1

t-1 m 1 dual Fack

■~y

3

3

VITAMINS AND MINERALS

IP/BP.

Vitamin-K 1Omg/ml
IP.
(100 AMPS IN CBB WITH HCP)
Folic Acid 5mq BP

3

1, 2, 3

e* IB

item Name

rcr.-nu 1 at ion

Leve1s
(3)

'■ 1 )

Vi tamin-A in Aoueous Base
50,000 IU,'ml USP.
(100 AMPS IN CBB WITH HCP)

Inj ec ticn

1 ,

Vitamin A 50,000 IU.

Tablet

1 , 2.,

V i t ami n A 50,000 lU/ml
in Aqueous Base

Drop5

1

-p

3

Vitamin-8 Complex MFI
(100 VIAL IN CBS WITH HCP)

Inj«etion

1 , r>

3

Vitamin B Complex-Therapeutic MFI

Tablet

1 , 2,

3

Vitamin—8 Complex Therapeutic MFI

Drops

1 ,

Vitamin-Bl-33mg Bo-33mq 8 12-33 ,-3mcq/m 1
(50 AMPS IN CBB WITH HCP)

Injection

1 ,

Riboflavin Vitamin 82 20mg

Tablet

1,

Vitamin C 500rag/5ml MFI
(50 AMFS IN CBB WITH HCP)

Injection

1

2

Vitamin C lOOmg/IP.

Tablet

1

2, 3

Dextrose 57. IV IP
(Packing in CBB)

I n j ec 11 on -1 v

• , 2,

3

Dextrose 10ZIV IP
(Packing in CBB)

I n J ec t i rn- I V

I 5

3

Dextrose 257IV IP
(50 AMPS IN CEB WITH HCP)

I n j' ec t i on -1V

1 ,

Dextrose 507.IV IF
(50 AMPS IN CEB WITH HCP)

Injection-tv

1

1actrc1yte Gastric Reolscement
Solution with 5X Dextrose

In j ec ti on-I V

1 , 2

Electrolyte Maintenance Solution
with 57. Dextrose

I n j ec t i on -1V

3•

3 .i

IV FLUIDS

r

-

'7?

=•

electrolyte Maintenance Paediatric
Solution with 5X Dextrose

■

'

■

■■

a

A •
:- _

y

. .

<

I tern Name
(1 )

Formula tion
(2)

Pctassium Chloride lo7. W/V CSP/EP

I nJ ectian

1 ,

Sodium Sic ar donate 7.37. W/V

Inj ection

1, 2,

Sodium Chloride 0.97. IP

Injection-IV

1 , 2, 3

Norma 1 Ba line IF

Injection-IV

1 , 2,

Sodium Chloride with Dextrose

I n j ec t i on -1V

1 , 2, 3

Sodium Lactate—Compound
(Molar-Lacbate) IP.

I n j ec t i on -1V

1 , 2, 3

Dextran 40 IN Normal Sa line IP.

Inj ec t ion-1V

1 , 2

Plasma Volume Substitute Containing
3.57. degraded Gelatine

I n j' ec tion-I V

1 , 2

Low Molecular WT Destran 540ml

Injection-IV

1 , 2

1 , 2,

3

1 ,

2 i

3

—^1

3

3

Mann i to 1

107

IV IF.

Inj’ec tion-IV

Mannitol

107.

IV IF

Injec tion-IV

Mannitol 207,

IV IP.

Inj’ec tion-IV

1 , 2,

3

Inj ec tion

1 , 2,

3

Tablet

1 9

3

Syrup

1 ,

3

In ha1 er

1 , 2

Water tor Inj’ection
(in Machine made AMPS)

S.

Levsis
<3)

5

IP.

fiNT I-4<STHM4)T IC

Salbutamol 4mq

IP.

L

Salbutamo1 2mg/5m1

Ja1butamo 1 Su1oha t e
< 200 Meter=d Doses}

100meg/mt

Terbuta 1 in 1.5mg/ml

Sy rup

Terbutai in 2.5mg/ml USP.

Tablet

1 , 2

3

Ter bu ta1in 0.5mg/m1
(50 AMPS IN CBS’WITH HCP)

Inj ec tion

1,

3

Aminophylline 2.57 IV IP.
(50 AMPS IN C3B WITH HCP)

Inj’ec tion

1, 2

3

Theophylline lOOmg IP/BP.

Tablet

1, 2,. 3

17

3

____

Lev^l

■ It=m Name
! ' 1 ’>

< 3)

.

SKIN
Cal amin =

a t ion

BP .

Liquid

1 . 2

Liquid

1 ,

Emu1 sion

1 ,

Gamma Benzene Hexachic ide 17.

Liquid

1 ,

2, 3

Certrimide Cream BP.

□ in tment

1,

2, 3

Silver Sulphadiazine 17.

Cream

1 ,

2, 3

Betamethasone 0.17.

□ intmen t

1,

2

Betamethasone Valerate 0.127. with
chinctorm 37 Base.

Cream

1

2

Betamethansone with Neomycin Sulphate

Cream

I ,

“n

Dexamethasone Acetate 0.17 and
Fremycetin Sulphate cream 17

Cream

1 ,

/7?

Cicbetasol Butyrate

Ointment

1 , 2

Nitrerurazone 0.27 water solubl e
Ease (skin) USP. ’

Cream

1 ,

'7

Pc id one iodine USP 57 W/W (0.57.
in cream base)

Cream

1 ,

■7

idone Lotion rUSP

Lotion

1

2, 3

Pamat r in White Sett IP.
□intment Ease

□ in tmen t

1 ,

3

cd o p hy 1 um Pes i n

Powder

Glycerin
BettzyI

Benzoate Application 257.

(Sx in )

IP .

otassium Permanganate IP..
(In Amber coloured bottle)

3

2

4

3 =

3

3

2

Crysta1s

1 , 2

Psoralen 5mc

Tablet

1 .

WhitField Ointment with
Be-zoic Acid 67

□ intmen t

1 , 2, 3

Sulphur Skin Ointment 107 IP.

Ointment

3

“7

■<

T' L->

V-.

'V-

I tern xlame
< 1 :

Coa1te

Levels
(3)!

oin tmen t US.- .

□ in tT.en t

1 ,

Liquid

1 ,

□ in t-T.en t

1 ,

2.,

3

Benzoin CO TR IP.

Liquid

1 ,

2,

3

Gentian Violet 27. USF, Topical

So 1uti on

1

25

3

Gentian Violet 17. USE. Topical
Hydrogen Peroxide (in unbreakable
dark Bottle) IP.

So 1utic

1,

2

3

Liquid

1 ■.

2, 3

Iodine-Weak Solution

L iqui d

1 .

3

Mythyl Salicylate IP. 47 W/W
Mephensin IF 77 Iodine TOP 37; W/W

Ointment

1 , 2,

3

Polymyxin B Sulphate 5000 Unit with
Bacitracin 400 units and Meomycine
3400 Un i t s/gm
IP/BP.

Powder

1 , 2, 3

Framycetin Sulphate 17. W/L'

Ointment

1 »

Dr cos

1,

3

Drops

1 ,

3

□ in tment

1 , 2, 3

Chloramphenicol c.SX EVE DRCFS

Drops

1 ,

3

^ramycetin Sulphate

Drops

1,

2, 3

Dexamethasone Sod. Mete suloheoenzcate
0.1167 W/V Framycetin

Drops

1

Ointment

1 <

3

Drops

1,

3

□intment

1

’ ur pen tine Li-■ i nen i
Zinc Oxide

(skin)

15’/. IF.

-IP

IF.

3

4

3

,

EYE/EAR

Chloraphenica 1 S7.

(Ear) EP.

Sulphacetamide 207 EAR EP
Chlcramphenico1

17

• EYE)

Chloraphenical Applicaps
(EYE) Sterile

IP/BF

r-:

G e n t a m i c i n 0.3 7. W / V L E p

Gentamicin

17.

(EVE}

L-SP

■

i

IF

■

•

L

&

. /

. ..

-■ <........

<r

■

.

-

2, 3
.

■

■:

p;-.. .

■

; 7

-

*
I I.

2?
No .

ACCESSORIES

Levels
(3>

Formu 1 a tion
(2)

I tern Name
( 1 )

01 .

Cotton wool, Absorbable IP, 50Cg.Nett

Dressing

1, 2, 3

02.

Steralised medicated parar-rin gauze
containing Framycetin 500 Units/gm
and Neomycin Sulphate IP 0.357. W/W
lOcms X lOcms.

Dressing

1, 2, 3

Dressing

1 , 2

03.

Gelatin Sponge-Absorbab1e
10mm X 10mm X 10mm (Dental) USE
Packing in CBB.

04 ,

Gelatin Sponge-Absorbable
70mm X 50mm X 1mm (nasal)
Packing in CBB

Dressing

1 ,

2

Gelatin Sponge- Absorbable
80mm
X 25mm X 7mm (Gynec.)USP
Packing in CEB

Dressing

1 ,

'n

Gelatin Sponge-Absorbable
70mm X 50 mm (general) USP
Packing in CBB

Dressing

P1aster-Adhesive Zinc Oxide
207; - 10cm X ION
USP.

Dressing

-5.

06.

07.

OS.

09.

10.

tr’ansparer.t Hypo Allergi c Plaster
having Bi-directiona 1 tear, size
5cms X 9.14NTS

12.

Plaster of Paris

D r e s s in g

1,

Dressing

1 , 2

E
■—!

Dressing

[

11 .

2, 3

■<

£

Porous elastic Adhesive Bandage
Sems X 4MTS
Transparent Hype Allergic
Plaster having Bi-directional tear
size 7.5cms X 9.1 ANTS

2

IP. .

Drip set-poly there -For IV
administration- sterlised with
- Gamma irradiation - Batch
certificate from B.A.R.C./K.M.I.0.

^7

3

Powder

1 ?

App1iance

1, 2, 3

Bags

1

£

13.

Disposable Blood collection bags
(CPDA Solution) 350 ml capacity

M ’ ■ •

21

_1

B|i1

: ..s' 1
. .. .

..

2

....

.:

.

.

Formu 1 a ticn
(2)

Levels
(3)

Disposable Blood collection doub1e
bags (CPDA Solution) 350 mi capac i ty

Bags

1 , 2

15.

Disposable Blood Lancets

Lancet

1 , 2, 3

16,

Disposable Blood Drawing Sets

Drawing Set

b 2, 3

17.

Hypodermic Needles SS ISI

1.5" X

IS

Appliance

i, 2, 3

IS.

Hypodermic Needles SS ISI

1 .5" X 20

Appliance

b 2,

19.

Hypodermic Needles SS ISI

1.5" X 2^

Appliance

1, 2« 3

20.

Hypodermic Needles SS ISI Z1.5" X 24

App1iance

1 , 2, 3

SI .
No.

14 .

I tern Name
(1 )

3

Hypodermic Needles SS ISI

1"

X

IS

Appliance

1, 2,

3

22.

Hypodermic Needles SS ISI

1”

X 20

Appliance

2

3

- "T

Hypodermic Needles S.S.

Appliance

1 , 2, 3

.4 .

Hypodermic Needles S.S.ISI

App1iance

1, 2_, 3

25.

Disposable Needles 20G X 1 "

Appliance

1, 2

26.

Disposable Needles 22 G X

1"

Appliance

1 , 2

Disposable Needles 24 G X

1"

App1iance

1,

■n

3

1 , 2

3

3

1"

ISI

1 " X 24

28.

Disposable Needles 26G X 1 "

Appliance

29.

Syringe 2CC Al 1 Glass
Interchangeable ISI .

Syringe

1 , 2

Syringe

1, 2

L

. 5~ 1

30.

Disposable Syringe

31 ,

Syringe 5CC All G1 a s s
Interchangeable ISI

Syringe

1 , 2, 3

Disposable Syringe

Syringe

1 , 2

Syringe 10CC all glass
Interchangeable ISI

Syringe

1 , 2

34 .

Disposable Syringe 10 ml

Syringe

1 , 2,

35.

Syringe 20CC all glass
Interchangeable ISI

Syringe

1- 2-3

33.

3 ;

■

22

...

.

■

.

..■■■£..

w.

p
I ‘
i

i

t
Si .
Nc .

I tern Name
• 1 )

PormuI ation
C 2)

Levels
(3)

36 .

Cli n i ca 1 Thermometer Centigrade ISI’
Packing in plasti
tube with cap.

37.

Rectal Thermometer Centigrade
Packing in plastic tube with cap.

Appliance

1 , 2, 3

38.

Gloves Surgical 6 size ISI
Each Fair in Plastic coyer and
25 pair in CBB

Appli ance

1

2

39.

Disposable Gioves 6 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1,

2

40.

Gloves Surgical 6.5 size ISI
Each Fair in Plastic cover and
25 pair in CE5

Appliance

1, 2

41 .

Disposable Gloves 6.5 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1,

Gloves Surgical 7 size ISI
Each Pair in Plastic cover and
25 pair in CBS

Appliance

1, 2

Disposable Gloves 7 size ISI
Each Pair in Plastic cover and
25 pair in‘CBS

Appliance

1 ,

2

Gloves Surgical 7.5 size ISI
Each Pair in Plastic cover and
25 pair in CBB

Appliance

1 ,

2

Examination Gloves Size 6
Not for surgical procedures
25 pairs in plastic bag in carton

Appliance

1 , 2w

Examination Gloves Size 6.5
Not tor surgical procedures
25 pairs in plastic bag in carton

Appliance

1 ,

—>

3

Examination Gloves Size 7.5
Not for surgical procedures
25 pairs in plastic bag in carton

A p p1i anee

1 ,

2

3

Disposable Gloves size 7.5 ISI
Each pair in plastic cover and
25 pairs in CBB

Appliance

2

,:

43.

45.

46.

48.

23

1,

2,

3

•"T’

i
__

si.

Item Name
( *

-ormu I a t ion

Sheeting waterprco-F mackintosh
uc" width

---------- -Levels
(3>

Sheeting

1, 2, 3

Pcwder

1 , 2

3

3

50.

Acid Benzioc Powder IP 450qm
Bleaching Powder GR 2 337. Chlorine
ISI (Laminated HDPE Packing)

51 .

Chlorine tablet 2.5gm
Containing 300mg Chlorine

TabIet

1 , 2,

Denture Ease Material
Heat curing ISI ADAS

Powder

1

Denture Ease Material
Cold curing ISI ADAS

Powder

1

Denture Impression Material
ISI ADAS

Powder

1

Gum Paint-TPS Aconite, Belladonna,
Icdimitis, Benzo in Methopip

Gum Paint

1

Mercury Ip

Liquid

1

Silicate Cement ISI/ADAS
Glass ionomer -Filling material powder
15 gms and Liquid 10 gms

Cemen t

1

5S.

Den ta1 Prophylaxis paste

Paste

1

5'-.

Sterile Absorbent Dental Points

Dents 1-poin t

1

60.

Dental Restorative Universal and
Catalyst.
Catalyst Paste-1, Un i v e r s a 1 Paste-1.
Mixing stick-35

Appliance

1

Dental Restcrative Acid Etch Bond
Technique catalyst and Universal Resins
Etching liquid 1 Brush Handle 100
disposable brushes and 100 disposable
mixing wells.

Appliance

62.

Dental P1 oss

St inc

63.

Denta1 Stone Plaster ADAS

Powder

64.

Mercury triple Distil les for
Dental Use
ISI,ZADAS

Mercury

51.

54.

55.

56.

-4

24

. . . B&a
■■

i

■

■

Si .
Mo .

Item Marne
( 1 >

Parma 1 a tion
(2)

LeveIs
. <3)
-

o

66.

67.

68.

6?.

'0.

71 .

Silver Amalgam Alloy with 607.
Silver ISI
Orthodontic Wire Dentauram 0.6
0.7, 0.8, and 0.7 mm gauge.
Plastic packing in CBB

Arch Wire for Orthodontic purpose
gauge 0.014, 0.016, 0.018 & 0.20.
Plastic packing in CBB

1

Wire

1

Wire

1

Mou 1 d

1

Teeth

1

Posterior Teeth sets (Di -Freren t
Shades and Sizes)

T^eth

1

Calcium Hydroxide - Dycal catalyst
lugm Base llgm 1 PAD in CBB Packing

Paste

1

Dental Carving wax Block 4cms X
1 . Sems X 1 .’Sems

Wax

Pumice Powder for Polishing

Powder

Anterior Teeth Sets (lower
and Upper Square and Tapering ’
Mould Stellan Shades- 1, 2, 3, 4,
or equivalent

i

a

Full Teeth sets
Complete Square Mould, Tapering
Mould avoid Mould (shade stellon
1, 2, 3, 4, 5, or equivalent

Zinc Oxide euginol Impression
Paste.
Zinc.Oxide Paste 125gm‘
Eugincl Paste Sogms Mixing Pad 1.
•7 =

Powder

s.-

15 1 .

■4

Paste

1

Wire

1

Zinc Oxiphosphate Cement ISI/hDAS

Cement

1

Dextrose Anhydrous (injectable Grade)
IP/BP free from physical impurities.
<PKD. in Double Poly B AG in KEG with
Painted Label on KEG.

Powder

1f

Mannitol Powder for Injection in
Airtight Polybag IP/USP/BP Double
Polybag 0.2mm thickness, sealed,
painted labeT to be affixed with batch No.

Powder

Intra Dental Wi e Soft 16
E

76.

78.

25
■

'

'

'

.............................................

'

"

'

'

■"

'

■

'

■

'

|

/-i

•

Wz
■

I tern’Name
• 1 )

SI .
No .

- Z'-mu 1 a tion
(2 >

Levels

Powder

1, 2

Sodium Citrate IP. (INJ Grade)
PKD in Ploybag in Plastic Bottles.

Powder

I

Bott 1e-Approx 72 mm Dia 165mm
HT. 38.5mm Screw neck USP Type 1 .

Glass Bottle

1 , 2

Bott 1e-Approx 77.5mm Dia 210mm
HT 38.5mm screw neck USP Typel.25
Bottle in CBB with HCP. Overflow
capacity 685ml USP.

Glass Bottle

1 , 2

Cap Screw Aluminium with Centre open
■For manual srew sealing screw (Meek
Bottles to -Fixing the rubber plugs
LISP (Packing in CBS)

Closure Screw

1 , 2

• Foil Seals Aluminium Assorted colours
for- fixing and sealing over both screw
type and sealing Type Aluminium Caps
(Packing in CBB with Embosemen T
"Government of Karnataka".

C1 osu.re

1 , 2

Rubber Plugs for 540ml USP Type-1
Bottles of smooth surface alround with
one hole for infusion needle and other
for air inlet on top ISI packing in
polybag in corrugated CBB.

L1osure

1,

Sodium chloride •IMJ Grade? IP
free from physical impurities
PKD in airtight 0.2mm Fclybag
sealed- in carton.
80 .

81 .

S3.

84.

85.

86.

88.

Sodium Iodide 1'4 Solution W/V
( Disin-Fez t an f and Bactericidal
Packed in CBS.)

(S)

•1

-

Li qui d

IV Cannula Set (made of leflon) Hinge
Typ e bi way conn ec t ion st ’the top,?
Sizes 14, 16, 18, 20, 'ZT’
Gammai rrad ia t ion certificate froml
B.A.R.C./K.M.I.C. Packing in CBB.

P.ppl iance

Autoo 1 ave Indicator Labe1s
2.Corns X 5c
1 ms

Labels

■i
■
.
•

a

z-'

•

I ■

■111

IS
■

Levels
(3)

For mu I a tier(2 >

Item Name
(1 )

SI .
No .

n
Jell y

1 , 2

Sterilised Surgical Suture
Plain Catgut 2/0 USP.

Suture

1 , 2

Sterilised Surgical Suture
Plain Catgut 1/0 USP.

Suture

89.

Skin Contact Jelly
Ultra Sound

90.

91 .

•

1,

i
92.

93.

94 .

95.

□.

97.

98.

99.

Sterilised Surgical Suture
Plain Catgut 1 USP.

Suture

1 , 2

Sterilised Surgical SuturePlain Catgut 2
USP.

Suture

1,

Sterilised Surgical Suture
Plain Catgut 3
USP.

Suture

1, 2

Sterilised Surgical Suture
Chromic Catgut 3/0 USP.

Suture

1,

Sterilised Surgical Suture
Chromic Catgut 2/0 LISP.

Suture

b

2

Sterilised Surgical Suture
Chromic Catgut 1/0 USP.

Suture

1 ,

*7?

Sterilised Surgical Suture
Chromic Catgut 1
USP.

Suture

1 , 2

Sterilised Surgical Suture
Chromic Catgut 2 USP.

Suture

4

2

ICO. Sterilised Surgical Suture
Straight Needle Chromic 2/0 USP.
Round Body 60mm.

Suture +MeedIe

1 , 2

101 . Sterilised Surgical Suture
Straight Needle Chromic 2/0
Round Eody 45mm USP.

Suture - Needle

1 5

102. Sterilised Surgical Suture
Straight Needle Chromic 2/0
Round Eody 60mm USP.

Suture - Meed1e

1,

103. Sterilised Surgical Suture
Straight Needle Chromic 1/0
Round Body-45mm USP.

Suture

1,2

Needle

2

■

27
'

■

I tern Name
( 1 )

S'..
Nc .

-ormu I ation

<2>

Levs 15
(3)

104 . Sterilised Surgical Suture
Curved Needle Chromic 4/0
Round Body 16mm USP.

3'j ture * Need 1 e

105. Sterilised Surgical Suture
Curved Needle Chromic 3/z0
Round Body 22mm LISP.

Suture

Need 1e

1 ,

Sterilised Surgical Suture
Curved Needle Chromic 2/0
Round Body 65mm USP.

Suture

Need 1e

1 , 2

107. Sterilised Surgical Suture
Curved Needle Chromic 2/z0
Round Body 45mm USP.

Sutu re

Need 1 e

1, 2

J. Sterilised Surgical Suture
Curved Needle Chromic 2/0
Round Body 30mm USP.

Suture

Need 1 e

1 ,

■-7

Suture + Needle

1

2

' Need 1 e

1 ,

■”7

Ne e d 1 e

1, 2

106.

?.

Sterilised Surgical Suture
Curved Needle Chromic 1/0
Round Body 45mm USP.

1, 2
i

1 10. Sterilised Surgical Suture
Curved Needle Chromic 1/0
Round Body 30mm USP.

Suture

Sterilised Surgical Suture
Curved Needle Chromic 1
Round Body 45mm USP.

S >_? t Lt r e

a

'"i

r

112.

14 .

15.

Sterilised Surgical Suture
Curved Cutting Needle Chromic
60mm USP.
’
1

Suture

Need 1e

1 ,

Sterilised Surgical Suture
Curved Cutting Needle Plain 4/0
16mm USP.

Sutur?

Need 1e

*£ 2

Sterilised Surgical Suture
Curved Cutting Needle Plain 3/0
16mm USP.

Su ture

Need 1e

1.

Sterilised Surgical Suture
Curved Rev. Cutting Needle Chromic A./o
Round Body 8mm USP.

Suture

Needle

1, 2

■-y

tlS
■■

■

..

■

I

■

- 1
-•

.I
I ’:em Name

SI .
Nc .

lie.

For mu 1 a tier.
(2 )

Sterilised Surgical
u tu r=
Curvec Blunt Needle Chromic
Round Body 63mm USP.

1

Levs 1 5.
(3)

Suture + Needle

1

117. Sterilised Surgical Suture
1/2 Circle Chromic 1
Heavy 45mm Needle USP.

Suture + Needle

1 , 2

1 IS. Sterilised Surgical Suture
1/2 Circle Trocar Point 1
40mm Needle USP.

Su ture

Need 1e

1 ,

Suture

Need 1e

1,

120. Sterilised Surgical Suture
1/2 Circle Round Body 1/0 Chromic
40mm Heavy Needle USP.

Suture + Need l’e

1 ,

121 . Sterilised Surgical Suture
1/2 Circle Round Body 3/0 Chromic
25mm Needle USP.

Suture + Needle

1 , 2

122. Sterilised Surgical Suture
1/2 Circle Round Body 2/0 Chromic
45mm Needle USP.

Suture

1 ,

123. Sterilised Surgical Suture
1/2 Circle Round Body 1/0 Chromic
45mm Needle USP.

Suture + Needle

1 , 2

Sterilised Surgical Suture>
1/2 Circle Round Body 1/0 Chromic
30mm USP.

Suture

Need 1e

1 ,

2

Sterilised Surgical Suture
1/2 Circle Mayo's Chromic 1/0
4omm Heavy Needle USP.

Suture 4- Need1e

1 ,

T1

Suture + Needle

1

2

Suture + Needle

1, 2

Sterilised Surgical Suture
1/2 Circle Trccar Point Cutting 2
Chromic 40mm Heavy Needle USP.

125.

126. S ter ilised Surgical Suture
1/2 Circle Reverse Cutting Chromic I

Need 1e

2

—i

2

50mm Needle USP.

127. Sterilised Surgical Suture
1/2 Circle Reverse Cutting and
Round Body 2/0 Chromic 36mm Needle USP.

• ir ■< ■

29

I

'W

SI . •
No .

Item Name
\ 1)'

^ormuI ation

•28. Sterilised Surgical Suture
5/8 Circle Round Bed/ Chromic
55mm Needle USP.

t /C

Sul

129. Sterilised Surgical Suture
3/8 Circle Round Body Chromic
45mm Needle
USP.

1/0

Suture

130. Sterilised Surgical Suture
8/0 60mm Curved Micro Point USP.
Round Body 45mm USP.
131 . Black Virgin Silk, Spatulated
8/0 60mm Curved Micro Point Double
Needle USP.

2. Black Virgin Slik, Spatulated
8/0 60mm Curved Micro Point Double
Nee'dle USP.

+ Needle

Levels
(3)

1

2

Need 1e

2

Suture + Needle

Suture

Need 1e

Suture

Need 1e

1

133. Mersilk Black Braided Silk
4/0 16mm Curved Round Body Needle USP.

Suture + Needle

1 , 2

134. Virgin Black Braided Silk
8/0 8mm 1/2 Circle Reverse Cutting
Micro Point Needle USP.

Suture + Needle

1 ,

135. Mersilk Bick Braided Silk
6/0 8mm 1/4 Circle Spatulated Micro
Point Needle USP,

Su ture + Need 1e

4

13o. Mersilk Black uraided Silk
~/0 20mm 1/2 Circle Round Eody Needle
USP .

Suture

Need 1e

1 , 2

Me^ s i 1 k Black Braided Silk
3/0 2 5mm 1/2 Circle Round Body Needle
USP .

Suture

Need 1e

1

133. MersiIk Black Braided Silk
2/0 30mm 1/2 Circle Round Body Needle
USP.

Suture + Needle

1 ,

Mersi1k Slack Braided Silk
1/0 30mm 1/2 Circle Round Body Needle
USP .

Suture + Needle

1, 2

140. Mersilk Black Braided Silk
2/0 50mm 1/2 Straight Round Body Needle
USP.

1,2

2

a[pasf-j 4. ajn;ng

s fcl

aipseft 4- ajnins

‘‘ T

3

arpaa^ + ajn^ng

‘ I

3

afpaaw -»- aun^ng

<I

'dSH aipaaftj
qng uadej. aiD-irg z/i muizj o/£
aunqng arqeqjosqH □TqaqquX.g

’£ST

•dSCI ajpaau
qng uadei aiaurg g/j wmog o/^
ajnqng ajqeqjosqy □xqaqq.uAg

•ZST

*dsn sipaaN
/Uean Apos punoy syzuTg z/\ ^Otz I
a^nqng aiqeqjogqy DyqaqquAg

' 1ST

‘dSD aipaah|
Apog punoy aiajig 3/1 wiuotz 0/1
ajnqng axqeqjosqy □iqaqquAg

•OST

3

Z •

T

arpaa^ + a^n^ng

Z

,: I

afpsaftj 4. aun^ng

■dSD sypaa^
X-Aean ;nDjadei apjjg 3/j ujuj?t o/J
awning aiqequosqy DT^aq^uXg -gtry

Z

‘ I

afpaapj 4- ajn^ng

•dSH aipaaN
Apog puno^j apjTg z/1 ujujo£ 0/Z
ajnqng auf af tauaiu papiejg

*ZVT

"dSA aipaa^ pa^ein^edg
;uTOd ojdtu aiDJTg tz/T UJUJ3 o/tz
aun^ng au{a{isuaw pa^eog paprejg

* 9VT

’dSH ajpaaw aiqnoQ paq.e{nqsdg
;uToy ojDiuj apjTO V/T WLBB 0/2
aunyng-aujaiTsuan paprejg

'St!

aipaa^ 4- sun}ng

‘‘ T

Z

3[paaN 4- ajn;ng

*' I

aipaaftj 4- aurpng

‘ I

a{paa|j + aun^ng

axpaafti 4- ajrpng

Z ‘I

sz

‘I

.

‘dSH aipaaN
Apog punoy apjTQ g/x wwofr o/^
a^nq.ng aiqaqjosqy □Tqaqq.uZg ‘btrT

‘ dSH stung/, x 01 0/£ s>jned deuw u^ao
aiT-taqg ut aunqng qng ajg ^ednqng * tizl
•dSA stung/. X Z X IT s>jned dejw ubao
aiTJaqg ut aunqng qng aug >jednqng

•dsn SUJD£2. X Z X 0/Z s>jDed dejw ja/kO
aiTja^g ut ajn;ng
ajj ^edn^ng •Zt7l

afpaaN 4- aun^ng
qniuadei AAeay nJiu^tr
papiejg paqeog

C£)
siaAaq

K
■

(Z)

□o:;ei niujo -j

•£t7l

'dSH aiPasN
jaqsa/qsg
‘Z szig uaa-jg

{ I )

aine\» tna^ j

•IM

•ot-j

* IS

•

7“

...

..

.

...

II
I tern Name
• 1 )

No .

154.

Synthetic Absorbable Suture
1/0 40mm 1/2 Circle Taper Cut
Needle USP.

155. Synthetic Absorbable Suture
Violet Size 1 POcms 1/2 Circle,
40mm Tapercut Heavy Needle USP.

156.

Synthetic Absorbable Suture
Violet Size 1 90 ems 1/2 Circle,
Cutting 45mm Heavy Needle USP.

Synthetic Absorbable Suture
Violet Size 5/0 4Sems 1/2 Circle Round
Body 16mm Double Needle
USP .

160.

161 .

162.

.

Synthetic Absorbable Suture
Undyed Braided Size 2/0 76cms Straight
Cutting 60mm Needle USP.

Mono-Fi lament Nylon Suture
10/0 6mm curved Spatulated Micro Point
Needle USP.

Monofilament -Nylon Suture
10/0 6mm 3/8 Circle Spatulated Micro Point
Double Needle USP.
Mono-Filament Nylon Suture
8/0 8mm Curved Reverse cutting Micro Point
Needle USP.

'.65.

Monofilament Polymade Suture
2/0 45mm Curved Reverse Cutting Needle
USP.

1,

Suture + Needle

. 'J 26)
1 , 2

Suture

Needle

1 ,

2

Suture + Needle

1,

2

Suture + Need 1e

1 .

2

Suture

1 , 2

Needle

Suture x Needle

1

Needle

1

Suture

t
Suture 4- Needle

1

Suture * Needle

1,

S u t u r •= -r N e e d 1 e

1 ,

Suture + . Needle

1,

Monofilament Polymade Suture

3/0 26mm Curved Cutting USP.
. 66 .

Suture -*- Needle

Monofilament Polymade Suture

5/0 12mm Curved Reverse Cutting Needle
USP.
164.

Levels
(3)

Monofilament Polymade Suture
1/0 4Omm 1/2 Circle Round Body
(Loop Suture) Needle USP.

2

Reverse

157. Synthetic Absorbable Suture
Violet Size 4/0 70cmsl/2 Circle Round '
Body 16mm Needle USP.

159.

Pormu1 a ti on
<2’

•
Suture + Needle

=

1,

—7

i

7"

11

'"Z: ■

Si .
No .

f- or mu 1 a t ion

I tern Name
( 1 >

■ Z)

Levels
(3)

Monofilament Pol •/made Sutur =

1
50mm 1/2 Circle Round Body Heavy
(Loop Suture) Needle USP.

Suture + Needle

1, 2

168. Mono-filament Polymade Suture
1/0 40mm 1/2 Circle Heavy Needle USP.

Suture + Needle

1< 2

169. Monofilament Polymade Suture
1 40mm
40 mm 1/2 Circle Heavy Needle USP.

Suture + Needle

1 , 2

170. Monofilament Polymade Black Size 1,
lOOcms 1/2 Circle Reverse, Cutting,
SOOmm*Heavy Needle USP.

Suture + Needle

1 , 2

171 . Polypropylene Mesh
Size 6cm * 11cm

Need

1,

172. Po1ypropy1ene Mesh
Size 15cm * 15cm

Need

1 , 2

Need

1

174. Monofilament Prolene Suture
6/0 13mm Curved Round Body Double
Needle USP.

Suture + Needle

1 ,

175. Mono-filament Prolene Suture
3/C 22mm curved Cutting Needle USP.

Su tu re ■+• Need 1 e

176. Monofilament Prolene Suture
2/0.25mm Taper Cut Needle
(POcms Suture)
USP.

Suture

177. Monofilament Prolene Mesh
17cms X Hems USP.

Ne:e t

1 .

17S. Monofilament Prolene Mesh
8.Some X 11 cms USP.

Need

1 ,

173. Fo1yprop/1 erne Mesh
Size 30cm $ 30cm

J

i

Monofilament Prolene Suture
2/0 17mm 1/2 Circle Taper Cut
Needle USP.
ISO. Monofilament Prolene Suture
1/0 25mm 1/2 Circle Tape Cut
Needle USP.

33

'-■•j

Suture

Need 1e

Need 1e

Suture + Need1e

•~5

*7

1 , 2

1 -

'n

1, 2

WT......

'

'

-

'

-

‘

• ' •

‘ -•

-

■

■

Formu1 ation
(2)

I tern Name
( 1)

SI .
No .

' ••

Levels
(3>

X-PftY
Powde

1, 2

Suspension

1, 2

183. Sodium Meglumine Amidotrizoate
(Iodine Content 607. USP)
(10 AMPS IN CBS)

I nJ ection

1 , 2

194 . Sodium meglumine Amidotrizoate
(Iodine Content 767. USP.)
(10 AMPS IN CBS)

Injection

1

185.

lohexol 10ml 180mg/ml
(25 AMPS IN CBB WITH HCP)

Injection

1 , 2

196.

lohexol 10ml 240mg/ml
,(25 AMPS IN CBS WITH HCP)

Inj ection

1,

187.

lohexol 10ml 300mg/ml
(25 AMPS IN CEB WITH HCP)

Injection

1 , 2

191 . Barium Sulphate - Compound IF.
182. Barium Sulphate Suspen sion 957.
W/V (Micropaque Suspension ■for
Double Contrast -For Gastro
Intestinal Tract) IP/BP.

2

NOTE :
1 .
*7

3.

where Dental Surgeon is aval Table.
Items No. 52 to 76 will be in use
-Fluid preparation -Facility
use where Intravenous
I terns No. 7/ to 87 will be in
is available.
-facilities
where Eye/ENT/Plastic Surgery
use
be
in
140
will
Items No. 130 to
are available.

expiry dates .
All suture material have
indenting
and on regular basis.
Check -For some on
• '■ separately are more
and
suture material when bought
5. Need les
without
wasting.
use-Fu 1 to the surgeons who can use w-----

4.

economica 1

and

to
ly used end■ very expensive and need
not
synthetic suture material are rare
Hl 1
■for
accounting.
They
are
them
to individual surgeon who use
be given
economical to be pctrc based and stoi ed .

-o-o-o-o-o-o-

k

-

•

■

:

-

' J
■

LABORATORY CHEMICALS

0 • . Acetic Acid 17. IP
02.

Benedict’s qualitative reagent
(20 Bots. in a CB box with Honeycomb partition NFI

03. Benedict’s quantative solution reagent
04.

Xy1ene

pure.

05. Chloroform A.R.

06. Acetone Extra Pure
07 .

Paraffin Wax MP- 53 degree C to 60 degree C

08. Potassium Aluminium Sulphate purified
09. Haematoxy11 in
10. Mercuric Chloride purified
11 . Eosin

12.

Bismack Brown

13. Light Green
14. Potassium Iodine IP.
15. Forma 1dehyde
16. Gold Chloride Igm

17. Activated Charcoal
IS.

Sodium Bicarbonate

19. Glacial Acetic Acid

20. Methylene Blue .

21 . Gentian Violet
22. Sodium Chloride

23. Carbo 1-Fusehin

24. Glycerine

25. Sodium Meta-Bisulphate

a

I'
35
■

•cW-’X' ■

RX'W- ■ S " ■ ■ L-X'

.

.

....

.

:■

if- JR' O'O’
■

261 Potassium Hydrcger. Ortho Phosphate
".

I

Sodium H /drcgen Crthe ’Phosphate

23.

Potass iu:n D i-cbromate

2‘? .

Conceotrated Sulphuric Acid

30.

Concentrated Nitric Acid

31 .

Tri-5cdium Citrate

Orange-G
3. Schiff Reagent
i

34 . Neutra1 Red

35.

Sudan I I I

3o. Mercuric Oxide

37.

Sodium Thiosulphate

3c .

Iod ine

39 .

A1c ian Slue

40.

Phospho-tungstic Acid

■

41. Liquid Paraffin

42. DPX Mountant
43. Liquid Ammonia

44 . Concentrated Hydrochloric Acid

45.

Sulpho Salicylic Acid

46 . Sodium Nitro Prusside
47 .

Thrcmbok inase 10 mg Tablet

4G.

Silver Nitrate

49 .

Egg Albumin R1 axes

7$

50. Potassium Hydroxide

■

'

"

E

■

<

!

■

f

; -./I

36
■

• ••

: V.

;.

' '

- •

'

L/vLuJ

I

ill

(2>

(3)

(4)

(5)

(6)

(7>

iSSENriftl DRUGS LIST

ANr100 FES

I.

Atropine sulphate

2.

Hagnesiua Sulphate

0.6ag/aI

SI.
No.
Ig/lOal (powder)

3. Pralidoxiae

Metronidazole

Capsule

(3)

(4)

Injections
(5)

Syruo

Others

(6)

(7)

AIMES I HE TICS
Inhalation

1. Ether, Anaesthetic
2.
100ag

Inhalation

Halothane

lOOig/Sal

0.5g asp

J. Thiopental

Anti-asoebic

I.

(2)

Tablets

0.5g powd. in vial

Anti-helninthic
Mebendazole

: Prepared by Community Health Cell for Govt, of Karnataka.

Haas of Drug

(1)

ANn-INFECTIVES

i

/

Inhalation

4. Nitrous Oxide

200aq
400flg

lOOsg/Ssl
5.

(Peter Emergency Drugs)

Oxygen

Anti bacterial
1.

Benzyl Pencil 1 in

2.

Procaine Penci Ilin

1.

ParacetasC'I

5'»o.

2.

Aspirin

30(>ag

,3.

Ibuprofen

200og
lOOag

250aq

4.

Indcsethacin

lOOag

5.

Pentazocine lactate

400000U/vial
200000011/via I

3. Benzathine Pencillin

*>.

600000U/vial
!200000U/vial
2400000U/viai

Tetracycline

5. Doxycycline
6.

Chlorasphenicol

7.

Co-triaor.azole

9.

Erythroaycin

250«g

250sg

10. Aapicillin

Rifampicin

Clofazimine

150«g/5aI

Pethidine

T.40»g»S.200flg/5al

ANTI ALLEF.GICS

300ig./2sl .asp

125sg/5«l

25«g
30«g/il

25*g

50sg/«l

125«g/5sl
250ag

lOOsg/vial

125ag/5sl

250ag

250ag/vial

125ag/5al

AMHIFPfiOSY

2.

Ig/vial

T.90agrS.400sg

loxyci11 in

1. Dapsone

ANALC’ESlC/ANTIPYREHrs

500000U/vial
lOOOOOOU/vial

1.

Chlorpheniraains naleate

4 ng

2.

Pr>?}ethazine

l'?ag
25*g

25'-i/al

I in 1000, lai atp

Adrenaline

Dexamethasone

25ag
50ag
lOOag

5ag/5al

0.5s j

Ang/il, 2a 1 vial

30sg
SOag

2OOsig/al

ANTl-EPILEPTlCj

I SOag
300ag
SOag
lOOag

Phenobarbitone

2. Diazepam

5ag/il

2ag/5al

50ag/al

100sg/4al

lOsg
3. Phen;*

i Sodius

4. Carbamazepine

10 r-g

ICvig
20'hg

-r

■1)

(2)

(51

i-H

(5)

(6)

11}

Anti hycertensive
(I)

(2)

(3)

(4>

(5)

1. Hydrochloroth i a ? ide
(6)

2.

ANTI-TUBERCULAR

1.

INH

2.

Streptomycin

3.

Thioacetazone

lOOag

5. Ethambutol

4.

Reserpine

0. hq

H/dralaune

25«a

A,en<U<?l

50-.g
lOOng

Ig/vial
Cardiac glycoside

150ig

Rifaapicin

503J

(7)

1. Digoxin

(Refer Anti--Leprosy)

0.2*^

0.25ngZ«l

OliJSEHCS

20019
40C»g

1. f ru'-e^ide

(Please see NNational
‘
'
Tuberculosis
Control Programme i banned combinations in the
treatment of Tuberculosis)

Spironolactone

lOmg/ml
25eg

ANTI-FILARIAL
5.

1.

Di-ethyl carbasazine

Mannitol

2n inrusiwi

CASTRO INTESTINAL

5-' ’g

120ag/5*l

ANTI-FUNGAL
An tar ids
1.

GriseofuI in

2.

faphotericin 9

1.

125*9

filusinii'ii Hydrodde

250«q

Magnesium Trisilicate

SOag/vial

Ranitidine

ANII-HALARIAl

25mg/ml

Anti-emetics
1.

Chloroquin

lOOmg base

2.

Primaquin

2.Sag

SulfadoxiniPyreaethamine

4. Quinine Sulphate

40mg/ml

I.

S.5')0eg»P.25mg

300mg

Metoclopramide

I Osg

r< i

(Refer Anti AUer

inp

5tg/a]

5ag/5*l

i'-Ji sj.a^sodic
300mg/amp

1.

Atropine sulphate (Refer Anitdotes)

0.5*g

Oic/clomin

lOag

0.6mg/«l

HAEMOPOIETIC

rrous SulphatetFolic Acid

200agi0.5*g

2.

Ferrous F"'»arateiFolic Acid

ISOmgiZ.^mg

3.

Folic Acid

Sag

Fr-'metlid’its? (Refer Anti-AIlergics)

I’fil 1 •DIAIWEAI;;

I.

GF3 Packets ’lil'i] Ferculai

2.

loperaeide Hydrochloride
(not for children/

CARDIOVASCULAR

2sg

Anti -anginal

LAZATIVFS
1.

Isosorbide Nitrate

I Ong

2.

Propranolol

I Gag
40mg

7

1.

hpaght'la husk

2.

Paraffin, liquid

3.

Glycerine

Grar.'i’.es

Liquid
S'.'pposit r

sc

E

;

f I

sf
'TT

LS

1

x-'

I 11 •f f .1i If

■=

3

I I

I I

3?

1

£

s

3

5

| Ii 5H?

I

J

§

I

s.

I =•

S'

F.

f
I

.•’ J

<□»

S tn

£.2

s;

=g £

I

<

*
£

c.

.?

i

1

-

^.3

KJ
<_n

5

I

■J

i

I

£.J

f

i:
•i.

5:

3

i

i t
T

!!

11

9

«2
cn

§

y

z

I

X

1

I I
s
.u

i

!

5

s'

J-1

{ i i I I I i ii I
3

?

=•.

g

I
I I I I
3-

s

!

?n

I

ig

I

£

.

I

/

1
I
I
1 I I I I Liis
I tI
B

2

cn

i B

:r

>
!

s
•tt

I i
I

3

g
g-

If

s

z

’

I

I
I I

3

KH

3

Iz
cp

I
i
g

E

n

£

£

I J
■3

i

3

«

II

I ?
5

K

f I

g

S’

I

<=>
w«

SE
ss
5 =

O
e

3

I°

m

s

3

r“
J-

=

3

f
f =

co

C.H

HfflSf > I
M =f. Lqiffi

I

*
.9

8

2

j

g. , . - - -

- o-

£4>

!*

< -s

-T

£

H ■_-£ =

j3
”

i

IifI

?■

f

S ? f

£

g:

'
•
t
•
1

3>
i—»
c—j
m
cza

• <r>

: §
» 2?

~

i s

J I

2.

9

2

!

£

f
*

9

f

I

T2

ui

*

IX

ru

»

r-

ac

o

S.

5

I 4 I

3’

r

2
g

a

i

o
to

is
iS

3

i

S’
v»

\l 5

sI
. •3—

TO
TO

TO

tn

«n

CM
“

3^3

o.

>

►*.

2 ’

I I
£
I I

I ? 9 ?
?

s

9

i

I 1 If
i 11

!

2

s

~ Z

<
8

I

»

XX3’

(
x»

’

?

JO

'!

9

■B1

c>

£

e

I

f

a

r

i

c«

x»

S X -S X ==

X
•2

H SJl I

h r ■
? =. £ ; =

1
is = s s.

1s.

!!

cn

cu
S’

■ I
: s

Le
x»

f
in
fXJ

9

2

i

c

■Q

2

If

- -S- S'

I

n
' i I
s

9

5E f
I
i!
i

I
I

|!il I-f
HF 9
I
ilf £

9
XX

<o

i E

<

9
s

9

?

I ?f J
I I 9
=■

.? ?

I ki

£

II

9

or

i

O

=

I
s

3

f A
£

9

f
9

9

5

I
Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

25.2 ANTITUSSIVES

“dextromethorphan

26.3 MISCELLANEOUS

oral solution,
3.5 mg (bromide)/5 ml

Section 26:
Solutions correcting Water, Electro
lyte and Acid-base Disturbances

water for injection

2-ml, 5-ml, 10-ml ampoules

Section 27: Vitamins and Minerals
ascorbic acid

tablet, 50 mg

“ergocalciferol

capsule or tablet, 1.25 mg
(50 000 IU)

26.7 ORAL
oral rehydration salts (for glucoseelectrolyte solution)

for composition
see section 17.7.1

potassium chloride

powder for solution

oral solution,
250 pg/ml (10 000 lU/ml)
iodine (8)

26.2 PARENTERAL
glucose

glucose with
sodium chloride

potassium chloride (2)

sodium chlonde

sodium hydrogen
carbonate

injectable solution,
5% isotonic, 10% isotonic,
50% hypertonic
injectable solution. 4%
glucose, 0.18% sodium chlonde
(equivalent to Na* 30 mmol/l
Cl' 30 mmol/l)

solution, 0.57 ml, (308 mg iodine)
in dispenser bottle
capsule, 200 mg

“nicotinamide

tablet, 50 mg

pyridoxine

“retinol

tablet, 25 mg (hydrochloride)
sugar-coated tablet. 10 000 IU
(as palmitate) (5.5 mg)

11.2% solution in
20-ml ampoule, (equivalent to
K* 1.5 mmol/ml. Cl' 1.5 mmol/ml)

capsule. 200 000 IU (as
palmitate) (110 mg)

oral oily solution,
100 000 lU/ml in multidose
dispenser (as palmitate)

injectable solution. 0.9%
isotonic (equivalent to Na* 154
mmol/l, Cl' 154 mmol/l)
injectable solution. 1.4%
isotonic (equivalent to Na* 167
mmol/l, HCO3' 167 mmol/l)
8.4% solution in 10-ml ampoule
(equivalent to Na* 1000 mmol/l,
HCO3' 1000 mmol/l)

“ compound solution of
sodium lactate

iodized oil, 1 ml (480 mg iodine),
0.5 ml (240 mg iodine) in
ampoule (oral or injectable)

injectable solution

water-miscible injection,
100 000 IU (as palmitate)
(55 mg) in 2-ml ampoule
riboflavin

tablet. 5 mg

“sodium fluoride

in any appropnate formulation

thiamine

tablet, 50 mg (hydrochloride)

Complementary drug
calcium gluconate (C) (2, 8)

a

injection. 100 mg/ml
in 10-ml ampoule

Example of a therapeutic group. Various drugs can serve as alternatives.

The following changes in the WHO Model List were approved by the WHO Expert Committee on
the Use of Essential Drugs which met in December 1999. The report of the meeting will be
published in the WHO Technical Report Series.
Deletions:, albumin (human); antiscorpion sera.
Additions: acetylcysteine; rifampicin + isoniazid + pyrazinamide + ethambutol; nevirapine; artesunate;
chlorambucil; daunorubicin; ethanol; iohexol.

Replacements: fluconazole to replace ketoconazole; prazosin to replace doxazosin.

262

Volume 13, Number 4, 1999

r»

World Health Organization, Geneva

n

WHO Drug Information
Contents

a

Regulatory and Safety Matters

General Policy Issues
i

Access to essential drugs
W d?u|sOle ln ensuring access t0 essential

217

^Xions ediCineS: 30 Ur9ent need for

217

Amsterdam statement on access to

220
medicines 223

Reports on Individual Druos
Atnv!n2a preDaredness Plan: antiviral <drugs
Atovaquone and proguaml hydrochloride:9

a new antimalarial combination

225
226

Current Topics
Roll Back Malaria
The Medicines for Malaria Venture (MMV)
The Japanese alliance
alar'al dOna,,on Programme
Roll Back Malaria in Europe
The WHO Antimicrobial Resistance
Information Bank

228
228
228
229
229
230

mide: pancyt0Pen’a and skin reactions 238
Didanosme and pancreatitis
So
Sertraline for post-traumatic stress disorder
238
Pemoline withdrawal following liver
complications
238
Me\!t,raCetam: new dru9for epilepsy
239
Methotrexate: monitoring essential
239
Methotrexate: care in prescribing
239
Grepafloxacin withdrawal: severe
cardiovascular events
239
Reteotase incompatible with heparin
239
Postmarketing system to be revised
240
Abacavir: hypersensitivity reactions
240
the'lnteme*1116931 3316 °f dRJ9S °Ver
Unaoproved HIV test kits available on
the Internet
V-KingO: unapproved use of sildenafil
Miralexts): undeclared corticosteroid
ules for dietary supplements finalized

242
245

Vaccines and Biomedicines
Essential Drugs
231

235
237

WHO Model List (revised December 1999)

249

Proposed International
Nonproprietary Names: List 82 263

7

7/cT ?

hea/.' .7

A*'

0

1

240
241
241
241

ATC/DDD Classification
Temporary list
Final list

Quality assurance and safety of
biologicais
Influenza preparedness plan: vaccine
production and availability
Thiomersal: theoretical risk leads to
phasing out

240

y

WHO Drug Information Vol. 13, No. 4, 1999

Essential Drugs
WHO Model List (revised December 1999)
injection for spinal anaesthesia,
0.5% (hydrochloride) in 4-ml ampoule
to be mixed with 7.5% glucose solution

Section 1: Anaesthetics
1.1 GENERAL ANAESTHETICS AND OXYGEN

ether, anaesthetic (1c) (2)

inhalation

halothane (2)

inhalation

ketamine (2)

injection, 50 mg (as hydrochlonde)/ml in 10-ml vial

oxygen
“thiopental (2)

injection for spinal anaesthesia,
5% (hydrochloride) in 2-ml ampoule
to be mixed with 7.5% glucose solution

inhalation (medicinal gas)

topical forms, 2-4% (hydrochloride)

powder for injection, 0.5 g, 1.0 g
(sodium salt) in ampoule

dental cartridge, 2% (hydrochlonde)
+ epmephnne 1:80 000
Complementary drug

1.2 LOCAL ANAESTHETICS
°bupivacaine (2. 9)

injection, 1%, 2% (hydrochloride)
+ epinephrine 1:200 000 in vial

inhalation

nitrous oxide (2)

injection, 1%, 2%
(hydrochloride) in vial

“lidocaine

injection. 0.25%, 0.5%
(hydrochloride) in vial

injection. 30 mg
ephedrine (C)
(hydrochlonde)/ml in
(For use in spinal anaesthesia
1-ml ampoule
dunng delivery to prevent hypotension)

o Example of a therapeutic group. Vanous drugs can serve as alternatives.
Explanatory Notes

When the strength of a drug is specified in terms of a
selected salt or ester, this is mentioned in brackets: when it
refers to the active moiety, the name of the salt or ester in
brackets is preceded by the word "as".
Many drugs included in the list are preceded by a box (°) to
indicate that they represent an example of a therapeutic
group and that various drugs could serve as alternatives. It
is imperative that this is understood when drugs are selected
at national level, since choice is then influenced by the
comparative cost and availability of equivalent products.
Examples of acceptable substitutions include:

3 Hydrochlorothiazide: any other thiazide-type diuretic cur
rently in broad clinical use.
° Hydralazine: any other peripheral vasodilator having an
antihypertensive effect.
0 Senna: any stimulant laxative (either synthetic or of plant
origin).
0 Sulfadiazine: any other short-acting, systemically active
sulfonamide unlikely to cause crystalluria.

Numbers in parentheses following drug names indicate:
(1) Drugs subject to international control under: (a) the
Single Convention on Narcotic Drugs (1961); (b) the Con
vention on Psychotropic Substances (1971); or (c) the

United Nations Convention against Illicit Traffic in Narcotic
Drugs and Psychotropic Substances (1988).
(2) Specific expertise, diagnostic precision, individualization
of dosage or special equipment required for proper use.
(3) Greater potency or efficacy.
(4) In renal insufficiency, contraindicated or dosage adjust
ments necessary.
(5) To improve compliance.
(6) Special pharmacokinetic properties.
(7) Adverse effects diminish benefit/risk ratio.
(8) Limited indications or narrow spectrum of activity.
(9) For epidural anaesthesia.
(10) Sustained-release preparations are available. A pro
posal to include such a product in a national list of essential
drugs should be supported by adequate documentation.
(11) Momtonng of therapeutic concentrations in plasma can
improve safety and efficacy.
Letters in parentheses following the drug names indicate the
reasons for the inclusion of complementary drugs:
(A) When drugs in the main list cannot be made available.
(B) When drugs in the main list are known to be ineffective or
inappropriate for a given individual.
(C) For use in rare disorders or in exceptional circumstances.
(D) Reserve antimicrobials to be used only when there is
significant resistance to other drugs on the list.

Drugs are listed in alphabetical order.

249

Essential Drugs
WHO Drug Information Vol. 13, No. 4, 1999

1.3PREOPERATIVE MEDICATION & SEDATION
FOR SHORT-TERM PROCEDURES
atropine

injection, 1 mg (sulfate)
in 1-ml ampoule

chloral hydrate

syrup, 200 mg/5 ml

“diazepam (1b)

“morphine (la)

injection, 5 mg/ml
in 2-ml ampoule

2.4 DISEASE-MODIFYING AGENTS USED
IN RHEUMA TIC DISORDERS

azathioprine (2)

tablet, 100 mg, 150 mg
(as phosphate or sulfate)

cyclophosphamide (2)

tablet, 5 mg

methotrexate (2)

injection, 10 mg (sulfate or
hydrochloride) in 1-ml ampoule

penicillamine (2)

“promethazine

elixir or syrup. 5 mg
(hydrochloride)/5 ml

Section 2: Analgesics, Antipyretics,
Nonsteroidal Anti-Inflammatory
Drugs (NSAIDs), Drugs Used to
Treat Gout and Disease-Modifying
Agents used in Rheumatic
Disorders (DMARDs)

sulfasalazine (2)

tablet. 100-500 mg

“chlorphenamine

tablet. 200 mg, 400 mg

paracetamol

tablet. 100-500 mg

suppository. 100 mg

syrup. 125 mg/5 ml

2.2 OPIOID ANALGESICS

“codeine (la)

tablet. 30 mg (phosphate)

“morphine (la)

injection. 10 mg (sulfate or
hydrochlonde) in 1-ml ampoule
oral solution. 10 mg (hydrochloride
or sulfate))/5 ml

tablet, 10 mg (sulfate)

Complementary drug

“pethidine (A) (la, 4)

“dexamethasone

tablet. 100 mg

COlchicine<7>

tablet. 500 gg

“ Example of a therapeutic group. Various drugs

250

tablet. 500 pg, 4 mg

injection, 1 mg (as hydro
chloride or hydrogen tartrate)
in 1-ml ampoule

hydrocortisone

powder for injection. 100 mg
(as sodium succinate) in vial

“prednisolone

tablet, 5 mg

Section 4: Antidotes and Other
Substances Used in Poisonings
4.1 NON-SPECIFIC

“charcoal, activated
ipecacuanha

powder

syrup, containing 0.14% ipecacuanha
alkaloids calculated as emetine

4.2 SPECIFIC

atropine
calcium gluconate (2, 8)

allOpurinol(4>

tablet. 4 mg (hydrogen maleate)

epmephnne

tablet, 50 mg, 100 mg (hydrochloride)
2.3 DRUGS USED TO TREAT GOUT

tablet. 500 mg

injection. 4 mg
dexamethasone phosphate
(as disodium salt) in 1-ml ampoule

acetylcysteine

injection, 50 mg
(hydrochloride) in 1-ml ampoule

capsule or tablet, 250 mg

injection, 10 mg (hydrogen
maleate) in 1-ml ampoule

suppository, 50-150 mg
“ibuprofen

tablet, 25 mg

tablet, 2.5 mg (as sodium salt)

Section 3: Antiallergics and
Drugs Used in Anaphylaxis

2.1 NON-OPIOID ANALGESICS & NSAIDs
acetylsalicylic acid

tablet. 50 mg

chloroquine (2)

deferoxamine

can serve as alternatives.

injection. 200 mg/ml
in 10-ml vial
injection, 1 mg (sulfate)
in 1-ml ampoule

injection, 100 mg/ml
in 10-ml ampoule
powder for injection, 500 mg
(mesilate) in vial

4
9

Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

dimercaprol (2)

injection in oil, 50 mg/ml
in 2-ml ampoule

°DL-methionine

tablet, 250 mg
injection, 10 mg/ml
in 10-ml ampoule

methylthioninium chloride
(methylene blue)

injection, 400 jig (hydrochloride)
in 1-ml ampoule

naloxone

capsule or tablet, 250 mg

penicillamine (2)

potassium ferric hexacyanoferrate(ll) -2H2O (Prussian blue)

powder for oral
administration

sodium calcium edetate (2)

injection, 200 mg/ml
in 5-ml ampoule

sodium nitrite

injection, 30 mg/ml
in 10-ml ampoule

sodium thiosulfate

injection, 250 mg/ml
in 50-ml ampoule

Section 6: Anti-infective Drugs
6.1 ANTHELMINTHICS

6.1.1 INTESTINAL ANTHELMINTHICS
albendazole

chewable tablet, 400 mg

levamisole

tablet, 50 mg, 150 mg
(as hydrochloride)

"mebendazole

chewable tablet, 100 mg, 500 mg

niclosamide

chewable tablet, 500 mg

praziquantel

tablet, 150 mg, 600 mg

pyrantel

chewable tablet, 250 mg
(as embonate)
oral suspension. 50 mg
(as embonate)/ml

6.1.2 ANTIFILARIALS
tablet, 50 mg, 100 mg
(dihydrogen citrate)

diethylcarbamazine

Section 5: Anticonvulsants/
Antiepileptics

ivermectin

carbamazepine (10,11) scored tablet, 100 mg, 200 mg

suramin sodium (B) (2. 7)

injection, 5 mg/ml in 2-ml
ampoule (intravenous or rectal)

"diazepam (1b)

capsule. 250 mg

ethosuximide

syrup, 250 mg/5 ml

injection. 500 mg/ml
in 2-ml ampoule
and 10-ml ampoule

magnesium sulfate

phenobarbital (lb. 11)

scored tablet. 3 mg, 6 mg

Complementary drug
powder for injection,
1 g in vial

6.1.3 ANTISCHISTOSOMALS AND OTHER
ANTITREMATODE DRUGS
praziquantel

tablet. 600 mg

triclabendazole

tablet. 250 mg

Complementary drug
capsule. 250 mg

oxamniquine (C) (8)

tablet. 15-100 mg

syrup, 250 mg/5 ml

elixir. 15 mg/5 ml
phenytoin (7. 11)

capsule or tablet.
25 mg, 50 mg, 100 mg (sodium salt)
injection. 50 mg
(sodium salt)/ml in 5-ml vial

valproic acid (7. 11)

"amoxicillin

capsule or tablet. 250 mg,
500 mg (anhydrous)

powder for oral suspension,
125 mg (anhydrous)/5 ml

enteric coated tablet.
200 mg, 500 mg (sodium salt)

Complementary drug
"clonazepam (B)(1b)

6.2 ANTIBACTERIALS
6.2.1 BETA LACTAM DRUGS

ampicillin

powder for injection. 500 mg,
1 g (as sodium salt) in vial

benzathine
benzylpenicillin

powder for injection,
1.44 g benzylpenicillin
(= 2.4 million IU) in 5-ml vial

benzylpenicillin

powder for injection,
600 mg (= 1 million IU),
3 g (= 5 million IU)
(sodium or potassium salt) in vial

scored tablet, 500 pg

° Example of a therapeutic group. Various drugs can serve as alternatives.

251

F'

Essential Drugs
WHO Drug Information Vol. 13, No. 4, 1999

“cloxacillin

capsule, 500 mg, 1 g (as sodium salt)

“metronidazole

tablet, 200-500 mg
injection, 500 mg in 100-ml vial

powder for oral solution, 125 mg
(as sodium salt)/5 ml

suppository, 500 mg, 1 g

powder for injection, 500 mg
(as sodium salt) in vial

phenoxymethylpenicillin

tablet, 250 mg
(as potassium salt)

powder for oral suspension, 250 mg
(as potassium salt)/5 ml
procaine benzylpenicillin
powder for injection,
1 9 (= 1 million IU),
3 g (= 3 million IU) in vial
Restricted indications
“amoxicillin +
“clavulanic acid (D)
ceftazidime (D)

nalidixic acid (8)

tablet, 250 mg, 500 mg

nitrofurantoin (4, 8)

tablet, 100 mg

spectinomycin (8)

powder for injection. 2 g
(as hydrochloride) in vial

“sulfadiazine (4)

tablet, 500 mg
injection. 250 mg (sodium salt)
in 4-ml ampoule

tablet, 500 mg + 125 mg

“sulfamethoxazole +
trimethoprim (4)

tablet, 100 mg + 20 mg,
400 mg + 80 mg

powder for injection, 250 mg
(as pentahydrate) in vial

“ceftriaxone (D)

oral suspension,
200 mg + 40 mg/5 ml

powder for injection. 250 mg
(as sodium salt) in vial

imipenem +
cilastatm (D)

powder for injection. 250 mg
(as monohydrate) + 250 mg,
(as sodium salt)
500 mg (as monohydrate) +
500 mg m vial (as sodium salt)
6.2.2 OTHER ANTIBACTERIALS

“chloramphenicol (7)

powder for injection. 1 g
(sodium succinate) in vial

“ciprofloxacin

tablet. 250 mg
(as hydrochloride)

“doxycycline (5, 6)

capsule or tablet,
100 mg (hydrochloride)

“erythromycin

capsule or tablet. 250 mg
(as stearate or ethyl succinate)
powder for oral suspension, 125 mg
(as stearate or ethyl succinate)

powder for injection, 500 mg
(as lactobionate) in vial
“gentamicin (2, 4, 7, 11)

injection, 10 mg, 40 mg
(as sulfate)/ml in 2-ml vial

I

injection, 80 mg +16 mg/ml
in 5-ml and 10-ml ampoule

trimethoprim (8)

tablet. 100 mg. 200 mg

injection, 20 mg/ml
in 5-ml ampoule

Complementary drugs

chloramphenicol (C)

capsule. 250 mg

oral suspension. 150 mg
(as palmitate)/5 ml

J

oral suspension, 200 mg
(as benzoate)/5 ml

i

I

oily suspension for injection,
0.5 g (as sodium succmate)/ml
in 2-ml ampoule

clindamycin (B) (8)

capsule, 150 mg

injection. 150 mg
(as phosphate)/ml
Restricted indications

vancomycin (D)

powder for injection 250 mg (as
hydrochloride) in vial

6.2.3 ANTILEPROSY DRUGS
clofazimine

capsule, 50 mg, 100 mg

dapsone
rifampicin

tablet. 25 mg. 50 mg, 100 mg

capsule or tablet. 150 mg, 300 mg

6.2.4 ANTITUBERCULOSIS
ethambutol (4)

isoniazid

isoniazid + ethambutol (5)

DRUGS

tablet, 100-400 mg
(hydrochloride)

tablet, 100-300 mg

tablet, 150 mg + 400 mg

’ Example of a therapeutic group. V'arrous drugs can serve as alternatives.

252

J

I,
9

WHO Drug Information Vol. 13, No. 4, 1999

pyrazinamide

Essential Drugs

tablet, 400 mg

rifampicin

6.4.2 ANTIRETROVIRAL DRUGS
Adequate resources and specialist oversight are a prerequisite for the introduction of this class of drugs.

capsule or tablet, 150 mg, 300 mg

rifampicin +
isoniazid (5)

tablet, 60 mg + 30 mg, 150 mg + 75 mg,
300 mg + 150 mg

nevirapine (8)

tablet, 60 mg + 60 mg, 150 mg + 150 mg
(for intermittent use 3 times weekly)

zidovudine (8)

rifampicin + isoniazid +
pyrazinamide (5)

rifampicin + isoniazid +
pyrazinamide + ethambutol

streptomycin (4)

oral solution, 50 mg/5 ml
Drugs for treatment of HIV/AIDS include nucleoside
reverse transcnptase inhibitors (NRTIs), non-nucleoside
reverse transcriptase inhibitors (NNRTIs) and protease
inhibitors (Pls). Zidovudine and nevirapine have been
shown to reduce or prevent mother-to-child transmission
of HIV infection. This is the only indication for which |
they are included here. Single drug use with zidovudine, j
except in pregnancy, is now regarded as obsolete be- ;
cause of the development of resistance. Triple therapy is i
beyond the budgets of most national drug programmes I
and therefore HIV/AIDS treatment policies must be de- ■
cided at country or institutional level.

tablet, 150 mg + 75 mg +
400 mg +• 275 mg

powder for injection.
1 g (as sulfate) in vial

Complementary drug
thioacetazone +
isoniazid (A) (5. 7)

tablet, 50 mg + 100 mg,
150 mg + 300 mg

Additional reserve antituberculosis drugs for the treatI ment of drug-resistant tuberculosis should be used in
! specialized centres only with WHO-recommended TB
I control strategy, DOTS, and treatment programmes.

6.5 ANTIPROTOZOAL DRUGS

6.5.1 ANTIAMOEBIC AND ANTIGIARDIASIS
DRUGS
o

6.3 ANTIFUNGAL DRUGS
amphotericin B (4)

capsule, 100 mg, 250 mg

injection, 10 mg/ml in 20-ml vial

tablet,
60 mg + 30 mg + 150 mg,
150 mg + 75 mg + 400 mg

tablet, 150 mg + 150 mg + 500 mg
(for intermittent use 3 times weekly)

/

tablet. 200 mg
oral solution, 50 mg/5 ml

diloxamde

tablet. 500 mg (furoate)

°metronidazole

tablet. 200-500 mg

powder for injection. 50 mg in vial

injection. 500 mg in 100-ml vial

capsule. 50 mg

oral suspension. 200 mg
(as benzoate)/5 ml

°fluconazole

injection. 2 mg/ml in vial
oral suspension. 50 mg/5-ml
gnseofulvin (7)

capsule or tablet. 125 mg, 250 mg

nystatin

6.5.2 ANTILEISHMANIASIS DRUGS
“meglumine antimoniate

injection.
30%. equivalent to approx.
8.5% antimony, in 5-ml ampoule

tablet. 100 000. 500 000 IU

lozenge, 100 000 IU

pentamidine (5)

pessary, 100 000 IU

powoer for injection. 200 mg,
300 mg (isetionate) in vial

Complementary drug

Complementary drugs

flucytosine (B) (4. 8)

capsule. 250 mg

amphotericin B (B) (4)

powder for injection.
50 mg in vial

infusion. 2.5 g in 250 ml
potassium iodide (A)

saturated solution

6.5.3 ANTIMALARIAL DRUGS

(a) FOR CURATIVE TREATMENT

6.4 ANTIVIRAL DRUGS

“chloroquine
6.4.1 ANTIHERPES DRUGS
aciclovir (8)

tablet, 200 mg

powder for injection, 250 mg
(as sodium salt) in vial

tablet. 100 mg, 150 mg
(as phosphate or sulfate)

syrup. 50 mg
(as phosphate or sulfate)/5 ml
injection, 40 mg (as hydro
chloride. phosphate or sulfate)/ml
in 5-ml ampoule

Example of a therapeutic group. Various drugs can serve as alternatives.

253

Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

primaquine

tablet, 7.5 mg, 15 mg
(as diphosphate)

- “quinine

tablet. 300 mg (as bisulfate or sulfate)
injection, 300 mg (as dihydrochloride)/ml
in 2-ml ampoule

Complementary drugs

tablet, 100 mg

nifurtimox (2, 8)

tablet, 30 mg, 120 mg, 250 mg

6.6 INSECT REPELLENTS
diethyltoluamide

“doxycycline (B) (for use only in
capsule or tablet,
combination with quinine)
100 mg (hydrochloride)
mefloquine (B)

(b) AMERICAN TRYPANOSOMIASIS
benznidazole (7)

topical solution, 50%, 75%

Section 7: Antimigraine Drugs

tablet, 250 mg (as hydrochloride)

7.1 FOR TREATMENT OF ACUTE ATTACK

“sulfadoxine +
pyrimethamine (B)

tablet. 500 mg + 25 mg

Restricted indications
artemether (D)

injection, 80 mg/ml
in 1-ml ampoule

artesunate (D)

tablet. 50 mg

acetylsalicylic acid

tablet. 300-500 mg

ergotamine (1c) (7)

tablet, 1 mg (tartrate)

paracetamol

tablet. 300-500 mg

7.2 FOR PROPHYLAXIS

“propranolol

(b) FOR PROPHYLAXIS

chloroquine

tablet. 150 mg
(as phosphate or sulfate)
syrup. 50 mg (as phosphate
or sulfate)/5 ml

doxycycline

capsule or tablet.
100 mg (hydrochlonde)

mefloquine

tablet. 250 mg (as hydrochlonde)

proguaml (for use only in
combination with chloroquine)

tablet. 100 mg
(hydrochlonde)

tablet. 20 mg, 40 mg
(hydrochloride)

Section 8: Antineoplastic and
Immunosuppressive Drugs and
Drugs Used in Palliative Care

tablet. 200 mg, 300 mg

pyrimethamine

tab|et 25 mg

sulfamethoxazole +
tnmethopnm

tablet 50 mg

“azathiopnne (2)

(a) AFRICAN TRYPANOSOMIASIS
melarsoprol (2)

injection, 3.6% solution

pentamidine (2)

powder for injection, 200 mg,
300 mg (isetionate) in vial

suramin sodium

powder for injection. 100 mg
(as sodium salt) in vial

“ciclosponn (2)
(for organ transplantation)

powder for injection, 1 g in vial

8.2 CYTOTOXIC DRUGS
Adequate^ resources and specialist oversight are a prerequisite for the introduction of this class of di
asparaginase (2)

bleomycin (2)
calcium folinate (2)

Complementary drug

eflomithine (C)

capsule. 25 mg
concentrate for injection,
50 mg/ml in 1-ml ampoule

injection. 80 mg + 16 mg/ml
in 5-ml and 10-ml ampoule

6.5.5 ANTITRYPANOSOMAL DRUGS

I

8.11MMUNOSUPPRESSIVE DRUGS
Adequate resources and specialist oversight are a pre
requisite for the introduction of this class of drugs.

6.5.4 ANTIPNEUMOCYSTOSIS AND
ANTITOXOPLASMOSIS DRUGS

pentamidine (2)

I

powder for injection,
10 000 IU in vial
powder for injection, 15 mg
(as sulfate) in vial

tablet, 15 mg
injection, 3 mg/ml in 10-ml ampoule

injection. 200 mg (hydrochloride)/ml in 100-ml bottles

chlorambucil (2)

tablet, 2 mg

chlormethine (2)

powder for injection, 10 mg
(hydrochloride) in vial

Example of a therapeutic group. Various drugs can serve as alternatives.

254

r -

WHO Drug Information Vol. 13, No. 4, 1999

cisplatin (2)

powder for injection,
10 mg, 50 mg in vial

cyclophosphamide (2)

tablet, 25 mg

Essential Drugs

Section 9: Antiparkinsonism Drugs
“biperiden

tablet, 2 mg (hydrochloride)

injection, 5 mg (lactate)
in 1-ml ampoule

powder for injection,
500 mg in vial
cytarabine (2)

powder for injection,
100 mg in vial

dacarbazine (2)

powder for injection,
100 mg in vial

daunorubicin (2)

powder for injection,
50 mg (as hydrochloride) in vial

dactinomycin (2)

powder for injection
500 pg in vial

°doxorubicin (2)
etoposide (2)

capsule, 100 mg

levamisole (2)
mercaptopurine (2)

methotrexate (2)

injection, 50 mg/ml
in 5-ml ampoule

tablet. 50 mg
(as hydrochloride)

tablet, equivalent
to 60 mg iron +
400 pg folic acid

folic acid (2)

tablet, 1 mg, 5 mg

injection. 1 mg (as sodium salt)
in 1-ml ampoule
hydroxocobalamm (2)

powder for injection. 50 mg
(as sodium salt) in vial

airon dextran (B) (5)

vinblastine (2)

powder for injection.
10 mg (sulfate) in vial

vincristine (2)

powder for injection.
1 mg, 5 mg (sulfate) in vial

“prednisolone

ferrous salt + folic acid
(nutritional supplement for use
dunng pregnancy)

Complementary drug

capsule. 50 mg (as hydrochlonde)

tablet, equivalent to 60 mg iron
oral solution, equivalent to
25 mg iron (as sulfate)/ml

tablet. 2.5 mg (as sodium salt)

8.3 HORMONES AND ANTIHORMONES
i

10.1 ANTIANAEMIA DRUGS

ferrous salt

tablet. 50 mg

procarbazine

tablet, 100 mg + 10 mg,
250 mg + 25 mg

Section 10: Drugs affecting the
Blood

powder for injection, 10 mg,
50 mg (hydrochloride) in vial

injection, 20 mg/ml in 5-ml ampoule

fluorouracil (2)

levodopa +
“carbidopa (5, 6)

injection. 1 mg
in 1-ml ampoule

injection, equivalent to 50 mg
iron/ ml in 2-ml ampoule

10.2 DRUGS AFFECTING COAGULATION

desmopressin (8)

injection. 4 pg (acetate)/ml
in 1-ml ampoule
nasal spray. 10 pg (acetate)/
metered dose

hepann sodium

injection. 1000 lU/ml.
5000 lU/ml. 20 000 lU/ml
in 1-ml ampoule

phytomenadione

injection. 10 mg/ml
in 5-ml ampoule

protamine sulfate

injection. 10 mg/ml
in 5-ml ampoule

tablet. 5 mg

i

powder for injection, 20 mg,
25 mg (as sodium phosphate or
sodium succinate) in vial

tamoxifen
I

tablet, 10 mg, 20 mg (as citrate)

tablet. 10 mg

8.4 DRUGS USED IN PALLIATIVE CARE

“warfarin (2, 6)
The WHO Expert Committee on Essential Drugs recom
mended that ail the drugs mentioned in the WHO publi
cation Cancer Pain Relief: with a Guide to Opioid Avail
ability, 2nd edition, be considered essential. The drugs
are included in the relevant sections of the model list
according to their therapeutic use, e.g. analgesics.

tablet. 1 mg, 2 mg and 5 mg
(sodium salt)

0 Example of a therapeutic group. Various drugs can serve as alternatives.

255

&

I
Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

Section 11: Blood Products and
Plasma Substitutes

“procainamide (B)

tablet, 250 mg,
500 mg (hydrochloride)

injection, 100 mg
(hydrochloride)/ml
in 10-ml ampoule

11.1 PLASMA SUBSTITUTES
“dextran 70

injectable solution, 6%

“polygeline

injectable solution, 3.5%

“quinidine (A) (7)

11.2 PLASMA FRACTIONS FOR SPECIFIC USE '
Complementary drugs

“factor VIII concentrate (C) (2, 8)

dried

“factor IX complex (coagulation
factors II. VII, IX, X) concentrate (C) (2, 8)

dried

Section 12: Cardiovascular Drugs
12.1 ANTIANGINAL DRUGS

“atenolol

glyceryl trinitrate
“isosorbide dinitrate

‘verapamil (10)

tablet, 50 mg, 100 mg

tablet, 200 mg (sulfate)

12.3 ANTIHYPERTENSIVE DRUGS
“atenolol

tablet, 50 mg, 100 mg

“captopril

scored tablet, 25 mg

“hydralazine

tablet. 25 mg, 50 mg
(hydrochloride)

powder for injection, 20 mg
(hydrochlonde) in ampoule
“hydrochlorothiazide

tablet, 250 mg

“nifedipine (10)

sustained-release formulations

tablet (sublingual), 500 pg
tablet (sublingual), 5 mg

tablet. 40 mg, 80 mg
(hydrochloride)

tablet, 10 mg
“reserpine

tablet, 100 pg. 250 pg

injection, 1 mg in 1-ml ampoule
Complementary drugs

12.2 ANTIARRHYTHMIC DRUGS

prazosin

“atenolol

“sodium nitroprusside

digoxin (4. 11)

tablet. 50 mg, 100 mg

injection, 250 pg/ml
in 2-ml ampoule

verapamil (8, 10)

tablet. 500 pg. 1 mg (mesilate)

(C) (2. 8)

powder for infusion,
50 mg in ampoule

tablet. 62.5 pg, 250 pg
oral solution, 50 pg/ml

lidocaine

scored tablet, 25 mg

methyldopa (7)

12.4 DRUGS USED IN HEART FAILURE

“captopril

injection. 20 mg
(hydrochlonde)/ml
in 5-ml ampoule
tablet, 40 mg,
80 mg (hydrochlonde)

injection, 2.5 mg
(hydrochlonde)/ml
in 2-ml ampoule
Complementary drugs

scored tablet. 25 mg

digoxin (4, 11)

tablet. 62.5 pg, 250 pg
oral solution. 50 pg/ml
injection, 250 pg/ml in 2-ml ampoule

dopamine

“hydrochlorothiazide

injection, 1 mg
(as hydrochloride)/ml

isoprenaline (C)

injection. 20 pg
(hydrochloride)/ml

tablet. 25 mg, 50 mg

12.5 ANTITHROMBOTIC DRUGS
acetylsalicylic acid

epinephrine (C)

injection. 40 mg
(hydrochloride)/ml in 5-ml vial

tablet, 100 mg

Complementary drug
streptokinase (C)

powder for injection,
100 000 IU, 750 000 IU in vial

“ Example of a therapeutic group. Various drugs can serve as alternatives.
’All plasma fractions should comply with the Requirements for the Collection, Processing and Quality Control of Blood Blood
Components and Plasma Derivatives (Revised 1992). WHO Technical Report Series, No. 840, 1994, Annex 2.

256

-’I

WHO Drug Information Vol. 13, No. 4, 1999

Essential Drugs

12.6 LIPID-LOWERING AGENTS

13.4 ASTRINGENT DRUGS

The WHO Expert Committee on Essential Drugs recog
nizes the value of lipid-lowering drugs in treating patients
with hyperiipidaemia. Beta-hydroxy-beta-methylglutarylcoenzyme A (HMG CoA) reductase inhibitors, often re
ferred to as 'statins', are potent and effective lipidlowering drugs with a good tolerability profile. Several of
these drugs have been shown to reduce the incidence of
fatal and non-fatal myocardial infarction, stroke and mor
tality (all causes), as well as the need for coronary by
pass surgery. All remain very costly but may be costeffective for secondary prevention of cardiovascular dis
ease as well as for primary prevention in some very highrisk patients. Since no single drug has been shown to be
significantly more effective or less expensive than others
in the group, none is included in the model list; the choice
of drug fcr use in patients at highest risk should be
decided at national level.

aluminium diacetate

Section 13:
Dermatological Drugs (topical)

solution, 13% for dilution

13.5 DRUGS AFFECTING SKIN
DIFFERENTIATION AND PROLIFERATION
benzoyl peroxide

lotion or cream, 5%

coal tar

solution, 5%

dithranol

ointment, 0.1-2%

fluorouracil

ointment, 5%

“podophyllum resin (7)

solution. 10-25%

salicylic acid

solution 5%

urea

ointment or cream, 10%

13.6 SCABICIDES AND PEDICULICIDES
“benzyl benzoate

lotion, 25%

permethrin

cream, 5%
lotion, 1%

13.7 ULTRAVIOLET-BLOCKING AGENTS
13.1 ANTIFUNGAL DRUGS

Complementary drugs

benzoic acid + salicylic acid

“miconazole

ointment or
cream. 6% + 3%

topical sun protection agent with
activity against UVA and UVB (C) cream, lotion or gel

ointment or cream. 2% (nitrate)

sodium thiosulfate

solution, 15%

Section 14: Diagnostic Agents

Complementary drug

14.1 OPHTHALMIC DRUGS

selenium sulfide (C)

detergent-based
suspension. 2%

13.2 ANTI-INFECTIVE DRUGS
“methylrosanilimum chloride
(gentian violet)

aqueous solution, 0.5%
tincture, 0.5%

neomycin + -'bacitracin (7)

ointment. 5 mg
neomycin sulfate
+ 500 IU bacitracin zinc/g

potassium permanganate

silver sulfadiazine

aqueous solution. 1:10 000

eye drops, 1% (sodium salt)

“tropicamide

eye drops. 0.5%

14.2 RADIOCONTRAST MEDIA
°amidotrizoate

injection. 140-420 mg iodine
(as sodium or meglumine
salt)/ml in 20-ml ampoule

banum sulfate

aqueous suspension

°iohexol

cream. 1%, in 500-g container

injection. 140-350 mg lodine/ml
in 5-ml, 10-ml and 20-ml ampoule

“iopanoic acid

13.3 ANTI-INFLAMMATORY AND
ANTIPRURITIC DRUGS

“betamethasone (3)

fluorescein

ointment or cream.
0.1% (as valerate)

°calamine lotion

lotion

°hydrocortisone

ointment or cream, 1% (acetate)

“propyliodone
(For administration only into
the bronchial tree).

tablet. 500 mg

oily suspension.
500-600 mg/ml
in 20-ml ampoule

Complementary drug

“meglumine iotroxate (C)

solution, 5 - 8 g iodine
in 100-250 ml

0 Example of a therapeutic group. Various drugs can serve as alternatives.

257

1
I

■*

Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

Section 15:
Disinfectants and Antiseptics

17.2 ANTIEMETIC DRUGS
metoclopramide

injection, 5 mg (hydrochloride)/ml
in 2-ml ampoule

15.1 ANTISEPTICS
solution. 5%
(digluconate) for dilution

°chlorhexidine

“promethazine

elixir or syrup, 5 mg .
(hydrochloride)/5 ml

solution, 10%

“polyvidone iodine

injection, 25 mg (hydrochloride)/ml
in 2-ml ampoule

15.2 DISINFECTANTS

“chlorine base compound

powder (0.1% available
chlorine) for solution

solution, 4.8%

“chloroxylenol

solution, 2%

glutaral

17.3 ANTIHAEMORRHOIDAL DRUGS
ointment
or suppository

“local anaesthetic, astnngent
and anti-inflammatory drug

17.4 ANTI-INFLAMMATORY DRUGS
suppository. 25 mg
(acetate)

hydrocortisone

Section 16: Diuretics
“furosemide

tablet, 10 mg,
25 mg (hydrochloride)

solution, 70% (denatured)

“ethanol

“amiloride (4. 7. 8)

tablet, 10 mg (hydrochloride)

“ retention enema

tablet, 5 mg (hydrochlonde)
tablet. 40 mg

“sulfasalazine (2)

tablet. 500 mg

suppository. 500 mg

injection. 10 mg/ml in
2-ml ampoule

“hydrochlorothiazide
spironolactone (8)

tablet. 25 mg, 50 mg
tablet. 25 mg

retention enema
17.5 ANTISPASMODIC DRUGS

“atropine

tablet. 0.6 mg (sulfate)

injection. 1 mg (sulfate)
in 1-ml ampoule

Complementary drug

“mannitol (C)

injectable solution. 10%. 20%
17.6 LAXATIVES

Section 17: Gastrointestinal Drugs

“senna

17.1 ANTACIDS AND OTHER ANTIULCER
DRUGS

17.7 DRUGS USED IN DIARRHOEA

aluminium hydroxide

17.7.1 ORAL REHYDRATION

tablet. 500 mg

oral suspension. 320 mg/5 ml
“cimetidine

tablet, 200 mg

injection. 200 mg in 2-ml ampoule
magnesium hydroxide

oral suspension,
equivalent to 550 mg
magnesium oxide/10 ml

tablet. 7.5 mg (sennosides)
(or traditional dosage forms)

oral rehydration salts (for glucoseelectrolyte solution)
Components
sodium chloride
trisodium citrate dihydrate 2
potassium chloride
glucose

I

powder. 27.9 g/l

qa
3.5

2.9
1.5

i

I

1

20.0

:i

“ Example of a therapeutic group. Various drugs can serve as alternatives.
2Trisodium citrate dihydrate may be replaced by sodium bicarbonate (sodium hydrogen carbonate) 2.5 g/l. However, as the
stability of this latter formulation is very poor under tropical conditions, it is only recommenaed when manufactured for
immediate use.

258

■ w

r»

Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

17.7.2 ANTIDIARRHOEAL (SYMPTOMATIC)
DRUGS
tablet, 30 mg (phosphate)

“codeine (1a)

Section 18: Hormones, other Endo
crine Drugs and Contraceptives
18.1 ADRENAL HORMONES AND
SYNTHETIC SUBSTITUTES

condoms with or without spermicide
(nonoxinol)
diaphragms with spermicide
(nonoxinol)

18.4 ESTROGENS

injection, 4 mg dexamethasone
phosphate (as disodium salt)
in 1-ml ampoule
hydrocortisone

powder for injection, 100 mg
(as sodium succinate) in vial

“prednisolone

tablet, 1 mg, 5 mg

18.5 INSULINS AND OTHER ANTIDIABETIC
AGENTS

injection.
40 lU/ml in 10-ml vial.
100 lU/ml in 10-ml vial
(as compound insulin zinc suspension
or isophane insulin)

intermediate-acting insulin

metformin

Complementary drug
testosterone (C) (2)

injection.
40 lU/ml in 10-ml vial.
100 lU/ml in 10-ml vial

insulin injection (soluble)

tablet. 100 pg (acetate)

18.2 ANDROGENS

tablet. 2.5 mg, 5 mg

“glibenclamide

Complementary drug

fludrocortisone (C)

tablet, 10 pg, 50 pg

“ethinylestradiol

tablet, 500 pg, 4 mg

“dexamethasone

18.3.3 BARRIER METHODS

tablet. 500 m (hydrochloride)

18.6 OVULATION INDUCERS
injection, 200 mg
(enantate) in 1-ml ampoule

“clomifene (2. 8)

tablet. 50 mg (citrate)

18.7 PROGESTOGENS

18.3 CONTRACEPTIVES

18.3.1 HORMONAL CONTRACEPTIVES

tablet. 5 mg

norethisterone

Complementary drug

°ethinylestradiol +
“levonorgestrel

tablet. 30 pg + 150 pg,

“ethinylestradiol +
“levonorgestrel

tablet. 50 pg
+• 250 pg (pack of four)

18.8 THYROID HORMONES AND
ANTITHYROID DRUGS

’ethinylestradiol +
’norethisterone

tablet. 35 pg + 1.0 mg

levothyroxine

levonorgestrel

tablet, 0.75 mg (pack of two)

Complementary drugs

norethisterone
enantate (B) (7, 8)

tablet. 50 pg, 100 pg
(sodium salt)

potassium iodide

tablet. 60 mg

“propylthiouracil

tablet. 50 mg

tablet. 30 pg

“levonorgestrel (B)
medroxyprogesterone
acetate (B) (7. 8)

tablet. 5 mg

medroxyprogesterone acetate (B)

depot injection.
150 mg in 1-ml vial

oily solution. 200 mg/ml in
1-ml ampoule

Section 19: Immunologicals
19.1 DIAGNOSTIC AGENTS
tuberculin,3
punfied protein derivative (PPD)

injection

18.3.2 INTRAUTERINE DEVICES
copper-containing device

“ Example of a therapeutic group. Various drugs can serve as alternatives.
3 All tuberculins should comply with the Requirements for Tuberculins (Revised 1985). WHO Technical Report Series. No.
745. 1987, Annex 1.

259
9

Essential Drugs

WHO Drug Information Vol. 13, No. 4, 1999

19.2 SERA AND IMMUNOGLOBULINS4
anti-D immunoglobulin
(human)
“antitetanus immunoglobulin
(human)

injection, 250 pg in
single-dose vial
injection, 500 IU
in vial

antivenom serum

injection

diphtheria antitoxin

injection, 10 000 IU,
20 000 IU in vial

immunoglobulin,
human normal (2)

injection (intramuscular)

immunoglobulin,
human normal (2, 8)

injection (intravenous)

“rabies immunoglobulin

injection, 150 lU/ml

Section 20:
Muscle Relaxants (peripherally act
ing) and Cholinesterase Inhibitors
“alcuronium chloride (2)

injection, 5 mg/ml
in 2-ml ampoule

“neostigmine

tablet, 15 mg (bromide)

injection. 500 pg, 2.5 mg
(metilsulfate) in 1-ml ampoule
pyridostigmine bromide (2, 8)

19.3 VACCINES5
19.3.1 FOR UNIVERSAL IMMUNIZATION
BCG

tablet, 60 mg
injection, 1 mg
in i-ml ampoule

suxamethonium
chloride (2)

injection, 50 mg/ml
in 2-ml ampoule

powder for injection
Complementary drug

vecuronium bromide (C)

powder for injection.
10 mg in vial

diphtheria
. pertussis

hepatitis B

Section 21:
Ophthalmological Preparations

measles

21.1 ANTI-INFECTIVE AGENTS

tetanus

poliomyelitis

19.3.2 FOR SPECIFIC GROUPS OF INDIVIDUALS

“gentamicin

solution (eye drops). 0.3%
(as sulfate)

“idoxuridme

solution (eye drops), 0.1%

eye ointment. 0.2%

influenza

silver nitrate

solution (eye drops), 1%

meningitis

“tetracycline

eye ointment, 1% (hydrochloride)

mumps

rabies

21.2 ANTI-INFLAMMATORY AGENTS

“prednisolone

solution (eye drops), 0.5%

rubella

(sodium phosphate)

typhoid

21.3 LOCAL ANAESTHETICS

yellow fever

“tetracaine

solution (eye drops), 0.5%
(hydrochloride)

21.4 MIOT/CS AND ANTIGLAUCOMA DRUGS

acetazolamide

tablet, 250 mg

1

“ Example of a therapeutic group. Various drugs can serve as alternatives.
Blood^om^onentt^Plasma^XXTfReXdTgga) Who’S"'C0"™ Of B'°Od'
AN vaccines should compiy with current WHO recommend^foTJ^XXTncTs"65'

0'

260

r
i

I

■:

5

—J
r»

WHO Drug Information Vol. 13, No. 4, 1999

“pilocarpine

solution (eye drops), 2%, 4%
(hydrochloride or nitrate)

°timolol

solution (eye drops), 0.25%, 0.5%
(as maleate)

Essential Drugs

24.2 DRUGS USED IN MOOD DISORDERS
24.2.1 DRUGS USED IN DEPRESSIVE
DISORDERS
“amitriptyline

tablet, 25 mg (hydrochloride)

21.5 MYDFIIATICS

atropine

solution (eye drops),
0.1%, 0.5%, 1% (sulfate)

Complementary drug

24.2.2 DRUGS USED IN BIPOLAR DISORDERS
carbamazepine (10,11) scored tablet, 100 mg, 200 mg

lithium carbonate (2, 4)

epinephrine (A)

solution (eye drops), 2%
(as hydrochloride)

Section 22:
Oxytocics and Antioxytocics

valproic acid (7, 11)

capsule or tablet. 300 mg
enteric coated tablet,
200 mg, 500 mg (sodium salt)

24.3 DRUGS USED IN GENERALIZED
ANXIETY AND SLEEP DISORDERS
“diazepam (1b)

scored tablet. 2 mg, 5 mg

22.1 OXYTOCICS

Oergometrine (1c)

tablet. 200 pg (hydrogen maleate)
injection. 200 pg (hydrogen maleate)
in 1-ml ampoule

oxytocin

injection. 10 IU in 1-ml ampoule

24.4 DRUGS USED IN OBSESSIVE
COMPULSIVE DISORDERS AND
PANIC ATTACKS

clomipramine

capsules. 10 mg, 25 mg
(hydrochloride)

22.2 ANTIOXYTOCICS

“salbutamol (2)

tablet. 4 mg (as sulfate)

injection. 50 pg (as sulfate)/ml
in 5-ml ampoule

25.1 ANTIASTHMATIC DRUGS

“aminophylline (2)

Section 23: Peritoneal
Dialysis Solution
intraperitoneal dialysis solution
(of appropriate composition)

Section 25: Drugs Acting on
the Respiratory Tract
injection, 25 mg/ml
in 10-ml ampoule

“beclometasone

inhalation (aerosol). 50 pg, 250 pg,
(dipropionate) per dose

parenteral solution
°epinephnne

Section 24:
Psychotherapeutic Drugs

injection. 1 mg (as hydrochloride
or hydrogen tartrate) in 1-ml ampoule

ipratropium bromide
“salbutamol

tablet. 2 mg. 4 mg (as sulfate)
inhalation (aerosol). 100 pg
(as sulfate) per dose

24.1 DRUGS USED IN PSYCHOTIC DISORDERS

“chlorpromazine

“fluphenazine (5)

°haloperidol

inhalation (aerosol), 20 ug/dose

tablet, 100 mg (hydrochloride)

syrup, 2 mg (as sulfate)/5 ml

syrup, 25 mg
(hydrochloride)/5 ml

injection. 50 pg (as sulfate)/ml
in 5-ml ampoule

injection. 25 mg
(hydrochloride)/ml in 2-ml ampoule

respirator solution for use in nebulizers.
5 mg (as sulfate)/ml

injection. 25 mg
(decanoate or enantate)
in 1 -ml ampoule

tablet. 2 mg. 5 mg

theophylline (10. 11)

tablet, 100 mg, 200 mg, 300 mg

Complementary drug
°cromoglicic acid (B)

injection, 5 mg in
1-ml ampoule

inhalation (aerosol),
20 mg (sodium salt) per dose

“ Example of a therapeutic group. Various drugs can serve as alternatives.

261

TH

ESSENTIAL DRUG UST
(PREPARED BY COMMUNITY HEALTH CELL)

SI.
No.

Name of Drug

1.
2.
3.
4.
5.

ANAESTHETICS
Ether
Halothene
Thiopental
Nitrous Oxide
Oxygen

1.
2.
3.
4.

ANTI - ALLERGICS
Chlorpheniramine maleate
Promethazine
Adrenaline
Dexamethasone

1.
2.
3.

ANTIBODIES
Atropine sulphate
Magnesium Sulphate
Pralidoxime

1.
2.
3.

ANTI - LEPROSY
Dapsone
Rifampicin
Clofazimine
a

SI.
No.

Name of Drug

1.
2.
3.
4.

ANALGESIC/ANTIPYRETICS
Paracetamol
Aspirin
Ibuprofen
Indomethacin
Pentazocine Lactate
Pethidine
ANTI - EPILEPTICS
Phenobarbitone
Diazepam
Phenytoin Sodium
Carbamazepine

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

ANTI - INFECTIVES
Mebendazole
Metronidazole
Benzyl Pencillin
Procaine Pencillin
Benzathine Pencillin
Tetracycline
Doxycycline
Chloramphenicol
Co-trimoxazole
Erythromycin
Amoxycillin
Ampicillin

1.
2.
3.
4.
5.

ANTI-TUBERCULAR
INH
Streptomycin
Thioacetazone
Rifampicin
Ethambutol

1.
2.
3.
4.
5.
6.

1.

ANTI - FILARIAL
Di-ethyl carbamazine

ANTI - FUNGAL
Griseofulvin
Amphotericin B

1.
2.
3.
4.

ANTI-MALARIAL
Chloroquin
Primaquin
Sulfadoxin Pyremethamine
Quinine Sulphate

1.
2.
3.

HAEMOPOIETIC
Ferrous Sulphate + folic Acid
Ferrous Fumarate 4- folic Acid
Folic Acid

1.
2.

CARDIOVASCULAR
Isosorbide Nitrate
Propranolol

1.
2.
3.
4.

ANTI - HYPERTENSIVE
Hydrochlorothiazide
Reserpine
Hydralazine
Atenlol

1.

CARDIAC GLYCOSIDE
Digoxin

1.
2.
3.

DIURETICS
Frusemide
Spiranolactone
Mannitol

1.
2.
3.

LAXATIVES
Isapaghula husk
Paraffin, liquid
Glycerine

GASTRO INTESTINAL
Antacids
1.
2.
3.

Aluminium Hydroxide
Magnesium Trisilicate
Ranitidine

1.
2.

Anti-emetics
Metoclopramide
Promethazine

1.
2.
3.

Anti spasmodic
Atropine sulphate
Dicyclomin
Promethazine

Anti -Diarrhoeals
ORS packets
Loperamide Hydrochloride
(not for children)

1.
2.

HARMONES
Prednisolone
Hydrocortisone sodium succinate

1.
2.
3.

PSYCHO THERAPEUTIC
Imipramine
Chlorpromazine
Diazepam

1.
2.

OBSTETRICS
Methergin
Oxytocin

1.
2.
3.

VITAMINS / MINERALS
Ascorbic Acid
Vitamin A
Vitamin B complex

1.
2.
3.

ANTI DIABETIC
Insulin (plain)
Insulin (Lente)
Glibenclamide
RESPIRATORY
Anti asthmatic

Deriphylline

1.
2.
3.
4.
5.

Aminophylline
Salbutamol
Terbutaline
Oxygen

1.

Anti-tussive
Codeine Phosphate

1.
2.
3.
4.
5.
6.

REHYDRATION ACID BASE
ELECTROLYTE balance
I.V. Dextrose
I.V. Sodium Chloride
I.V. Dextrose + Saline
I.V. Molar Lactate
I.V. Sodium Bicabonate
Potassium Chloride

1.
2.
3.
4.
5.
6.
7.
8.
9.

SKIN & STD
Zinc Oxide Ointment
Whitfield ointment
Benzyl benzate
Neomycin+bacitracin
Gention violet
Miconazole ointment
Pencillin
Doxycyclin
Norfloxacin

1.
2.
3.
4.

EYE DROPS
Tetracycline
Pilocarpine
Humatropine
Chloramphenical

1.
2.
3.
4.
5.
6.
7.
8.

ACCESSORIES
Water for injection
Hydrogen peroxide
Chlorhexidine
Absorbent Cotton
Gauze, small & large
Bandage
Butterfly (scalp) venesets 18,21,24
Sutures
Black braided silk
Mersilk
Catgut, plain
Catgut Chromic
Prolene, atraumatic
Vicryl
Cotton thread

9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.

Suture Needles
Hypodermic Needles
Gloves, surgical
Ryles Tubes
Adhesive Plaster
Elastocrepe bandage
Plaster of Paris
Surgical Spirit
Drip set: administration; fluid, blood
Cannula, IV for venesection
Syringes
Catheters, plain
Catheters, Foley’s
Bleaching powder

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11
12.
13.

EMERGENCY DRUGS
Oxygen cylinders on trolleys, with
flow meters and mask
Dopamine
Hydro cortisone
Lignocaine
Atropine
Sodium Bicarbonate
Pralidoxime
Adrenaline
Mephentermine
Mannitol
Magnesium sulphate
Trachestomy set, 24,27,30,36

1.
2.
3.
4.

VACCINES & SERA
All vaccines as per National
Universal Immunization Programme
Anti Rabies serum
Anti Snake Venom Serum

DIAGNOSTIC AGENTS
As needed
This listjias been prepared using the following lists for reference:

1. model list of essential list
2. Essential drugs in Primary Health Care in India, Southern region list, prepared at
National Seminar conducted by NIPCCD.
3. Lists
'nigs received from Government and other sources
4. CHAi
iAI formulary.

CAMPAIGN FOR

ACCESS

_________ TO_________

ESSENTIAL
MEDICINES

k MEDKINS
^^SANS FRONTIERES

EXAMPLES OF THE IMPORTANCE OF INDIA
AS THE “PHARMACY FOR THE DEVELOPING WORLD”
Quick Overview:
•
•
•

•
•
•
•

India is the main supplier of essential medicines for developing countries.
67 % of medicines produced in India are exported to developing countries.
Main procurement agencies for developing countries’ health programmes purchase their
medicines in India, where there are quality products and low prices.
Approx. 50% of the essential medicines that UNICEF distributes in developing countries
come from India
75-80% of all medicines distributed by the International Dispensary Association (IDA) to
developing countries are manufactured in India. (IDA is a medical supplier operating on a
not-for-profit basis for distribution of essential medicines to developing countries.)
In Zimbabwe, 75% of tenders for medicines for all public sector health facilities come from
Indian manufacturers
The state procurement agency in Lesotho, NDSO, states it buys nearly 95% of all ARVs
from India.

Antiretroviral medicines (ARVs) for AIDS treatment:

India is the world’s primary source of affordable ARVs, as it is one of the few countries with the
capacity to produce these newer medicines as generics. Therefore, all AIDS programmes use
India as their main source of products.
•

•
•

•

80% of ARVs MSF uses are purchased in India and are distributed in treatment projects in
over 30 countries.
Globally, 70% of the treatment for patients in 87 developing countries, purchased by
UNICEF, IDA, the Global Fund (GFATM) and the Clinton Foundation since July 2005
has come from Indian suppliers.
PEPFAR, the US President’s AIDS initiative also purchases ARVs from India for
distribution in developing countries, thus resulting in cost-savings of up to 90%. 89% of the
generic ARVs approved by the US Food and Drug Administration for PEPFAR are from
India.1
90% of the ARVs used in Zimbabwe’s national treatment programme come from India.

Raw materials:

In addition, raw materials are exported from India to other countries, such as Brazil, for local
production of affordable medicines. This has been crucial to enabling national AIDS
programmes to provide universal free access to ARVs.

In Detail:
India is the main supplier of essential medicines for developing countries. This applies not only to
AIDS medicines, but to medicines to treat other diseases, as well. India is the world’s leading
supplier of inexpensive generic medicines, with approximately 67% of them being exported to

developing countries.2

1 with partial data available for fiscal year 2006
2 Oxfam

1) International procurement agencies____________________________________________
The main procurement agencies for health programmes in developing countries purchase their
medicines in India, where quality products can be purchased at low prices.
MSF:
• 40% of the money MSF spends on oral medicines is used to buy drugs from India (if
injectables are included, the average lies at 26,5%).

UNICEF:
• India ranks second on the list of countries from which UNICEF purchases medical supplies.
India has a considerable lead over all countries below it on the list, and Belgium only ranks
first because of vaccines (e.g. combination vaccines are not yet being produced in India)3.
• If vaccines are excluded, India is the source of approx. 50% of the essential medicines
UNICEF distributes in developing countries (see figure 1).

... AND WHERE WE BUY IT
TOP 20 SUPPLIER COUNTRIES 2005
(mBkMis of United States Dolars)
Belgium ............ .
India ..................

France ..............
Japan ..............
Switzerland .....
Denmark ...........
United States ...
Italy.....................
Germany ...........
United Kingdom

222
205
.82
..54
..43
..40
..33
.33
..31
..31

Pakistan......................
China ..........................

29
26

Kenya.......................

21
20 |
14 '
11 i

Indonesia ..................
Thailand......................
Sudan..........................
South Africa..............
Sweden......................
United Arab Emirates
Republic of Korea ...

11

W9 II
-..9
\

Figure 1: Top 20 supplier countries for UNICEF4

IDA (International Dispensary Association)

•

75-80% of all medicines distributed by IDA to developing countries are manufactured in
India. (IDA is a medical supplier operating on a not-for-profit basis for distribution of
essential medicines to developing countries.)

2) National supply stores for public/non profit sector:
Zimbabwe
• The National Pharmaceutical Company, Natpharm, (formerly Governmental Central Stores),
states 75% of tenders for supply to national health facilities are won by Indian
manufacturers.

3) Antiretrovirals - ARVs
India is the world’s primary source of affordable ARVs, as it is one of the few countries with the
capacity to produce these newer medicines as generics. Therefore, all AIDS programmes use
India as their main source of products.

•

80% of ARVs MSF uses are purchased in India and are distributed in treatment projects in
more than 30 countries.

3 http.7/wx\'w.uniccf.org/supply/files/SD AnnualReport 2005.pdf
4 ibid

•

•

•
•

Globally, 70% of the treatment for 900,000 patients in 87 developing countries, purchased
by UNICEF, IDA and the Global Fund (GFATM) since July 2005 has come from Indian
suppliers.
PEPFAR, the US President’s AIDS initiative also purchases ARVs from India for
distribution in developing countries, thus resulting in cost-savings of up to 90%. 89% of the
generic ARVs approved by the US Food and Drug Administration for PEPFAR are from
India.5
90% of the ARVs used in Zimbabwe’s national treatment programme come from India.
The state procurement agency in Lesotho, NDSO, states it buys nearly 95% of all ARVs
from India.

PEPFAR: The vast majority of ARVs used by PEPFAR come from India. "In every case
generic prices present an opportunityfor cost savings; in some cases, the branded price per
pack ofa drug is up to 11 times the cost of the approved generic version.6"
PEPFAR purchases of generic ARVs compared with
Branded ARVs in FY06
(all generics manufactured in India)

■■Branded ;
■ Generic

70%

Figure 2: Bringing Hope: Supplying ARVs for HIV/AIDS treatment, PEPFAR, May 20067

4) Active Pharmaceutical Ingredients (APIs)
Raw materials from India are also exported to other countries for production of affordable
medicines. This has been key in the success of national AIDS programmes’ ability to provide
universal free access to ARVs.

As an example, generic production of medicines in Brazil is heavily dependent on APIs purchased
from India. At the third meeting of the Commission on Intellectual Property Rights, Innovation and
Public Health (CIPIH)8, Brazil stated: “Brazil is concerned whether the application of TRIPS in
India and China may affect access to APIs, and thus their treatment programmed

5 with partial data available for fiscal year 2006
6 Bringing Hope: Supplying ARVs for HIV/AIDS treatment, PEPFAR, May 2006
7 Note only several months of 2006 are included
8 Third meeting of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH), 31 Jan.- 4 Feb.
2005

1
Campaigns for Essential
Medicines
- For Batch 4 CHFS Orientation (August 14,
2006). Facilitated by NT

Answers
• When was the first synthetic pharmaceutical
introduced? (1897)
• When was the first modern antibiotic introduced?
(1941)
• When was the first commercially formulated antimalarial? (1943)
• When was the first anti-tubercular produced? (1944)
• What about the first clinical use of oral contraceptives,
of drugs for diabetes and of drugs for mental illness
(1950s)
• And when was drugs for other infectious diseases, for
cardiovascular diseases and for a wide range of other
conditions developed? (50s onwards, in 60s and 70s)

Quiz on pharma development

A

• When was the first synthetic pharmaceutical
introduced?
• When was the first modern antibiotic introduced?
• When was the first commercially formulated
antimalarial?
• When was the first antitubercular produced?
• What about the first clinical use of oral contraceptives,
of drugs for diabetes and of drugs for mental illness.
• And when was drugs for other infectious diseases, for
cardiovascular diseases and for a wide range of other
conditions developed?

Model List of Essential Drugs
• WHO published the first Model List of
Essential Drugs in 1977, it identified 208
individual medicines.
• The current Model List of Essential
Medicines, prepared by the WHO in
March 2005 is the 14th ed. It contains
312 individual medicines, including
antiretroviral medicines.

1

Essential medicines

\

Those that satisfy the:
• priority health care needs of the population
Selected with due regard to:
• disease prevalence
• evidence on efficacy and safety &
• comparative cost-effectiveness

This year

>40 million
people will
die

A

Essential medicines
Are intended to be available:
• within the context of functioning health
systems
• at all times
• in adequate amounts
• in the appropriate dosage forms
• with assured quality
• at a price the individual and the community
can afford.

Of the over 40 million deaths

\

one-third will be
children under
age five.

in developing countries.

2

Of the over 40 million deaths

X

due to conditions for which

10 million will be due to
acute respiratory
infections, diarrhoeal
diseases, tuberculosis,
and malaria

WHO estimates
• more than half of all medicines are
• prescribed,
• dispensed or
• sold inappropriately,
• half of all patients fail to take them
correctly.

10 million avoidable deaths .

safe, inexpensive,
essential drugs
can be

life-saving

A

Irrational use of medicines

\

• overuse,
• underuse or

• misuse of medicines

• It results in
• wastage of scarce resources and
• widespread health hazards

3

Examples - irrational use of medicines

X

• use of too many medicines per patient ("poly
pharmacy");
• inappropriate use of antimicrobials,

• Over the past 30 years, the number of
drugs targeting neglected diseases is ten
if we consider the most neglected
diseases,

• often in inadequate dosage.
• for non-bacterial infections;

• over-use of injections when oral formulations would be
more appropriate;
• failure to prescribe in accordance with clinical
guidelines;
• inappropriate self-medication, often of prescriptiononly medicines;
non-adherence to dosing regimes.

What are neglected diseases?
• Neglected diseases, such as malaria and
tuberculosis, mainly affect people in poor
countries.
• Most neglected diseases, such as sleeping
sickness, Chagas disease, visceral
leishmaniasis (Kala azar), Buruli ulcer etc.
almost exclusively affect people in developing
countries who are too poor to pay for any kind
of treatment. These patients are too deeply
impoverished to constitute a market that can
^attract investment in drug R&D.

Neglected diseases

• 18 if we add malaria,
• and 21 if we add tuberculosis.
• These totals still represent only around
1 % of all new drugs (1,556)

X

India response

\

• All India Drug Action Network
• medico friends circle
• Drug Action Forum
• Jan Swasthya Abhiyan
• National Working Group on Patent Laws
• WTO Wirodhi Bharatiya Jan Abhiyan
(Indian People's Campaign against WTO)
etc, etc

4

Page 1 of 1

Community Health Cell

From:

cehatpun@vsnl.com on behalf of SATHI [cehatpun@vsnl.com]

Sent:

VJednesday, December 06,2006 2:59 PM
Vandana Prasad: Amlt Sen Gupta; Ekbal;Amltava Guha; N. B. Sarojini; Sundar gmail:
Thelmanarayan

To;

jsa delhi
Cc:
Subject: Rabies vaccine -Letterto AS Anand, Chairperson, NHRC
Dear All,
I am fotwarding herewith the letter which we faxed todayto NHRC with copy to Mrs. Aruna Sharma. Abh ay was to
meet Mrs. Aruna Sharma today and would hopefully be able to push this matter about Intra dermal Rabies
Vaccine because she had specifically shown interest in taking up this issue when Dhananjaymet her a few days
back.

Sincerely yours,
Anant

— Original Message —
From: SATHI
To: ABHAY TRAVELLING
Sent: Wednesday, December 06,2006 2:34 PM
Subject: Letter to . A.S Anand, Chairperson, NHRC
Please find attached herewith letter to Justice Dr. AS Anand, Chairperson, NHRC

SATHI-CEHAT
3 & 4, Aman E Terrace,
Dahanukar Colony, Kothrud,
Pune -411029
Phone: 020-25451413,25452325

X

Q\ TCT

A

VoCO

LxlokS i c
(A?

Jan Swasthya Abhiyan
(People’s Health Movement - India)
Health for All - Howl
Health is a Basic Human Right!

It is the duty of the State to protect all citizens against this invariably fatal disease. But this
fundamental right to life is being violated by not sufficiently increasing the budget to provide this
‘new’ vaccine and by not continuing the earlier policy of providing free Anti Rabies Vaccine to all
cases of dog bite who report to Public Health facilities.
We urge you to urgently intervene in this matter so that the direct threat to the lives of so
many poor people in India due to Rabies is annulled.

Attached herewith is our letter to Mr. P. Hota, Health Secretary, in which we have suggested
two specific measures to overcome this problem. This letter has been handed over on 17th October
05 in a meeting to Ms. Rita Teotia, Joint Secretary, Health and Family Welfare, with a plea for
urgent action. We trust that in this instance too, you would take necessary steps to help protect the
lives of a large number of needy people in the country, by asking the Health ministry to institute the
necessary measures urgently.
Awaiting your positive response.

Sincerely yours.

If*

Dr. B. Ekbal.

National Convenor, JSA

Dr. Abhay Shukla

National Joint Convenor, JSA

PS. Attachment: - Letter to Mr. P. Hota, Secretary, Ministry of Health and Family Welfare

Addresses for Correspondence:
National Secretariat c/o SATH1- CEHAT, 3&4, Aman Terrace, Plot No. 140, Dahanukar Colony, Kothrud, Pune
411029 Ph: (020) 25451413 / 25452325 Email: cehatpun@vsnl.con
c/o Delhi Science Forum, D-158, Lower Ground Floor, Saket, New Delhi -110017.
Ph: (011) 26524324,26862716 (Telfax). Email: ctddsf@vsnl.com
c/o Sama Resource Group for Women and Health ,G-19, 2nd Floor, Marg no.24, Saket,
New Delhi 17. Phone 011- 26562404, 26968972 Email- sama_womenshealth@vsnl.net

Jan Swasthya Abhiyan
(People’s Health Movement - India)
Health is a Basic Human Right!

Health for All - Now!

6tn December 2006
Chairperson:
N.H. Antia

Convenor:
B. Ekbal
Jt. Convenors:
Abhay Shukla
Amit Sen Gupta
Amitava Guha
T. Sundararaman
Thelma Narayan
National secretariat members:
Vandana Prasad
N.B. Sarojini

National Co-ordination Committee:
All India People’s Science Network (AIPSN)
All India Drug Action Network (AIDAN)
Asian Community Health Action Network (ACHAN)
All India Democratic Women’s Association (AIDWA)
Association for India's Development (AID)
Bharat Cyan Vigyan Samiti (BGVS)
Breastfeeding Promotion Network of India (BPNI)
Catholic Health Association of India (CHAI)
Centre for Community Health and Soc. Medicine, JNU
Christian Medical Association of India (CMAI)
Community Health Cell (CHC)
Forum for Creche and Child Care Services (FORCES)
Fed. of Medical Representative Assns. of India (FMRAI)
Health Watch- UP- Bihar
Joint Women’s Programme (JWP)
Medico Friends Circle (MFC)
National Alliance of People’s Movements (NAPM)
National Federation of Indian Women (NFIW)
National Association of Women’s Organisations (NAWO)
Sama- Resource Group for Women and Health
SATHI-CEHAT
Voluntary Health Association of India (VHAI)

Participating Organisations:
Over 1000 organisations concerned with health care
and health policy from both within and outside
the above networks.

To,
Justice Dr. A.S. Anand,
Chairperson,
National Human Rights Commission,
New Delhi
Subject: - Unavailability since June 05 in Public Health
Facilities throught India, of free vaccine against the invariably fatal
Rabies, leading to serious human rights violation
Respected Justice Anand,

This is in continuation with the complaint that we have
launched on 31st October, 2005 about the subject mentioned
above. Copy of this letter is enclosed herewith for your ready
reference.
In February 06, Drugs Controller of India sent a circular to
the manufacturers of Rabies Vaccine in India giving them
permission to use the Intra Dermal Route of this vaccine. This was
probably because of the action initiated by your office in response
to our complaint. However, there is a crucial rider in the letter
issued by the Drugs Controller of India, which says that the Intra
Dermal Route can be used only if there are more than fifty patients
of dog bite report to the Health Centre in a day.
Barring one or two exceptions in all other public hospitals in
any state and certainly in Primary Health centres, there is certainly
no possibility of having the fifty cases of dog bite in a day. This
strange condition has no medical or any other logic whatsoever.
The effect of this circular is that the cheaper Intra Dermal Route is
not being used in any of the Primary Health Centres or in Rural
Hospitals in India. Only those patients with dog bite who posses
yellow card (BPL card) are given the conventional Intra Muscular
Regimen, which consumes four to five times the volume of vaccine
that is used in Intra Dermal Regimen. Given the very limited budget
being made available for purchase of rabies vaccine, the continued
use of Intra Dermal Regimen means in effect denial of vaccine
protection to large number of people who have been afflicted by
dog bite. As is well known, rabies caused by rabid dog bite is
invariably fatal and hence this denial of vaccine protection effectively
means denial of right to life. It is necessary that Drugs Controller of
India and the Health Secretary give a very clear instruction in favour
of use of Intra Dermal Regimen without putting the condition of at
least fifty cases of dog bite a day.

Addresses for Correspondence:
National Secretariat c/o SATHI-CEHAT, 3&4, Aman Terrace, Plot No. 140, Dahanukar Colony, Kothrud, Pune 411029
Ph: (020) 25451413 / 25452325 Email: cehatpun@vsnl.com
c/o Delhi Science Forum, D-158, Lower Ground Floor, Saket, New Delhi -110017.
Ph: (Oil) 26524324,26862716 (Telfax). Email: ctddsf@vsnl.com
C/o Sama Resource Groupfor IVomen and Health ,G-19, 2nd Floor, Marg no.24, Saket
New Delhi 17. Phone 011- 55637632/3, 26968972 Email- sama_womenshealth@vsnl.net

Page 1 of 2

Jan Swasthya Abhiyan
(People’s Health Movement - India)
Health for All - Now!

Health is a Basic Human Right!

We request you to personally intervene in this matter and see to it that this absurd condition is
withdrawn and Drugs Controller, India is questioned for jeopardizing the lives of thousands of cases of dog bite
that are being denied vaccine protection because of this absurd condition.

Looking forward to a positive response and an early action.

Thanking you,

Sincerely yours,

Dr. B. Ekbal
National Convenor, JSA

Dr. Abhay Shukla
National Joint Convenor, JSA

Dr. Anant Phadke
Co-Convenor- Maharashtra JSA-

Addresses for Correspondence:
National Secretariat c/o SATHI- CEHAT, 3&4, Aman Terrace, Plot No. 140, Dahanukar Colony, Kothrud,
Pune 411029 Ph: (020) 25451413 / 25452325 Email: cehatpun@vsnl.com
c/o Delhi Science Forum, D-158, Lower Ground Floor, Saket, New Delhi -110017.
Ph: (011) 26524324,26862716 (Telfax). Email: ctddsf@vsnl.com
c/o Sama Resource Group for Women and Health ,G-19, 2nd Floor, Marg no.24,Saket
New Delhi 17. Phone Oil- 26562404, 26968972 Email- sama_womenshealth@vsnl.net
Page 2 of 2

Jan Swasthya Abhiyan
(People’s Health Movement - India)
Health bs a Basic Human Right!

Health for All - Now!

31 st October 2005

Chairperson:
N.H. Antia
Vice-Chairperson:
D. Banerjee
Convenor:
B. Ekbal

Jt. Convenors:
Abhay Shukla
Amit Sen Gupta
Amitava Guha
T. Sundararaman
Thelma Narayan

National secretariat members:
Vandana Prasad
N.B. Sarojin:

To,
Justice Dr. A.S. Anand,

Chairperson,
National Human Rights Commission,
New Delhi
4' '

Subject: - National unavailability in Public Health
Facilities of free vaccine against the invariably fatal
Rabies front Jubc 05, leading to serious human rights
violation

Respected Justice Anand,

National Co-crdlnation Committee:
AJ1 India People’s Science Netwoik (A1PSN)
All India Drug Action Network (AIDAN)
Asian Community Health Action Network (ACHAN)
Ail India Democratic Women’s Association (AIDWA)
Association fpr India’s Development (AID)
Bharat Cyan Vigyan Samiti (BGVS)
Breastfeeding Promotion Network of India (BPNI)
Catholic Health Association of India (CHAI)
Centre for Community Health and Soc. Medicine, JNU
Christian Medical Association of Inoia (CMAI)
Community Health Cell (CHC)
Forum for Creche and Child Cate Services (FORCES)
Fed. of Medical Representative Assns. of India (FMRAI)
Joint Women’s Programme (JWP)
Medico Friends Circle (MFC)
National Alliance of People’s Movements (NAPM)
National Federation of Indian Women (NFTV)
National Association of Women’s Organisations (NAWO
Ramakrishna Mission (RK)
SATHI-CEHAT
Voluntary Health Association of India (VHAI)

Participating Organisations:

Over 1000 organisations concerned with health can
and health policy from both within and outside
the above networks.

As you would be awaie, rabies caused by the bite of
rabid dog is a 100% fatal disease. Hence as a national policy, the
Anti R.abies Vaccine was made available free of charge in Public
Health facilities from Primary Health Centres upwards. In India,
due to paucity of ftirrcH, the obsolete sheep brain vaccine, the
'Semple Vaccine’ was being used till May 05. Now from June
05 this vaccine lias been withdrawn from the Indian market, a
welcome step. However the alternative to it. the new and safer
vaccine (the 'cell-culture vaccine’) is generally not available free
of cost in public health facilities. This new vaccine (marketed
under the brand name<: Rabipur, Verorab etc) costs about Rs.
390 per injection, or
cn Rs 1500 for the full course of five
injections. In principle, those who possess the Below' Poverty
Level (BPL) card are supposed to get this vaccine free, however
this system docs not always work; in addition many genuinely
poor people do not possess the BPL card; and even lower middle
class people cannot aftprd the cost of Rs. 1500; hence now a
very large number of people in India are left with no protection
from the fatal disease lybies after rabid dog bite.
na

urv.

Addresses for Correspondence:
National Secretariat c/o SA THl-CEHA T, 3&4, Aman Terrace, Plot No: • 1.Pahantikar Colony, Kothrucl, Pune 411029 ■
Ph: (020) 25451413 / 25452325 Email: cehatpun@vsnl.con
.
...
, ..c/o Delhi Science Forum, D-158, Lower Ground Floor, Saket, New Delhi - • ■’ T‘.
Ph: (Oil) 26524324,26862716 (Te’fax). Email: ctiidsf@vsnl.con-i
C/o Sama Resource Group for Women and Health' ,G-19. 2nd Floor, Marg no.2.4, Sake1,
New Delhi 17. Phone 011- 26562404, 26968972 Email- sama_womenshealth@vsnd.net

— Original Message —
To: naveenftsochara orq
Sent: Wednesday, Deeember 13, 200© §;S0 £M
Subject: Fwd: (reproheaiihjndia] tetter to communist leaders - test date Uth Dee

DearNaveen,

I think CHC should sign in on this.
rakhal

From: satinath sarangi [mailto:>jstrceinbhopal@yahoo,co.in ]
Sent: Saturday, December 09,2006 7:27 PM
To: icjb^lanning^lists,statentsforbhopal.org; sfbplanning; aid_bhopal@aidindia.org ; rememberbhopal@lists.5talent5forbhopal .org
Subject: [Norton AntiSpam] [remember-bhopal] tetter to communist leaders

dear all.

below is a letter we would like to send to the polit bureau of the communist party of india [marxist] or
cpm. the letter asks the members of the top decision making body of the party to disallow dow chemical's
proposed investment in west bengal - a state in which the cpm has been in power for more than 30 years.

the present "united progressive alliance" upagovernment at the centre is quite dependent on the support of
cpm. 43 out of 543 members of the indian parliament are from the cpm.
currently the cpm government in west bengal and the polit bureau is siezed with the issue of establishment
of an automobile factory by India's top capitalists - the Tatas - in the face of opposition by local farmers
and others whose lands have been taken away by force by the state government, author arundhati roy and
medhapatkar are among those supporting the agitating farmers and fisherpeople who were shot at by the
police during one of the recent demonstrations.
we aim to send this letter to the communist leaders and to the media on 15th morning while there is debate
within the party and much pressure from without on the issue of industrial investments in west bengal.
please try and get as many organizations signed on as possible and send us the names by 14th evening.

best wishes.
Vx,

sathyu
%

CF

To:
The Members of the Polit Bureau
Communist Party of India (Marxi£)
A.K. GopalanBhawan,
27-29, Bhai Vir Singh Marg
(Gole Market),New Delhi • 110001
Date: December 15, 2006
Subject: Open letter for disallowing American multinational Dow Chemical, owner of Killer Union Caibide, to invest
In West Bengal

Dear Members of the Polit Bureau of the Communist Party of India (Marxiit),
We, representatives of organizations of survivors of the Bhopal disaster and their supporters arc writing to you to urge that- you
reject the proposed inv estment in West Bengal by the current owner of Union Carbide Corporation, American multinational
The Dow Chemical Company.

As you must- know Union Carbide has killed well ov er 20 thousand people in Bhopal and injured more than half a million by
the leak of toxic gases in December 1984. You may also know that more than 25 thousand people living in the vicinity of the
abandoned pesticide factory are being poisoned through contaminations in their ground water.
We are sure you arc aware that- Unicn Carbide Corporation is criminally charged with manslaughter, grievous assault and other
serious offerices and the company is absconding from the ongoing criminal case since 1992. Successive Indian Governments
have failed to make any effort to enforce Carbide's appearance in Indian courts. We have recently presented evidence in the
criminal court- in Bhopal that- the fugitive American corporation continues to sell its products, technologies and processes
through Indian subsidiaries of The Dow Chemical Company with which it merged in 2001.

Like Union Carbide, Dow has left- a trail of massacre and misery all over the world. It was the major supplier of Napalm and
Dioxin-tainted Agent Orange used by the US military against communist Vietnam in the 1960s. Today more than 650,000
children suffer a range of physical and mental deformities as a result of Dow's poisons in Vietnam. In India Dow Chemical is
producing Dursban, a pesticide that was withdrawn from the US market in 2000 because of its harmful effect- on children’s
brains.
Rather than bring Union Carbide and Dow Chemical to own up to their responsibilities in Bhopal, the Indian Government has
gone out of its way to facilitate Dow's business in India. Last year the Prime Minister directed the setting up of a Special T ask
Force in the Planning Commission to facilitate Dow Chemical's petrochemical investments in West Bengal and Andhra
Pradesh.

Given the support- by the Communist Party of India (Marxist) and its allied groups to the 22 year long campaign for justice in
Bhopal it would be indeed ironic and unfortunate if Dow Chemical were allowed to invest in CPM ruled West Bengal. We are
hopeful that the CPM leadership will issue an unequivocal statement clarifying that Dow Chemical or any of its subsidiaries
will net- be entertained in West Bengal.
As we send this letter to you we are also releasing it to the media so as to communicate to the public the issue which we believe
is of critical national and international importance particularly to the progressive people in our country and the world.
Please let- us know if you would like us to send more information regarding this matter. We will appreciate an early response
from you.

Yours sincerely,

Representatives of organizations of survivors of the Union Carbide disaster in Bhopal and their supporters.

13

Rational Drug Therapy principles, realities and the road ahead
Sujith J Chandy, Clinical Pharmacology Unit, CMC, Vellore

Introduction
Ineffective, inappropriate and economically nonviable use of medicines is often observed in health
care throughout the world. This is more so in the developing countries. The need for achieving quality
use of medicines in the health care system is not only because of the financial reasons with which
policy makers and administrators are usually most concerned. Appropriate use of drugs is also one
essential element in achieving quality of health and medical care for patients and the community.

Defining Rational Drug Use
What is rational use of drugs? The Conference of Experts on the Rational Use of Drugs, convened by
the World Health Organization in Nairobi in 1985 defined it as:
"Rational use of drugs requires that patients receive medications appropriate to their
clinical needs, in doses that meet their own individual requirements for an adequate
period of time, and the lowest cost to them and their community."
These requirements will be fulfilled if the process of prescribing is appropriately followed. This will
include steps in defining patient’s problems (or diagnosis); in defining effective and safe treatments
(drugs and non-drugs); in selecting appropriate drugs, dosage and duration; in writing a prescription;
in giving patients adequate information; and in planning to evaluate treatment responses.
The definition implies that rational use of drugs, especially rational prescribing should meet certain
criteria :
Appropriate indication The decision to prescribe drug(s) is entirely based on
medical rationale and that drug therapy is an effective and safe treatment

Appropriate drug The selection of drugs is based on efficacy, safety, suitability and
cost considerations.
Appropriate patient No contra-indications exist and the likelihood of adverse
reactions is minimal, and the drug is acceptable to the patient.

Appropriate information. Patients should be provided with relevant, accurate,
important and clear information regarding his or her condition and the medication(s)
that are prescribed.
Appropriate monitoring The anticipated and unexpected effects of medications
should be appropriately monitored.

Unfortunately, as all of us are well aware, reality as regards to rational prescribing is
otherwise. Prescribing most often does not conform to these criteria and can be termed as
inappropriate or irrational prescribing.
Common examples of irrational prescribing are:
The use of drugs with doubtful/unproven efficacy, e.g., the use of antimotility agents in
acute diarrhea

The use of unnecessarily expensive drugs, e.g.the use of a third generation
cephalosprin, when a first line agent is indicated or a broad spectrum antimicrobial
when a narrow spectrum drug would do
The use of drugs when no drug therapy is indicated, e.g., antibiotics for upper
respiratory infections, diarroea and viral fevers
The use of drugs of uncertain safety status, e.g., use of dipyrone (Baralgan, etc.)

I

14
The use of the wrong drug for a specific condition requiring drug therapy, e.g.,
tetracycline in childhood diarrhea requiring ORS

Failure to provide available, safe, and effective drugs, e.g., failure to vaccinate against
measles or tetanus, failure to prescribe ORS for acute diarrhea
The use of correct drugs with incorrect administration, dosages, and duration, e.g., the
use of oral steroids in asthma when inhaled steroids would be much more efficient and
safe
Other common and widespread irrational prescribing practices include:

Overuse of antibiotics and antidiarrheals for non-specific childhood diarrhea,
Indiscriminate use of injections, e.g., in malaria treatment
Multiple drug prescriptions, fixed dose combinations

Use of antibiotics for treating minor ARI

Minerals and tonics for malnutrition
Of course, rational prescribing is not as easy as it sounds. The drug use system is complex and
varies from countrywise. Drugs may be imported or manufactured locally. The drugs may be used in
hospitals or health centers, by private practitioners and often in a pharmacy or drug shop where OTC
preparations are sold. In some countries all drugs are available over the counter! In India, there are a
lot of alternate systems of medicines and many practitioners prescribe allopathic medicines. There
are a large number of quacks without any knowledge of rational prescribing. Last but definitely not the
least the public includes a very wide range of people with differing knowledge, beliefs and attitudes
about medicines. Many a time, the patient expects a particular drug and hints or directly asks for that
to the doctor or pharmacist.

Factors Underlying Irrational Use of Drugs

There are many different factors which affect the irrational use of drugs. In addition, different cultures
view drugs in different ways, and this can affect the way drugs are used. In India, this can therefore
be a complex maze with multiple cultures, religions, dialects and castes.
If one were to broadly classify the factors, they could be divided into: those deriving from patients,
chemists shops, prescribers, the workplace, the supply system, industry influences, regulation drug
information and misinformation.
In each group, there can be various ways contributing to irrational use of drugs

Patients - drug misinformation, misleading beliefs, patient demands/expectations
Prescribers - lack of education and training, inappropriate role models, patient pressures, lack of
objective drug information, company incentives, limited experience,
misleading beliefs about drug efficacy, competition
Chemist shops — patient pressures, profit motives, competition
staffing906'
Pat,ent ,Oad’ pressure to Prescribe, lack of adequate lab capacity, insufficient
Drug Supply System - unreliable suppliers, drug shortages, limited budgets necessitating fixed
choices, expired drugs supplied
Drug Regulation - non-essential drugs available, inefficient audit system, inadequate legal
implementation, non-formal prescribers
Industry - promotional activities, misleading claims, incentives

15
Impact of Irrational Drug Use
Irrational drug use can have various consequences, for the patient, the public, the health system and
even the economy. A few important consequences are mentioned below:
Reduction in the quality of drug therapy — This can lead to increased
morbidity and mortality

Waste of resources - This can lead to reduced availability of other vital drugs
and increased costs
Increased risk of unwanted affects - adverse drug reactions and the
emergence of drug resistance
Psychosocial impacts - patients may believe that there is "a pill for every ill"

A focused case of irrational drug use and its consequence - the antimicrobial misuse problem

Irrational prescribing and dispensing issues come to the fore when it comes to antibiotic use. I would
like to therefore focus on this issue and how it has impacted society.

The problem of antimicrobial resistance was one of the important issues brought up at the World
Health Assembly (WHA) in 2005.
The WHO says that antimicrobial resistance is one of the world’s most serious public health
problems. A major reason is the irrational use of medicines.
According to WHO, worldwide, more than 50% of all medicines are prescribed, dispensed or sold
inappropriately, and 50% of patients fail to take them correctly. The consequence of this is seen
directly with the misuse of antibiotics
There is increasing antimicrobial resistance, with resistance of up to 70-90 percent to original first-line
antibiotics for dysentery (shigella), pneumonia (pneumococcal), gonorrhoea, and hospital infections
(staph. Aureus).
A WHO policy paper on “Containing antimicrobial resistance” says that many of the microbes that
cause infectious disease no longer respond to common antimicrobial drugs such as antibiotics
antiviral and antiprotozoal drugs.
The problem has reached unprecedented proportions that unless concerted action is taken
worldwide, we run the risk of returning to the pre-antibiotic era when many more children than now
lA/ur? infectl0us diseases and major surgery was impossible due to the risk of infection.
WHO s data show the following antimicrobial resistance global prevalence rates: malaria (chloroquine
In 81 °Ut °f 92 countries)’ tuberculosis (0-17% primary multi-drug resistance); HIV/AID8
(0-25/o primary resistance to at least one antiretroviral drug); gonorrhoea (5-98% penicillin
resistance); pneumonia and bacterial meningitis (0-70% penincillin resistance in streptococcus
pneumonia); diarrhoea: shigellosis (10-90% ampicillin resistance, 5-95% cotrimoxazole resistance):
A°S?ua
1e^'OnS (0‘70% resistance of staphylococcus aureus to all penicillins and cephalosporins)
Another WHO paper says that irrational medicines use includes use of more medicines than are
clinically necessary, inappropriate use of antimicrobial agents for non-bacterial infections;
inappropriate selection or dosing of antibiotics for bacterial infections; over-use of injections when oral
ormulations are more appropriate; failure to prescribe in accordance with clinical guidelines- and
inappropriate self medication often of prescriptions-only medicines.
Referring to the HIV/AIDS, TB and malaria epidemics, the paper says "concerns are growing about
accelerating rates of anti-microbial resistance and rising prices for alternative anti-microbial agents to
treat infections due to resistant pathogens."
y

16

Antimicrobial resistance in the Indian context is also on an ever increasing rise. This is mainly
attributed to antibiotic misuse at three levels, human misuse, animal misuse and environmental
misuse. It remains to be seen how each is having an impact on resistance levels. Human misuse is
the most widely documented of the three.
In a study done to measure the misuse of antimicrobials in predominantantly viral conditions such as
diarrhoea, URI and fever with myalgia, it was seen that a high percentage of patients received
antibiotics. In Uttar Pradesh, it was as high as 80%, in Tamil Nadu, 70%, whereas in Kerala it was
only 40%. This brings us to the fundamental question whether other factors besides drug promotions
and profit such as socioeconomic conditions, literacy etc are factors which influence use of drugs. In
another study supported by WHO in Vellore district, an attempt was made to establish a model to
compare antimicrobial resistance and usage patterns. It was found that approximately 42% of all
outpatients were being given antibiotics. It was also noticed that various stakeholders were
responsible for overusing various types of antibiotics. Private practitioners preferred antibiotics such
as ciprofloxacin, whereas pharmacists dispensed both amoxicillin and ciprofloxacin. Due to limited
availability of antibiotics in government facilities, cotrimoxazole was highly used.
These observations hold valuable lessons in pointing to the factors that drive irrational drug use.
Accessibility and availability were key issues in the governmental facilities whereas peer competition,
pressure to cure and industry incentives contributed in the private health facilities. In both areas,
patient expectations was a key contributing factor

What can be done?

The WHO lists measures that governments can take. One of the interventions suggested relate to
drug sales promotion. "Pharmaceutical promotion often has negative effects on prescribing and
consumer choice, but regulation of promotional activities has been proven to be one of the few
effective interventions,"
"Countries should therefore consider regulating and monitoring the quality of drug advertising and of
the pharmaceutical industry's promotional practices, and enforcing sanctions for violations."
Strategies to target the stakeholders such as doctors and pharmacists need to be thought about.
Proper training on the approach to therapeutics, minimizing the impact of industry incentives, a peer
process to reduce irrational prescriptions are just some of the ways that can be adopted. Last but not
the least, public awareness and health education are key issues to be dealt with. If a layman is made
to understand the difference between viral and bacterial illness, it makes it easier to understand that
antibiotics are not needed in viral conditions.
Although there have been previous WHA resolutions, and a WHO programme on rational drug use,
not much has been done in countries. Very little is being spent to promote rational use of medicines
The global sales of prescription drugs in 2000 were $282.5 billion and drug promotion costs in the US
were $15.7 billion the same year. In 2002-03, global WHO expenditure was $2.3 billion, of which the
WHO expenditure on promoting rational drug use was only 0.2%.
The WHO is tackling the issue through advocacy, the essential medicines list, training programmes
and a WHO global strategy on anti-microbial resistance.
There was inadequate implementation of rational medicines use in countries, with only 26% of
y^ntries havin9 a national strategy and only 50% of countries having public education in the past two
Irrational drug use is a very serious global public health problem and much more policy
implementation is needed at national level. Rational use could be greatly improved if a fraction of the
resources spent on medicines were spent on improving use.
Examples of successful national programmes for rational drug use are found in Indonesia and the
Swedish Strategic Programme for Rational Use of Anti-microbial Agents.

17
In conclusion, the need of the hour is to develop a coherent, comprehensive and integrated national
approach to implement the strategy for irrational use of drugs; to enhance the qualtiy use of
medicines through using national standard-practice guidelines for common diseases; and to
strengthen legislation; and to mobilize resources to promote sustainable, practical and cost - effective
interventions for rational use of medicines by providers and consumers. The question is - do we
have the courage and can we develop an optimal strategy to confront the factors promoting irrational
use and move towards rational drug use?

-•

■

S?i/
■

WHAT YOU CAN DO

L

I11UIC duuut the issue. Write to your pol
them about your concerns. Ask them to guarantee sufficient re
diseases by funding drug development based on the specific health needs of
developing countries. Write to pharmaceutical companies urging them to make
essental medicines <XVCU
available and affordable to people in poor countries. Ask the
industry to invest in and cooperate with initiatives aiming to develop new cures for
acted diseases.

::'

<fc/ —-

|
j

i

I

MILLIONS HAVE
A DRUG PROBLEM.

THfY CANT GET ANY;

i wUL find more information about access problems and possible solutions on the
i taess Campaign website www.accessmed-msf.org.

are

* t
j-y.... 1 -....

t Re KJ* 1
V '-*■ Wy
\

’W-

1
fc

In

A

E

* -

.. W

n

I 1 V

kljdgi

I
si

T®*,

■fUtey’r < ||
' Jt

|H

■

CAMPAIGN FOR

Medecins Sans Frontieres
Campaign for Access to Essential Medicines
Rue de Lausanne 78, PO Box 116, 1211 Geneva 21, SWITZERLAND
Tel ++41-22-8498 405
Fax ++41-22-8498 404
Email access@geneva.msf.org
www.accessmed-msf.org

ACCESS1
ESSENTIAL
MEDICINES

‘ndependent hu^nita^ ^dlcal relief organisation assisting victims of armed conflict, epidemics
m 1971'
natlOna'
OfTiCeS 'n 18 countriesdel1^ aid through over 500 medical
programmes in nearly 80 countnes around the world. MSF was awarded the Nobel Peace Prize in 1999.

IS

I

I
CAMPAIGN FOR

ACCESS

© MSF Ca,. paign for Access to Essential Medicines 2004
Printed on mx>% recycled, chlorine-free paper. Design/Artwork: Twenty 3 Crows Ltd +44 (0)1848 200401

i

.
FRONnenES

MEDICINES

i

.

\

’

---------------------------

\\

\\

INFECTIOUS
EASES KILL OVER 14 MILLION PEOPLE EVERY YEAR.
THAT’S OVER 38,000 DEATHS EACH DAY - NINE OUT OF TEN OCCURRING IN |EVELOPING COUNTRIES;

;?J^™?..C?UL?.BAAVOIDED WITH THE HELP 0F appropriate medicines.

BUT ESSENTIAL MEDICINES ARE A LUXURY: ONE THIRD OF THE WORLD’S POPULATION HAVE NO ACCESS TO THEM.
_____________________________

.

■-

y

TOO POOR TO BE
TREATED?

DOCTORS WITHOUT
MEDICINES

The extraordinary medical advances of

Medecins Sans Frontieres has been
delivering medical care to

the past decades currently benefit
mankind unequally. While pharmacies

in developed countries offer a huge
choice of treatments for a variety of
conditions, millions of the world’s
poorest and most vulnerable people
have no access to medicines that

could save or extend their lives.

populations in distress and victims of
disasters and armed conflict “without
discrimination and irrespective of
race, religion, creed or political

affiliation”(*) for more than 30 years.
Infectious diseases claim more lives
than wars. As a medical humanitarian

organisation, MSF redresses both
the open violence of conflicts and
the hidden violence and
discrimination brought about
when people can’t access life
saving medicines.
MSF’s charter

MSF staff are increasingly finding
that effective treatments are

unaffordable or unavailable. Many
life-saving drugs are priced out of
reach of the majority of those

who need them. Some drugs
have been withdrawn from the

market for lack of profitability.
This was the case of eflornithine,
a medicine used to treat people

with sleeping sickness, a fatal
disease only found in Africa. For

FROM FRUSTRATION
TO ACTION

©

In 1999, MSF launched a project

I

specifically aimed at getting essential

I

medicines to those who need them

most. A logical extension of MSF’s
tradition of speaking out, the
Campaign for Access to Essential
Medicines combines the expertise of
MSF medical staff, lawyers,
pharmacists and laboratory
technicians, as well as
communications and advocacy

professionals. The campaign is firmly
rooted in MSF’s field experience: the
lack of access to life-saving

medicines witnessed by our medical
professionals at local level drives our
advocacy at international level.

other diseases, there are simply

©

no drugs. For instance, there is
currently no cure for the chronic
form of Chagas, a disease that
kills 50,000 people in Latin
America every year.

The following pages describe the

access crisis and what MSF is doing
about it

■s

If
3

>903/

.

In 200t
'0 Thai people with
HIV/AIDS won a court case against the
pharmaceutical giant Bristol-Myers
Squibb, thus overturning BMS’s patent
on ddl, an AIDS drug. This opens the
way for generic production of the
medicine. Generic drugs produced by
the Thai government’s pharmaceutical
organisation are up to 25 times
cheaper than equivalent originator
products. The picture shows the
activists filing their claim at the Thai
Central Intellectual Property and
International Trade Court in 2002.

PATENTS :
medicines aren’t
just any
consumer goods

J

A drug patent holder
can sell its medicine
at any price for the

duration of the
patent, usually 20

years. But the high
price of a medicine
can be a matter of

^’1

life and death for a
patient, and amount to extraordinary

countries can use to ensure patents do not

health expenditures for governments
of developing countries.

limit access to medicines. For instance,
countries can allow the production or

PRICE : life-saving drugs must
be affordable

The rules governing pharmaceutical
patents are enshrined in the Trade

importation of generic medicines without
the consent of the patent holder, or look
for the cheapest available version of the

The single most important factor in
forcing down the prices of medicines is

Related Aspects of Intellectual

brand-name drug on the global market.

Property Rights (TRIPS) Agreement
of the World Trade Organization
(WTO), signed in 1994. The

MSF is encouraging implementation of
national regulations that will offer

OVERCOMING ACCESSHBARRIERS

generic competition. The lowest price of
an AIDS drug combination plummeted
from more than US$10,000 per patient
per year to less than US$200 between

. .

2000 and 2004. But many AIDS drugs,
malaria treatments, antibiotics and other
life-saving medicines are still unaffordable
for people and governments in
developing countries.

MSF constantly analyses drug prices and
makes updates available to national and
international buyers. We also negotiate
with generic and originator drug makers
to lower their prices.

4

agreement includes safeguards that

maximum flexibility to set patents aside
in order to “promote access to medicines

A small boy with sleeping sickness,
Uganda. 60 million Africans live in
areas infested with tse tse flies that
transmit sleeping sickness, a disease
that kills if left untreated. The
progression of the disease is
determined with the help of a lumbar
puncture, a painful and potentially
dangerous procedure. While some of
the current treatments are effective,
they require hospitalisation, wellequipped clinics and specialised staff.
Simpler drugs and diagnostics would
greatly improve prospects of
eliminating the disease. MSF has been
treating people with sleeping sickness
in sub-Saharan Africa nee -986.

for all” (Declaration on the TRIPS

’If f ■

Ik

Agreement and Public Health, adopted
at the WTO Ministerial meeting in
Doha, 2001).
MSF is also calling on governments to

keep intellectual property rights out of
regional or bilateral trade agreements

negotiated between countries. These
agreements impose more stringent patent
protection than required by the TRIPS

©

I

i

Agreement and hamper the use of more

affordable, generic medicines in other
ways.

Continued on page 8

5

THE ACCESS CRISIS G THE ACCESS CRISIS B THE ACCESS CRISIS
AIDS
40 million people infected, 90% of them
in developing countries. Three million
deaths in 2003.
Around 50 companies produce antiretroviral
(ARV) drugs worldwide, and new treatments
and potential vaccines are being developed because there is a Western market for them.
But people living with HIV/AIDS in
developing countries are still neglected: out
of the six million people who need ARV
treatment immediately, only 440,000 have
access to it.

MSF is providing ARV treatment as part of a
continuum of care for over 13,000 people in
more than 20 countries, and expects to be
treating many more in the years to come.
Our ability to increase the number of patients

Wanted: r

on treatment has partly depended on the use
of fixed-dose combinations (FDCs) of ARVs that is, pills containing several AIDS drugs in
one tablet, which makes them easy to use.
The cheapest FDCs are now offered for less
than US$200 per person per year.
But there are still major challenges in
accessing AIDS treatments. Pregnant women
and children with HIV/AIDS have few choices
of appropriate, affordable drugs. When
peoples’ first triple therapy fails and they need
to switch to second-line treatment, prices
shoot up. The least expensive second-line
treatment recommended by WHO costs five to
ten times more than the cheapest first-line
therapy.

In addition, monitoring treatment failure and
diagnosing common co-infections such as
tuberculosis is very difficult with current means.

-

Simplified, affordable AIDS drugs and new monitoring tools to
achieve access to ARVs for those who need it.

Malaria
500 million new infections and up to two million deaths every year.
Malaria is caused by parasites transmitted by mosquitoes. It kills one child every 30 seconds, and
children in rural Africa are particularly vulnerable to it.
Malaria parasites have become increasingly resistant to old drugs like chloroquine. Because easy-touse diagnostic tests to confirm whether a person actually has malaria are not available in poor
countries, many people who haven’t got malaria end up being treated for it. This encourages drug
resistance.

Effective drugs exist. Artemisinin, a potent drug extracted from a Chinese plant, has been used
successfully in Asia since the early 1990s. Combinations of drugs containing artemisinin (so called
ACTs) have now been internationally recommended as the best current treatment for malaria, and
governments in many countries are switching to using them.
MSF treats over one million people for malaria in nearly 40 countries every year.
VVanted. Affordable rapid diagnostic tests for malaria adapted for use in

resource-poor settings. Artemisinin-containing fixed-dose combinations. More R&D
to discover new classes of malaria medicines.

TB
One third of the world’s
population carries TB bacilli.
Every year, eight million
people develop active TB and
two million die from it.
Tuberculosis, or TB, is a bacterial
infection best known for the form
infecting the lungs. Fuelled by the
HIV/AIDS pandemic, TB is on the
rise, particularly in developing
countries. An estimated 12 million
people worldwide are infected
with both TB and HIV, but the co
infection is hard to diagnose and
treat.
Feeling better a few weeks into
their long and arduous TB
treatment, people often stop
taking their drugs. Treatment
interruption creates super-bugs
that don’t respond to any existing
treatment and can spread to
other people.

Chagas

©

&2-

100 million people at risk across Latin America.
50,000 deaths per year.

Chagas is caused by a parasite transmitted by blood
sucking insects. People can be infected but show no
symptoms for years. Developing over time, chronic Chagas
causes irreversible damage to the heart, oesophagus and
colon, and Chagas sufferers usually die of heart failure.
Existing Chagas treatments are toxic and take one to two
months to complete. They are only effective in the acute
and undetermined stage of the disease in children. There is
no treatment for chronic Chagas.

MSF cares for Chagas patients in Bolivia, Guatemala and
Nicaragua.

Wanted:

New diagnostic tests and medicines
for Chagas. Availability of existing drugs.

Kala azar
An estimated 60,000 deaths per year.

Despite these alarming facts, no
new cure for TB has been
introduced in the past 40 years.
In 2003, MSF treated over 20,000
people with TB in more than 20
countries worldwide.

Visceral leishmaniasis or kala azar, a parasitic disease
transmitted by flies, causes fever, anaemia and an enlarged
spleen. If left untreated, kala azar kills. Many infections and
deaths may go unreported as people suffering from kala
azar often live in remote areas and never make it to a
clinic. Co-infection with HIV/AIDS is worsening the situation.

Wanted: Diagnostic

MSF has treated over 60,000 people with kala azar in Africa
since 1988.

tests that detect all forms
of TB in all patients,
including children and HIV
positive people. Shorter
treatments with smaller pill
counts. Effective treatments
for multi-drug resistant TB.

But our efforts continue to be dwarfed because drugs
commonly given as first-line therapy are old, toxic,
expensive and impractical for use in poor countries. Rapid
diagnostic tests are also only just beginning to be
introduced and their affordability needs to be ensured.

Wanted:

New, easy-to-use and affordable
drugs and diagnostic tests for kala azar.

6
7

I

»

^ACCESS BARRIERS

•... T

Continued from page 5

NEGLECTED DISEASES :
MSF co-founded a new drug development organisation
Sleeping sickness, leishmaniasis and other diseases that afflict and
kill millions of poor people every year have so far attracted little
interest from profit-driven pharmaceutical companies. This is

compounded by the fact that governments and the international
community have failed to encourage research and development of
new drugs for these neglected diseases.

Aspiring to compensate for this
neglect by delivering new medicines
within the shortest possible time
frame, MSF has joined forces with
five renowned public and private
research institutes and the UN’s
health agency WHO to create the

Drugs for Neglected Diseases
initiative (DNDi). An independent notfor-profit organisation, DNDi was

launched in July 2003. Its objective is

DIAGNOSTIC TESTS : precision instead of guesswork
Many of the people MSF doctors see could be treated. But how do you prescribe a
cure if you can’t determine what ails the person to begin with? Most people coming
to a clinic in developing countries are diagnosed on the basis of clinical symptoms

©
2

2
CD

and signs, such as fever. This may lead to incorrect diagnosis and growing drug
resistance.
When there is a test, it is often poorly adapted to resource-poor settings. For
instance, the most commonly used TB diagnostic test was developed in 1882 and
detects only half of those with active TB - even when used by highly skilled staff.
The importance of easy-to-use diagnostic tests is growing. For instance, now that
new, more potent malaria medicines are becoming available to many developing
countries, reliable malaria tests are even more critical: they ensure that people are

“How much longer am I
supposed to tell my patients with
chronic Chagas they can’t be
treated because they are too
poor? Governments need to take
responsibility for public health drug development must be driven
by need, not profit.”

treated for the real cause of their fever, and that only those who actually have
malaria are treated for it, so we don’t create resistance to the new drugs within
communities that badly need them.
.........| ,

MSF calls for rapid
diagnostic tests that are

easy to use, affordable
and adapted to the
needs of developing
countries.

Dr Wilma Chambi, MSF, Bolivia

to develop new drugs to fight
neglected diseases, raise awareness
of the need for this work, and use

and strengthen existing R&D capacity
in the countries hardest hit by these
diseases. DNDi is working on nine

projects addressing identified needs
for the treatment of leishmaniasis,
sleeping sickness, Chagas disease
and malaria (see www.dndi.org for
more information),

8

The work of initiatives such as DNDi can

contribute to, but not replace,
governments’ efforts to address the
unmet medical needs of people in
developing countries. MSF will continue
to play an active role in DNDi, advocate
for more R&D into diseases that only
afflict people in developing countries,
support needs-driven drug
development, and participate in defining

the research needs for neglected
diseases.

h
i

The most modern TB treatments are
nearly half a century old. Like this man
in Kenya, people need to take their
drugs for several months under medical
supervision. Diagnosing TB reliably in
children, HIV positive people or people
with extra-pulmonary forms of the
disease is not possible with current
diagnostic tests. TB is the number one
killer of people with HIV/AIDS.

9

WHAT HAS BEEN ACHIEVED?
©

— I
s

MSF and others working to improve
access to medicines have catalysed
some change - because enough people
have made enough noise. The UN is
now putting more emphasis on

addressing and funding the fight against
HIV/AIDS, TB and malaria. Governments

example. Pharmaceutical companies
have reduced the prices of some of
their essential medicines.

5
£U
in

But this is just a fraction of what is
required. Governments, drug

manufacturers and international
organisations can, and must, do more.

of developing countries are beginning to

WE STILL NEED:

tackle the AIDS pandemic using cheaper,

SS More political will at national and

generic drugs, and these are being
funded through various international

©

international level to put lives
before profits.

initiatives and philanthropic
organisations. ‘Neglected diseases’ are

In 2001, over 250,000 people
worldwide signed a petition, joining
a wave of public opinion that
forced 5p pharmaceutical
companies to drop their court case
against the South African
government over a law designed to
make medicines more affordable.

getting more attention and initiatives are
being set up to develop new treatments
for them. The UN’s health agency WHO

“Millions of people worldwide
are dying of treatable diseases
like malaria while effective
drugs exist. It’s simply
unacceptable.3’

is reclaiming leadership on some issues
related to access to medicines, and is
giving more progressive advice to

countries on malaria treatment, for

O Increased competition between
drug producers in order to lower
drug prices.
® A boost in resources for research
and development into new

medicines and diagnostic tests based
on actual health needs in developing
countries.

Dr Gabriel Mufuta, MSF, Guinea

QUALITY of medicines :

10

MSF supports the World

It is critical that health

Health Organization’s

providers worldwide are able
to procure and use essential
medicines that meet adequate
quality standards.
.

prequalification project
that facilitates
identification of quality
essential medicines and
has dramatically

L

My

I

5.

T*'-'

’■ *

-

improved access to AIDS
drugs in part$ular*

ii- i

1110^

KA A
gSm..

it

11

Media: RF_DR_14_A_SUDHA.pdf

Position: 52 (23 views)